Author Index to Volume 44*

A

Abdalian R and Heathcote EJ. Sclerosing cholangitis: A focus on secondary causes. 2006;44:1063-1074 (Perspectives in Clinical Hepatology)
Abe K (*see* Ikeda M et al). 2006;44:117-125
Abecassis M (*see* Koffron A et al). 2006;44:1694-1700 (Special Article)
Abel M, Sène D, Pol S, Bourlière M, Poynard T, Charlotte F, Cacoub P, Caillat-Zucman S. Intrahepatic virus-specific IL-10-producing CD8 T cells prevent liver damage during chronic hepatitis C virus infection. 2006;44:1607-1616
Acharya SK (*see* Sugiyama M et al). 2006;44:915-924
ACTG Protocol A5127 Team (*see* Peters MG et al). 2006;44:1110-1116
Adelmeijer J (*see* Lisman T et al). 2006;44:53-61
Afdhal N (*see* Fontana RJ et al). 2006;44:925-935
— (*see* Kamal S et al). 2006;44:1051-1052 (Reply)
Afdhal NH (*see* Kamal SM et al). 2006;44:1055-1056 (Correction)
Ahmed A (*see* He XS et al). 2006;44:352-359
Akahane T (*see* Kitade M et al). 2006;44:983-991
Akamatsu M (*see* Tateishi R et al). 2006;44:1518-1527
Akarca US (*see* ter Borg MJ et al). 2006;44:721-727
Albrecht J and Norenberg MD. Glutamine: A trojan horse in ammonia neurotoxicity. 2006;44:788-794
Alison MR (*see* Forbes SJ and Alison MR). 2006;44:23-26 (Editorial)
Allain JP (*see* Brojer E et al). 2006;44:1666-1674
Almer S (*see* Prytz H et al). 2006;44:1572-1580
Alston-Smith B (*see* Peters MG et al). 2006;44:1110-1116
Alter H. Hepatology Highlights. 2006;44:3-6, 775-777
Alter MJ (*see* Hwang LY et al). 2006;44:341-351
Amadei B (*see* Urbani S et al). 2006;44:126-139
Anania FA (*see* Ding X et al). 2006;44:515 (Correction)
Andersen J (*see* Peters MG et al). 2006;44:1110-1116
Andrade RJ, Lucena MI, Kaplowitz N, García-Muñoz B, Borraz Y, Pachkoria K, García-Cortés M, Fernández MC, Pelaez G, Rodrigo L, Durán JA, Costa J, Planas R, Barriocanal A, Guarner C, Romero-Gomez M, Muñoz-Yagüe T, Salmerón J, Hidalgo R. Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry. 2006;44:1581-1588
— (*see* Lucena MI et al). 2006;44:850-856
Andriulli A (*see* Niro GA et al). 2006;44:713-720
Angeli P, Wong F, Watson H, Ginès P, CAPPS Investigators. Hyponatremia in cirrhosis: Results of a patient population survey. 2006;44:1535-1542
Angulo P (*see* Nobili V et al). 2006;44:458-465
Ansari AA (*see* Wakabayashi K et al). 2006;44:1240-1249
Antoniades CG, Berry PA, Davies ET, Hussain M, Bernal W, Vergani D, Wendon J. Reduced monocyte HLA-DR expression: A novel biomarker of disease severity and outcome in acetaminophen-induced acute liver failure. 2006;44:34-43
Aouizerat BE (*see* Merriman RB). 2006;44:874-880
Apte U, Zeng G, Muller P, Tan X, Micsenyi A, Cieply B, Dai C, Liu Y, Kaestner KH, Monga SPS. Activation of Wnt/β-catenin pathway during hepatocyte growth factor–induced hepatomegaly in mice. 2006;44:992-1002
Apte UM (*see* Limaye PB et al). 2006;44:379-388
Armengol JR (*see* González A et al). 2006;44:806-812
Arnell H (*see* Knisely AS et al). 2006;44:478-486
Arnold HL and Harrison SA. H. pylori and platelet counts. 2006;44:1685-1686 (Hepatology Elsewhere)
Arroyo V (*see* Esteva-Font C et al). 2006;44:1555-1563
— (*see* Fernández J et al). 2006;44:1288-1295
Ars E (*see* Esteva-Font C et al). 2006;44:1555-1563
Asada K (*see* Kitade M et al). 2006;44:983-991
Asada Y (*see* Zen Y et al). 2006;44:1333-1343
Asahina Y (*see* Ozasa A et al). 2006;44:326-334
Aswad F (*see* Kawamura H et al). 2006;44:936-944
Augustin S (*see* González A et al). 2006;44:806-812
Aukerman L (*see* Kneteman NM et al). 2006;44:515 (Correction)
Ausó E (*see* Jover R et al). 2006;44:771 (Correction)
Avila S (*see* Lucena MI et al). 2006;44:850-856

B

Baccaro ME (*see* Esteva-Font C et al). 2006;44:1555-1563
Baffet G (*see* Bessard A et al). 2006;44:152-163
Baffy G (*see* Fülöp P et al). 2006;44:592-601
Balanzó J (*see* Guarner C et al). 2006;44:633-639
Baldick CJ (*see* Colonno RJ et al). 2006;44:1656-1665
Ballarín JA (*see* Esteva-Font C et al). 2006;44:1555-1563
Banff Working Group. Liver biopsy interpretation for causes of late liver allograft dysfunction. 2006;44:489-501 (Special Article)
Bang CT (*see* Gopal K et al). 2006;44:335-340
Baragiotta A (*see* Donaldson PT et al). 2006;44:667-674
Barahmand-pour F (*see* Doyle SE et al). 2006;44:896-906
Barajas M (*see* Crettaz J et al). 2006;44:623-632
Barbier O (*see* Trottier J et al). 2006;44:1158-1170
— (*see* Verreault M et al). 2006;44:368-378
Barker KF (*see* Zeng MD et al). 2006;44:108-116
Barosi G (*see* Primignani M et al). 2006;44:1528-1534
Barriocanal A (*see* Andrade RJ et al). 2006;44:1581-1588
— (*see* Lucena MI et al). 2006;44:850-856
Barth H, Liang TJ, Baumert TF. Hepatitis C virus entry: Molecular biology and clinical implications. 2006;44:527-535 (Concise Review in Mechanisms of Disease)
Baskin-Bey ES, Huang W, Ishimura N, Isomoto H, Bronk SF, Braley K, Craig RW, Moore DD, Gores GJ. Constitutive androstane receptor (CAR) ligand, TCPOBOP, attenuates Fas-induced murine liver injury by altering Bcl-2 proteins. 2006;44:252-262

*July, 1-284; August, 285-518; September, 519-774; October, 775-1060; November, 1061-1372, December 1373-1752

Bass NM (*see* Merriman RB). 2006;44:874-880
Bassendine MF (*see* Donaldson PT et al). 2006;44:667-674
Bataller. Time to ban smoking in patients with chronic liver disease. 2006;44:1408-1410 (Editorial)
Battista Gaeta G (*see* Niro GA et al). 2006;44:713-720
Baumert TF (*see* Barth H et al). 2006;44:527-535 (Concise Review in Mechanisms of Disease)
Baxter RC (*see* Scarlett CJ et al). 2006;44:658-666
Bayne R (*see* Lieu HT et al). 2006;44:1452-1464
Beasley RP. Diabetes and hepatocellular carcinoma. 2006;44:1408–1410 (Editorial)
Beatty K (*see* Zein CO et al). 2006;44:1564-1571
Beaugrand M (*see* Ganne-Carrié N et al). 2006;44:1511-1517
Bedossa P (*see* Castelnau C et al). 2006;44:728-735
Behrens G (*see* Lankisch TO et al). 2006;44:1324-1332
Bélanger J (*see* Trottier J et al). 2006;44:1158-1170
— (*see* Verreault M et al). 2006;44:368-378
Belanger M (*see* Vaquero J et al). 2006;44:279-280 (Correspondence)
Belghiti J (*see* Plessier A et al). 2006;44:1308-1316
Bell AW and Michalopoulos GK. Phenobarbital regulates nuclear expression of HNF-4α in mouse and rat hepatocytes independent of CAR and PXR. 2006;44:186-194
Bell C (*see* Scarlett CJ et al). 2006;44:658-666
Belle SH (*see* Fontana RJ et al). 2006;44:925-935
Bellecave P and Moradpour D. A picture says more than a thousand words: Structural insights into hepatitis C virus translation initiation. 2006;44:1687-1689 (Hepatology Elsewhere)
Belli G (*see* Mazzaferro V et al). 2006;44:1543-1554
Benihoud K (*see* Descamps D et al). 2006;44:399-409
Benjaminov F (*see* Therapondos G et al). 2006;44:640-649
Benlloch S (*see* Golden-Mason L et al). 2006;44:1098-1109
— (*see* Guarner C et al). 2006;44:633-639
Bérangère Troadec M (*see* Zindy PJ et al). 2006;44:1296-1307
Berbel P (*see* Jover R et al). 2006;44:771 (Correction)
Berg T (*see* van Bömmel F et al). 2006;44:318-325
Bergamaschi G (*see* Primignani M et al). 2006;44:1528-1534
Bergasa NV, McGee M, Ginsburg IH, Engler D. Gabapentin in patients with the pruritus of cholestasis: A double-blind, randomized, placebo-controlled trial. 2006;44:1317-1323
Berishvili E (*see* Joseph B et al). 2006;44:1411-1420
Bernal W (*see* Antoniades CG et al). 2006;44:34-43
Bernuau J and Durand F. Intracranial pressure monitoring in patients with acute liver failure: A questionable invasive surveillance. 2006;44:502-504 (Hepatology Elsewhere)
Berraondo P (*see* Crettaz J et al). 2006;44:623-632
Berry PA (*see* Antoniades CG et al). 2006;44:34-43
Berthiaume EP (*see* Fülöp P et al). 2006;44:592-601
Bertolino P (*see* Warren A et al). 2006;44:1182-1190
Bessard A, Coutant A, Rescan C, Ezan F, Frémin C, Courselaud B, Ilyin G, Baffet G. An MLCK-dependent window in late G1 controls S phase entry of proliferating rodent hepatocytes via ERK-p70S6K pathway. 2006;44:152-163
Beuers U, Gerken G, Pusl T. Biliary drainage transiently relieves intractable pruritus in primary biliary cirrhosis. 2006;44:280-281 (Correspondence)
Bhargava KK (*see* Joseph B et al). 2006;44:1411-1420
Bhave VS (*see* Limaye PB et al). 2006;44:379-388
Bhoori S (*see* Mazzaferro V et al). 2006;44:1543-1554
Biesta PJ (*see* van der Molen RG et al). 2006;44:907-914
Bilezikçi B (*see* Knisely AS et al). 2006;44:478-486
Billiar TR (*see* Izuishi K et al). 2006;44:573-580
Bilonick R (*see* Fontana RJ et al). 2006;44:925-935
Birks C (*see* Doyle SE et al). 2006;44:896-906
Björnsson E (*see* Prytz H et al). 2006;44:1572-1580
Black D (*see* LaRusso NF). 2006;44:746-764 (Special Article)
Blackard JT, Kemmer N, Sherman KE. Extrahepatic replication of HCV: Insights into clinical manifestations and biological consequences. 2006;44:15-22 (Concise Review in Mechanisms of Disease)
Blanco S (*see* Lucena MI et al). 2006;44:850-856
Blechacz B, Splinter PL, Greiner S, Myers R, Peng KW, Federspiel MJ, Russell SJ, LaRusso NF. Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma. 2006;44:1465-1477
Blei AT. Innovations in Hepatology. 2006;44:1373 (Editor's Corner)
—. Intermezzo. 2006;44:2 (Editor's Corner)
— (*see* Vaquero J et al). 2006;44:279-280 (Correspondence)
Blomenkamp K (*see* Rudnick DA et al). 2006;44:976-982
Bode JG (*see* Graf D et al). 2006;44:1206-1217
Bodemar G (*see* Ekstedt M et al). 2006;44:865-873
Bodenheimer HC Jr (*see* Gopal K et al). 2006;44:335-340
Böller B (*see* van Bömmel F et al). 2006;44:318-325
Bongers TN (*see* Lisman T et al). 2006;44:53-61
Bonino F (*see* Mazzaferro V et al). 2006;44:1543-1554
Bonkovsky HL (*see* Everson GT et al). 2006;44:1675-1684
— (*see* Morishima C et al). 2006;44:360-367
Bonnier D (*see* Zindy PJ et al). 2006;44:1296-1307
Bonzo JA (*see* Verreault M et al). 2006;44:368-378
Borlak J (*see* Zschemisch NH et al). 2006;44:164-173
Borraz Y (*see* Andrade RJ et al). 2006;44:1581-1588
Bosch J (*see* Matei V et al). 2006;44:44-52
Bourd-Boitin K (*see* Zindy PJ et al). 2006;44:1296-1307
Bourlière M (*see* Abel M et al). 2006;44:1607-1616
Bouscarel B (*see* Zhang Y et al). 2006;44:612-622
Bowen DG (*see* Warren A et al). 2006;44:1182-1190
Boyer N (*see* Castelnau C et al). 2006;44:728-735
Braeuning A (*see* Hailfinger S et al). 2006;44:512-513 (Reply)
Braley K (*see* Baskin-Bey ES et al). 2006;44:252-262
Brancaccio G (*see* Niro GA et al). 2006;44:713-720
Bréchot C (*see* Lieu HT et al). 2006;44:1452-1464
Breiman A (*see* Vilasco M et al). 2006;44:1635-1647
Brenner DA (*see* Uchinami H et al). 2006;44:420-429
Brissot P (*see* Falize L et al). 2006;44:472-477
Brojer E, Grabarczyk P, Liszewski G, Mikulska M, Allain JP, Letowska M, Polish Blood Transfusion Service Viral Study Group. Characterization of HBV DNA^+/$HBsAg^-$ blood donors in Poland identified by triplex NAT. 2006;44:1666-1674
Broman KW (*see* Grant GR et al). 2006;44:174-185

Bronk SF (*see* Baskin-Bey ES et al). 2006; 44:252-262
Broomé U (*see* Prytz H et al). 2006;44: 1572-1580
Brosgart C (*see* Wursthorn K et al). 2006; 44:675-684
Brosgart CL (*see* Peters MG et al). 2006; 44:1110-1116
Broué P (*see* Serinet MO et al). 2006;44: 75-84
Brouillet A (*see* Lafdil F et al). 2006;44: 228-239
Browning JD, Davis J, Saboorian MH, Burgess SC. A low-carbohydrate diet rapidly and dramatically reduces intrahepatic triglyceride content. 2006;44:487-488 (Concise Communication)
—. Statins and hepatic steatosis: Perspectives from the Dallas Heart Study. 2006;44:466-471
Bucciarelli P (*see* Primignani M et al). 2006;44:1528-1534
Buch S (*see* Schafmayer C et al). 2006;44: 650-657
Buchmann A (*see* Hailfinger S et al). 2006; 44:512-513 (Reply)
Buggisch P (*see* Wursthorn K et al). 2006; 44:675-684
Bugianesi E, Marchesini G, Gentilcore E, Cua IHY, Vanni E, Rizzetto M, George J. Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis. 2006; 44:1648-1655
Bukh J (*see* Kuiken C et al). 2006;44:1355-1361
Bull L (*see* Hwang LY et al). 2006;44:341-351
Bull LN (*see* Knisely AS et al). 2006;44: 478-486
— (*see* Paulusma CC et al). 2006;44:195-204
Burgess SC (*see* Browning JD et al). 2006; 44:487-488 (Concise Communication)
Burton JR Jr (*see* Golden-Mason L et al). 2006;44:1098-1109
Butterworth RF (*see* Vaquero J et al). 2006; 44:279-280 (Correspondence)
Byrne JA (*see* Knisely AS et al). 2006;44: 478-486

C

Cacoub P (*see* Abel M et al). 2006;44: 1607-1616
Caillat-Zucman S (*see* Abel M et al). 2006; 44:1607-1616
Caldwell SH, Hoffman M, Lisman T, Macik BG, Northup PG, Reddy KR, Tripodi A, Sanyal AJ, Coagulation in Liver Disease Group. Coagulation disorders and hemostasis in liver disease: Pathophysiology and critical assessment of current management. 2006;44:1039-1046 (Special Article)
Callise F (*see* Mazzaferro V et al). 2006;44: 1543-1554
Camerini T (*see* Mazzaferro V et al). 2006; 44:1543-1554
Camp DG II (*see* Diamond DL et al). 2006;44:299-308 (Science Frontier)
Candela A (*see* Jover R et al). 2006;44:771 (Correction)
Cantarini MC, de la Monte SM, Pang M, Tong M, D'Errico A, Trevisani F, Wands JR. Aspartyl-asparagyl β hydroxylase over-expression in human hepatoma is linked to activation of insulin-like growth factor and Notch signaling mechanisms. 2006;44:446-457
CAPPS Investigators (*see* Angeli P et al). 2006;44:1535-1542
Capussotti L (*see* Mazzaferro V et al). 2006; 44:1543-1554
Cariti G (*see* De Rosa F et al). 2006;44:511 (Correspondence)
Caron P (*see* Trottier J et al). 2006;44: 1158-1170
— (*see* Verreault M et al). 2006;44:368-378
Carulli L, Lonardo A, Lombardini S, Marchesini G, Loria P. Gender, fatty liver and GGT. 2006;44:278-279 (Correspondence)
Caselmann WH (*see* Schmitz V et al). 2006;44:430-439
Casiraghi MA (*see* Valenti L). 2006;44: 857-864
Castedal M (*see* Prytz H et al). 2006;44: 1572-1580
Castelblanco N (*see* Golden-Mason L et al). 2006;44:1098-1109
Castelnau C, Le Gal F, Ripault MP, Gordien E, Martinot-Peignoux M, Boyer N, Pham BN, Maylin S, Bedossa P, Dény P, Marcellin P, Gault E. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: Relevance of quantitative RT-PCR for follow-up. 2006;44:728-735
Castera L (*see* Ganne-Carrié N et al). 2006; 44:1511-1517
Castiella A (*see* Lucena MI et al). 2006;44: 850-856
Cauli O (*see* Jover R et al). 2006;44:771 (Correction)
Cederbaum AI (*see* Lu Y and Cederbaum AI). 2006;44:263-274
Ceriani R (*see* Valenti L). 2006;44:857-864
Chagneau C (*see* Plessier A et al). 2006;44: 1308-1316
Chamgramol Y (*see* Jinawath N et al). 2006;44:1025-1038
Chan C (*see* Doyle SE et al). 2006;44:896-906
Chan CY (*see* Yam JWP et al). 2006;44: 881-890
Chan EY (*see* Diamond DL et al). 2006;44: 299-308 (Science Frontier)
Chang CNP (*see* Zeng MD et al). 2006;44: 108-116
Chang WY (*see* Yu ML et al). 2006;44: 1086-1097
Chang Y (*see* Chen CH et al). 2006;44: 1171-1181
Chantarangkul V (*see* Tripodi A et al). 2006;44:440-445
Chardot C (*see* Serinet MO et al). 2006;44: 75-84
Charlotte F (*see* Abel M et al). 2006;44: 1607-1616
Chazouilleres O (*see* Poupon R et al). 2006; 44:85-90
Chen CH, Kuo LM, Chang Y, Wu W, Goldbach C, Ross MA, Stolz DB, Chen L, Fung JJ, Lu L, Qian S. *In vivo* immune modulatory activity of hepatic stellate cells in mice. 2006;44: 1171-1181
Chen DS (*see* Liu CJ et al). 2006;44:770 (Correspondence)
Chen J (*see* Kamal SM et al). 2006;44: 1055-1056 (Correction)
Chen L (*see* Chen CH et al). 2006;44: 1171-1181
Chen SC (*see* Yu ML et al). 2006;44:1086-1097
Chen W (*see* Choi SS et al). 2006;44:1267-1277
Cheng L (*see* You Q et al). 2006;44:1421-1431
Cheung R (*see* He XS et al). 2006;44:352-359
Chiba T, Kita K, Zheng YW, Yokosuka O, Saisho H, Iwama A, Nakauchi H, Taniguchi H. Side population purified from hepatocellular carcinoma cells harbors cancer stem cell–like properties. 2006;44:240-251
Chiriva-Internati M (*see* Grizzi F et al). 2006;44:1701-1702 (Correspondence)
Chiva M (*see* Guarner C et al). 2006;44: 633-639
Chobert MN (*see* Lafdil F et al). 2006;44: 228-239
Choi SS, Sicklick JK, Ma W, Yang L, Huang J, Qi Y, Chen W, Li YX, Goldschmidt-Clermont PJ, Diehl AM. Sustained activation of Rac1 in hepatic stellate cells promotes liver injury and fibrosis in mice. 2006;44: 1267-1277
Chrétien Y (*see* Poupon R et al). 2006;44: 85-90
Christa L (*see* Lieu HT et al). 2006;44: 1452-1464
Chuang WL (*see* Yu ML et al). 2006;44: 1086-1097
Chuang YH (*see* Wakabayashi K et al). 2006;44:1240-1249
Chudy M, Schmidt M, Czudai V, Scheiblauer H, Nick S, Mosebach M, Hourfar MK, Seifried E, Roth WK, Grünelt E, Nübling CM. Hepatitis B virus genotype G monoinfection and

its transmission by blood components. 2006;44:99-107
Ciampalini P (*see* Nobili V et al). 2006;44: 458-465
Ciancio A (*see* Niro GA et al). 2006;44: 713-720
Cielecka-Kuszyk J (*see* Knisely AS et al). 2006;44:478-486
Cieply B (*see* Apte U et al). 2006;44:992-1002
Clain DJ (*see* Gopal K et al). 2006;44:335-340
Clegg CH (*see* Doyle SE et al). 2006;44: 896-906
Clément B (*see* Zindy PJ et al). 2006;44: 1296-1307
Clerici M (*see* Tripodi A et al). 2006;44: 440-445
Clothier B (*see* Grant GR et al). 2006;44: 174-185
Coagulation in Liver Disease Group (*see* Caldwell SH et al). 2006;44:1039-1046 (Special Article)
Cobos E (*see* Grizzi F et al). 2006;44:1701-1702 (Correspondence)
Codden T (*see* Lenaerts A et al). 2006;44: 844-849
Cohen DE. AASLD 2006 Distinguished Service Award to Allan W. Wolkoff. 2006;44:1376-1377
Colina F (*see* García-Ruiz I et al). 2006;44: 581-591
Collett M (*see* Kneteman NM et al). 2006; 44:515 (Correction)
Colletti LM (*see* Olle EW et al). 2006;44: 540-549
Colombo M (*see* Mazzaferro V et al). 2006; 44:1543-1554
Colomer D (*see* Matei V et al). 2006;44: 44-52
Colonno RJ, Rose R, Baldick CJ, Levine S, Pokornowski K, Yu CF, Walsh A, Fang J, Hsu M, Mazzucco C, Eggers B, Zhang S, Plym M, Klesczewski K, Tenney DJ. Entecavir resistance is rare in nucleoside naïve patients with hepatitis B. 2006;44:1656-1665
Combet C (*see* Kuiken C et al). 2006;44: 1355-1361
Compañ A (*see* Jover R et al). 2006;44:771 (Correction)
Comparcola D (*see* Nobili V et al). 2006; 44:458-465
Condat B (*see* Plessier A et al). 2006;44: 1308-1316
Connault E (*see* Descamps D et al). 2006; 44:399-409
Conner EA (*see* Coulouarn C et al). 2006; 44:1003-1011
Connors M (*see* Puig M et al). 2006;44: 736-745
Conrads TP (*see* Moon KH et al). 2006;44: 1218-1230
Consigny Y (*see* Plessier A et al). 2006;44: 1308-1316
Conway B (*see* Grebely J et al). 2006;44: 1139-1145
Coppel RL (*see* Wakabayashi K et al). 2006;44:1240-1249
Cornberg M (*see* Wedemeyer H et al). 2006;44:511-512 (Reply), 1051 (Correspondence)
Corpechot C, El Naggar A, Poupon R. Gender and liver: Is the liver stiffness weaker in weaker sex?. 2006;44:513-514 (Correspondence)
— (*see* Poupon R et al). 2006;44:85-90
Cortes A (*see* Lieu HT et al). 2006;44: 1452-1464
Costa J (*see* Andrade RJ et al). 2006;44: 1581-1588
— (*see* Lucena MI et al). 2006;44:850-856
Couchie D (*see* Lafdil F et al). 2006;44: 228-239
Coulouarn C, Gomez-Quiroz LE, Lee JS, Kaposi-Novak P, Conner EA, Goldina TA, Onishchenko GE, Factor VM, Thorgeirsson SS. Oncogene-specific gene expression signatures at preneoplastic stage in mice define distinct mechanisms of hepatocarcinogenesis. 2006;44:1003-1011
Courselaud B (*see* Bessard A et al). 2006; 44:152-163
Coutant A (*see* Bessard A et al). 2006;44: 152-163
Craig RW (*see* Baskin-Bey ES et al). 2006; 44:252-262
Crettaz J, Berraondo P, Mauleón I, Ochoa L, Shankar V, Barajas M, van Rooijen N, Kochanek S, Qian C, Prieto J, Hernández-Alcoceba R, González-Aseguinolaza G. Intrahepatic injection of adenovirus reduces inflammation and increases gene transfer and therapeutic effect in mice. 2006;44: 623-632
Cua IHY (*see* Bugianesi E et al). 2006;44: 1648-1655
Currie G (*see* Wursthorn K et al). 2006;44: 675-684
Czudai V (*see* Chudy M et al). 2006;44:99-107

D

Dabo S (*see* Vilasco M et al). 2006;44: 1635-1647
Dai C (*see* Apte U et al). 2006;44:992-1002
Dai CY (*see* Yu ML et al). 2006;44:1086-1097
Dai J (*see* Zhao J et al). 2006;44:205-215
Dandri M (*see* Wursthorn K et al). 2006; 44:675-684
Dansako H (*see* Ikeda M et al). 2006;44: 117-125
D'Armiento J (*see* Uchinami H et al). 2006;44:420-429
Davern T (*see* Taylor RM et al). 2006;44: 1589-1597
Davern TJ. Indeterminate acute liver failure: A riddle wrapped in a mystery inside an enigma. 2006;44:765-768 (Hepatology Elsewhere)
David E (*see* Niro GA et al). 2006;44:713-720
Davidson NO (*see* Newberry EP et al). 2006;44:1191-1205
Davies ET (*see* Antoniades CG et al). 2006; 44:34-43
Davies R (*see* Grant GR et al). 2006;44: 174-185
Davis J (*see* Browning JD et al). 2006;44: 487-488 (Concise Communication)
de Groot PG (*see* Lisman T et al). 2006;44: 53-61
de la Monte SM (*see* Cantarini MC et al). 2006;44:446-457
de Ledinghen V (*see* Ganne-Carrié N et al). 2006;44:1511-1517
— (*see* Plessier A et al). 2006;44:1308-1316
de Maat MPM (*see* Lisman T et al). 2006; 44:53-61
de Man RA (*see* ter Borg MJ et al). 2006; 44:721-727
De Rosa F, Cariti G, Di Perri G. Acute hepatitis C: Dosage and compliance. 2006;44:511 (Correspondence)
de Waart DR (*see* Paulusma CC et al). 2006;44:195-204
Debanne S (*see* Zein CO et al). 2006;44: 1564-1571
del Hoyo P (*see* García-Ruiz I et al). 2006; 44:581-591
Del Rio RA, Post AB, Singer ME. Cost-effectiveness of hematologic growth factors for anemia occurring during hepatitis C combination therapy. 2006;44:1598-1606
Deleage G (*see* Kuiken C et al). 2006;44: 1355-1361
DeLeve L. AASLD 2006 Distinguished Achievement Award to Neil Kaplowitz. 2006;44:1378-1379
Dell'Era A (*see* Primignani M et al). 2006; 44:1528-1534
— (*see* Tripodi A et al). 2006;44:440-445
Demetris AJ (*see* Luo JH et al). 2006;44: 1012-1024
Dennert G (*see* Kawamura H et al). 2006; 44:936-944
Denninger MH (*see* Plessier A et al). 2006; 44:1308-1316
Dény P (*see* Castelnau C et al). 2006;44: 728-735
Deogracias MP (*see* Olle EW et al). 2006; 44:540-549
Derdák Z (*see* Fülöp P et al). 2006;44:592-601
D'Errico A (*see* Cantarini MC et al). 2006; 44:446-457
Descamps D, Vigant F, Esselin S, Connault E, Opolon P, Perricaudet M, Benihoud K. Expression of non-signaling membrane-anchored death receptors protects murine livers in different models of hepatitis. 2006;44: 399-409

Deugnier Y (*see* Falize L et al). 2006;44: 472-477
Deulofeu R (*see* Matei V et al). 2006;44: 44-52
Devito R (*see* Nobili V et al). 2006;44:458-465
Dhillon AP (*see* Lagging M et al). 2006;44: 1617-1625
Dhumeaux D (*see* Ganne-Carrié N et al). 2006;44:1511-1517
Di Bisceglie AM (*see* Everson GT et al). 2006;44:1675-1684
— (*see* Morishima C et al). 2006;44:360-367
Di Perri G (*see* De Rosa F et al). 2006;44: 511 (Correspondence)
Diamond DL, Proll SC, Jacobs JM, Chan EY, Camp DG II, Smith RD, Katze MG. HepatoProteomics: Applying proteomic technologies to the study of liver function and disease. 2006;44: 299-308 (Science Frontier)
Díaz-Sanjuan T (*see* García-Ruiz I et al). 2006;44:581-591
Diehl AM (*see* Choi SS et al). 2006;44: 1267-1277
Diehl L (*see* Schmitz V et al). 2006;44:430-439
Dienstag JL (*see* Everson GT et al). 2006; 44:1675-1684
— (*see* Morishima C et al). 2006;44:360-367
Dierssen U (*see* Zschemisch NH et al). 2006;44:164-173
Dimou E (*see* Laras A et al). 2006;44:694-702
Ding X, Saxena NK, Lin S, Gupta NA, Anania FA. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. 2006;44:515 (Correction)
DITTO-HCV Study Group (*see* Lagging M et al). 2006;44:1617-1625
Dolganiuc A (*see* Szabo G et al). 2006;44: 287-298 (Concise Review in Mechanisms of Disease)
Dombrowski F (*see* Schmitz V et al). 2006; 44:430-439
Donaldson PT, Baragiotta A, Heneghan MA, Floreani A, Venturi C, Underhill JA, Jones DEJ, James OFW, Bassendine MF. HLA class II alleles, genotypes, haplotypes, and amino acids in primary biliary cirrhosis: A large-scale study. 2006;44:667-674
Dongiovanni P (*see* Valenti L). 2006;44: 857-864
Doo E (*see* LaRusso NF). 2006;44:746-764 (Special Article)
Dot J (*see* González A et al). 2006;44:806-812
Douglas D (*see* Kneteman NM et al). 2006; 44:515 (Correction)
Douvin C (*see* Ganne-Carrié N et al). 2006;44:1511-1517
Doy M (*see* Hirayama T et al). 2006;44: 602-611
Doyle SE, Schreckhise H, Khuu-Duong K, Henderson K, Rosler R, Storey H, Yao L, Liu H, Barahmand-pour F, Sivakumar P, Chan C, Birks C, Foster D, Clegg CH, Wietzke-Braun P, Mihm S, Klucher KM. Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. 2006;44:896-906
Dubuisson J (*see* Lavie M et al). 2006;44: 1626-1634
Durán JA (*see* Andrade RJ et al). 2006;44: 1581-1588
— (*see* Lucena MI et al). 2006;44:850-856
Durand F (*see* Bernuau J and Durand F). 2006;44:502-504 (Hepatology Elsewhere)
— (*see* Plessier A et al). 2006;44:1308-1316
Duverlie G (*see* Lavie M et al). 2006;44: 1626-1634

E

Edwards RE (*see* Grant GR et al). 2006;44: 174-185
Eggers B (*see* Colonno RJ et al). 2006;44: 1656-1665
Eichelbaum M (*see* Meier Y et al). 2006;44: 62-74
Eid P (*see* Vilasco M et al). 2006;44:1635-1647
Ekstedt M, Franzén LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, Kechagias S. Long-term follow-up of patients with NAFLD and elevated liver enzymes. 2006;44:865-873
El Gohary L (*see* Kamal S et al). 2006;44: 1051-1052 (Reply)
El Gohary LA (*see* Kamal SM et al). 2006; 44:1055-1056 (Correction)
El Naggar A (*see* Corpechot C et al). 2006; 44:513-514 (Correspondence)
Elferink RPJO (*see* Paulusma CC et al). 2006;44:195-204
Elias E. Hepatology Highlights. 2006;44: 519-520, 1374-1375
Emerick KM (*see* Knisely AS et al). 2006; 44:478-486
Engler D (*see* Bergasa NV et al). 2006;44: 1317-1323
Enomoto N (*see* Zheng DM et al). 2006; 44:1278-1287
Erceg S (*see* Jover R et al). 2006;44:771 (Correction)
Escorsell A (*see* Fernández J et al). 2006;44: 1288-1295
Esselin S (*see* Descamps D et al). 2006;44: 399-409
Esteban A (*see* Jover R et al). 2006;44:771 (Correction)
Esteban R (*see* González A et al). 2006;44: 806-812
Esteva-Font C, Baccaro ME, Fernández-Llama P, Sans L, Guevara M, Ars E, Jiménez W. Arroyo V, Ballarín JA, Ginès P. Aquaporin-1 and aquaporin-2 urinary excretion in cirrhosis: Relationship with ascites and hepatorenal syndrome. 2006;44:1555-1563
Everhart JE (*see* Morishima C et al). 2006; 44:360-367
Everson GT, Hoefs JC, Seeff LB, Bonkovsky HL, Naishadham D, Shiffman ML, Kahn JA, Lok ASF, Di Bisceglie AM, Lee WM, Dienstag JL, Ghany MG, Morishima C, HALT-C Trial Group. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C Trial. 2006;44:1675-1684
— (*see* Morishima C et al). 2006;44:360-367
Eyster ME (*see* Shire NJ et al). 2006;44: 1146-1157
Ezan F (*see* Bessard A et al). 2006;44:152-163

F

Fabris F (*see* Primignani M et al). 2006;44: 1528-1534
— (*see* Tripodi A et al). 2006;44:440-445
Factor VM (*see* Coulouarn C et al). 2006; 44:1003-1011
— (*see* Heo J et al). 2006;44:1478-1486
Falize L, Guillygomarc'h A, Perrin M, Lainé F, Guyader D, Brissot P, Turlin B, Deugnier Y. Reversibility of hepatic fibrosis in treated genetic hemochromatosis: A study of 36 cases. 2006;44:472-477
Fan ST (*see* Ho JWY et al). 2006;44:836-843
Fan YJ (*see* Ming Z et al). 2006;44:813-822
Fändrich F (*see* Schafmayer C et al). 2006; 44:650-657
Fang J (*see* Colonno RJ et al). 2006;44: 1656-1665
Farci P. Treatment of chronic hepatitis D: New advances, old challenges. 2006; 44:536-539 (Editorial)
Farges O (*see* Plessier A et al). 2006;44: 1308-1316
Fargion S (*see* Valenti L). 2006;44:857-864
Federspiel MJ (*see* Blechacz B et al). 2006; 44:1465-1477
Fehr J (*see* Kamal SM et al). 2006;44:1055-1056 (Correction)
Feinstone SM (*see* Heo J et al). 2006;44: 1478-1486
— (*see* Puig M et al). 2006;44:736-745
Feldstein AE (*see* Wieckowska A et al). 2006;44:27-33 (Rapid Communication)
Felipe V (*see* Fernández J et al). 2006;44: 1288-1295
Felipo V (*see* Jover R et al). 2006;44:771 (Correction)

Fernández J, Escorsell A, Zabalza M, Felipe V, Navasa M, Mas A, Lacy AM, Ginès P, Arroyo V. Adrenal insufficiency in patients with cirrhosis and septic shock: Effect of treatment with hydrocortisone on survival. 2006;44:1288-1295
Fernández M (*see* Matei V et al). 2006;44: 44-52
Fernández MC (*see* Andrade RJ et al). 2006;44:1581-1588
— (*see* Lucena MI et al). 2006;44:850-856
Fernandez-Checa JC (*see* Llacuna L et al). 2006;44:561-572
Fernández-Llama P (*see* Esteva-Font C et al). 2006;44:1555-1563
Ferrari C (*see* Lagging M et al). 2006;44: 1617-1625
— (*see* Urbani S et al). 2006;44:126-139
Ferrell LD (*see* Merriman RB). 2006;44: 874-880
Feucht HH (*see* van Bömmel F et al). 2006;44:318-325
Fischer C (*see* Wursthorn K et al). 2006;44: 675-684
Fischler B (*see* Knisely AS et al). 2006;44: 478-486
Fisicaro P (*see* Urbani S et al). 2006;44: 126-139
Floreani A (*see* Donaldson PT et al). 2006; 44:667-674
Fölsch UR (*see* Schafmayer C et al). 2006; 44:650-657
Fontana R (*see* Niro GA et al). 2006;44: 713-720
Fontana RJ, Kleiner DE, Bilonick R, Terrault N, Afdhal N, Belle SH, Jeffers LJ, Ramcharran D, Ghany MG, Hoofnagle JH, Virahep-C Study Group. Modeling hepatic fibrosis in African American and Caucasian American patients with chronic hepatitis C virus infection. 2006;44: 925-935
— (*see* Taylor RM et al). 2006;44:1589-1597
Fontenot AP (*see* Mack CL et al). 2006;44: 1231-1239
Forbes SJ and Alison MR. Side population (SP) cells: Taking center stage in regeneration and liver cancer?. 2006; 44:23-26 (Editorial)
Foster D (*see* Doyle SE et al). 2006;44:896-906
Fracanzani AL (*see* Valenti L). 2006;44: 857-864
Francés R (*see* Guarner C et al). 2006;44: 633-639
Franceschini B (*see* Grizzi F et al). 2006;44: 1701-1702 (Correspondence)
Francoz C (*see* Plessier A et al). 2006;44: 1308-1316
Franke A (*see* Schafmayer C et al). 2006; 44:650-657
Frantz RP (*see* Krowka MJ et al). 2006;44: 1502-1510
Franzén LE (*see* Ekstedt M et al). 2006;44: 865-873
Fraser R (*see* Warren A et al). 2006;44: 1182-1190
Frémin C (*see* Bessard A et al). 2006;44: 152-163
Frey FJ. Impaired 11β-hydroxysteroid dehydrogenase contributes to renal sodium avidity in cirrhosis: Hypothesis or fact?. 2006;44:795-801
Frezza EE (*see* Grizzi F et al). 2006;44: 1701-1702 (Correspondence)
Fujii T (*see* Zen Y et al). 2006;44:1333-1343
Fujiwara M (*see* Izuishi K et al). 2006;44: 573-580
Fukui H (*see* Kitade M et al). 2006;44:983-991
Fülöp P, Derdák Z, Sheets A, Sabo E, Berthiaume EP, Resnick MB, Wands JR, Paragh G, Baffy G. Lack of UCP2 reduces Fas-mediated liver injury in *ob/ob* mice and reveals importance of cell-specific UCP2 expression. 2006; 44:592-601
Fung JJ (*see* Chen CH et al). 2006;44: 1171-1181
Fung SK (*see* Yim HJ et al). 2006;44:703-712
Funk A, Mhamdi M, Hohenberg H, Will H, Sirma H. pH-Independent entry and sequential endosomal sorting are major determinants of hepadnaviral infection in primary hepatocytes. 2006;44:685-693
Furukawa Y (*see* Jinawath N et al). 2006; 44:1025-1038

G

Gamblin TC (*see* Koffron A et al). 2006; 44:1694-1700 (Special Article)
Gandhi CR (*see* Thirunavukkarasu C et al). 2006;44:389-398
Ganne-Carrié N, Ziol M, de Ledinghen V, Douvin C, Marcellin P, Castera L, Dhumeaux D, Trinchet JC, Beaugrand M. Accuracy of the measurement of liver stiffness for the diagnosis of cirrhosis in patients with chronic liver diseases. 2006;44:1511-1517
Gao B (*see* Jeong WI et al). 2006;44:1441-1451
— (*see* Sun R et al). 2006;44:955-966
Gao T (*see* Kneteman NM et al). 2006;44: 515 (Correction)
García-Ayllón MS (*see* Jover R et al). 2006; 44:771 (Correction)
García-Cortés M (*see* Andrade RJ et al). 2006;44:1581-1588
García-Muñoz B (*see* Andrade RJ et al). 2006;44:1581-1588
Garcia-Pagán JC (*see* Matei V et al). 2006; 44:44-52
Garcia-Ruiz C (*see* Llacuna L et al). 2006; 44:561-572
García-Ruiz I, Rodríguez-Juan C, Díaz-Sanjuan T, del Hoyo P, Colina F, Muñoz-Yagüe T, Solís-Herruzo JA. Uric acid and anti-TNF antibody improve mitochondrial dysfunction in ob/ob mice. 2006;44:581-591
Gault E (*see* Castelnau C et al). 2006;44: 728-735
Gaunitz F (*see* Werth M et al). 2006;44: 967-975
Gauthier F (*see* Serinet MO et al). 2006;44: 75-84
Gavrilova O (*see* Yim SH et al). 2006;44: 550-560
Gebhardt R and Ueberham E. Zonal gene expression in murine liver: Are tumors helping us to solve the mystery?. 2006;44:512 (Correspondence)
Gebhardt R (*see* Werth M et al). 2006;44: 967-975
Gehrmann T (*see* Graf D et al). 2006;44: 1206-1217
Geller D (*see* Koffron A et al). 2006;44: 1694-1700 (Special Article)
Genescà J (*see* González A et al). 2006;44: 806-812
Gentilcore E (*see* Bugianesi E et al). 2006; 44:1648-1655
George J (*see* Bugianesi E et al). 2006;44: 1648-1655
Gerken G (*see* Beuers U et al). 2006;44: 280-281 (Correspondence)
Gershwin ME (*see* Wakabayashi K et al). 2006;44:1240-1249
Ghany MG (*see* Everson GT et al). 2006; 44:1675-1684
— (*see* Fontana RJ et al). 2006;44:925-935
— (*see* Morishima C et al). 2006;44:360-367
Gianelli U (*see* Primignani M et al). 2006; 44:1528-1534
Gibson GJ (*see* Newton JL et al). 2006;44: 91-98
Gill RG (*see* Mack CL et al). 2006;44: 1231-1239
Ginès P (*see* Angeli P et al). 2006;44:1535-1542
— (*see* Esteva-Font C et al). 2006;44:1555-1563
— (*see* Fernández J et al). 2006;44:1288-1295
Ginsburg IH (*see* Bergasa NV et al). 2006; 44:1317-1323
Girona E (*see* Jover R et al). 2006;44:771 (Correction)
— (*see* Sugiyama M et al). 2006;44:915-924
Glaise D (*see* Zindy PJ et al). 2006;44: 1296-1307
Goldbach C (*see* Chen CH et al). 2006;44: 1171-1181
Golden-Mason L, Burton JR Jr, Castelblanco N, Klarquist J, Benlloch S, Wang C, Rosen HR. Loss of IL-7 receptor alpha-chain (CD127) expression in acute HCV infection

associated with viral persistence. 2006; 44:1098-1109
Goldina TA (*see* Coulouarn C et al). 2006; 44:1003-1011
Goldschmidt-Clermont PJ (*see* Choi SS et al). 2006;44:1267-1277
Gomez-Quiroz LE (*see* Coulouarn C et al). 2006;44:1003-1011
González A, Augustin S, Pérez M, Dot J, Saperas E, Tomasello A, Segarra A, Armengol JR, Malagelada JR, Esteban R, Guardia J, Genescà J. Hemodynamic response-guided therapy for prevention of variceal rebleeding: An uncontrolled pilot study. 2006;44:806-812
Gonzalez FJ (*see* Yim SH et al). 2006;44: 550-560
González-Aseguinolaza G (*see* Crettaz J et al). 2006;44:623-632
González-Navajas JM (*see* Guarner C et al). 2006;44:633-639
González-Peralta R (*see* Shneider BL et al). 2006;44:1344-1354 (Meeting Report)
Gopal K, Johnson TC, Gopal S, Walfish A, Bang CT, Suwandhi P, Pena-Sahdala HN, Clain DJ, Bodenheimer HC Jr, Min AD. Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment. 2006;44:335-340
Gopal S (*see* Gopal K et al). 2006;44:335-340
Gordien E (*see* Castelnau C et al). 2006;44: 728-735
Gores GJ (*see* Baskin-Bey ES et al). 2006; 44:252-262
— (*see* LaRusso NF). 2006;44:746-764 (Special Article)
Gottrand F (*see* Serinet MO et al). 2006; 44:75-84
Gouttenoire J, Penin F, Moradpour D. Surprises from the crystal structure of the hepatitis C virus NS2-3 protease. 2006;44:1690-1693 (Hepatology Elsewhere)
Govindarajan S (*see* Kawamura H et al). 2006;44:936-944
Grabarczyk P (*see* Brojer E et al). 2006;44: 1666-1674
Graf D, Kohlmann C, Haselow K, Gehrmann T, Bode JG, Häussinger D. Bile acids inhibit interleukin-6 signaling via gp130 receptor-dependent and -independent pathways in rat liver. 2006;44:1206-1217
Grant GR, Robinson SW, Edwards RE, Clothier B, Davies R, Judah DJ, Broman KW, Smith AG. Multiple polymorphic loci determine basal hepatic and splenic iron status in mice. 2006;44:174-185
Grayson D (*see* Raychaudhuri P et al). 2006;44:1364 (Obituary)
Grebely J, Conway B, Raffa JD, Lai C, Krajden M, Tyndall MW. Hepatitis C virus reinfection in injection drug users. 2006;44:1139-1145
Green K (*see* Smart DE et al). 2006;44: 1432-1440
Greenberg HB (*see* He XS et al). 2006;44: 352-359
Greiner S (*see* Blechacz B et al). 2006;44: 1465-1477
Grepper S (*see* Trottier J et al). 2006;44: 1158-1170
Gretch DR (*see* Morishima C et al). 2006; 44:360-367
Grimes CZ (*see* Hwang LY et al). 2006;44: 341-351
Grizzi F, Franceschini B, Musardo S, Frezza EE, Cobos E, Chiriva-Internati M. Pituitary tumor transforming gene 1 in the liver. 2006;44:1701-1702 (Correspondence)
Groen A (*see* Paulusma CC et al). 2006;44: 195-204
Grünelt E (*see* Chudy M et al). 2006;44: 99-107
Guardia J (*see* González A et al). 2006;44: 806-812
Guarner C, González-Navajas JM, Sánchez E, Soriando G, Francés R, Chiva M, Zapater P, Benlloch S, Muñoz C, Pascual S, Balanzó J, Pérez-Mateo M, Such J. The detection of bacterial DNA in blood of rats with CCl_4-induced cirrhosis with ascites represents episodes of bacterial translocation. 2006;44:633-639
— (*see* Andrade RJ et al). 2006;44:1581-1588
— (*see* Lucena MI et al). 2006;44:850-856
Guevara M (*see* Esteva-Font C et al). 2006; 44:1555-1563
Guha C (*see* Landis CS et al). 2006;44: 1250-1258
Guillygomarc'h A (*see* Falize L et al). 2006; 44:472-477
Guo Y (*see* He XS et al). 2006;44:352-359
— (*see* Zhao J et al). 2006;44:205-215
Gupta NA (*see* Ding X et al). 2006;44:515 (Correction)
Gupta S (*see* Joseph B et al). 2006;44: 1411-1420
— (*see* Wu YM et al). 2006;44:410-419
Gutiérrez A (*see* Jover R et al). 2006;44:771 (Correction)
Guyader D (*see* Falize L et al). 2006;44: 472-477

H

Haagmans BL (*see* Lagging M et al). 2006; 44:1617-1625
— (*see* ter Borg MJ et al). 2006;44:721-727
Hadziyannis SJ (*see* Laras A et al). 2006;44: 694-702
Hailfinger S, Jaworski M, Braeuning A, Buchmann A, Schwarz M. Zonal gene expression in murine liver: Are tumors helping us to solve the mystery?. 2006;44:512-513 (Reply)
Hakime A (*see* Plessier A et al). 2006;44: 1308-1316
Hale MB (*see* He XS et al). 2006;44:352-359
HALT-C Trial Group (*see* Everson GT et al). 2006;44:1675-1684
— (*see* Morishima C et al). 2006;44:360-367
Hampe J (*see* Schafmayer C et al). 2006;44: 650-657
Han SH (*see* Taylor RM et al). 2006;44: 1589-1597
Hansen BE (*see* ter Borg MJ et al). 2006; 44:721-727
Hardwick JP (*see* Moon KH et al). 2006; 44:1218-1230
Harrison SA (*see* Arnold HL and Harrison SA). 2006;44:1685-1686 (Hepatology Elsewhere)
Hasegawa K, Takayama T, Ijichi M, Matsuyama Y, Imamura H, Sano K, Sugawara Y, Kokudo N, Makuuchi M. Uracil-tegafur as an adjuvant for hepatocellular carcinoma: A randomized trial. 2006;44:891-895
Haselow K (*see* Graf D et al). 2006;44: 1206-1217
Hashash A (*see* Kneteman NM et al). 2006; 44:515 (Correction)
Häussinger D (*see* Graf D et al). 2006;44: 1206-1217
HBV 99-01 Study Group (*see* ter Borg MJ et al). 2006;44:721-727
HCC Italian Task Force (*see* Mazzaferro V et al). 2006;44:1543-1554
He XS, Ji X, Hale MB, Cheung R, Ahmed A, Guo Y, Nolan GP, Pfeffer LM, Wright TL, Risch N, Tibshirani R, Greenberg HB. Global transcriptional response to interferon is a determinant of HCV treatment outcome and is modified by race. 2006;44:352-359
Heathcote EJ (*see* Abdalian R and Heathcote EJ). 2006;44:1063-1074 (Perspectives in Clinical Hepatology)
Heller T (*see* Reshamwala PA et al). 2006; 44:7-14 (Perspectives in Clinical Hepatology)
Hellstrand K (*see* Lagging M et al). 2006; 44:1617-1625
Henderson K (*see* Doyle SE et al). 2006;44: 896-906
Heneghan MA (*see* Donaldson PT et al). 2006;44:667-674
Henry JP (*see* Lenaerts A et al). 2006;44: 844-849
Heo J, Factor VM, Uren T, Takahama Y, Lee JS, Major M, Feinstone SM, Thorgeirsson SS. Hepatic precursors derived from murine embryonic stem cells contribute to regeneration of injured liver. 2006;44:1478-1486
Hernández-Alcoceba R (*see* Crettaz J et al). 2006;44:623-632

Hetherington HP (*see* Landis CS et al). 2006;44:1250-1258
Hidalgo R (*see* Andrade RJ et al). 2006;44:1581-1588
Hige S (*see* Ozasa A et al). 2006;44:326-334
Hines IN (*see* Kremer M et al). 2006;44:216-227
Hino K (*see* Ozasa A et al). 2006;44:326-334
Hirayama T, Honda A, Matsuzaki Y, Miyazaki T, Ikegami T, Doy M, Xu G, Lea M, Salen G. Hypercholesterolemia in rats with hepatomas: Increased oxysterols accelerate efflux but do not inhibit biosynthesis of cholesterol. 2006;44:602-611
Ho JWY, Pang RWC, Lau C, Sun CK, Yu WC, Fan ST, Poon RTP. Significance of circulating endothelial progenitor cells in hepatocellular carcinoma. 2006;44:836-843
Hoeben KA (*see* Paulusma CC et al). 2006;44:195-204
Hoefs JC (*see* Everson GT et al). 2006;44:1675-1684
Hoek FJ (*see* Paulusma CC et al). 2006;44:195-204
Hoffman M (*see* Caldwell SH et al). 2006;44:1039-1046 (Special Article)
Hofmann AF (*see* Paulusma CC et al). 2006;44:195-204
Höhenberg H (*see* Funk A et al). 2006;44:685-693
Hol L (*see* Therapondos G et al). 2006;44:640-649
Holmqvist M (*see* Ekstedt M et al). 2006;44:865-873
Ho-Mok KS (*see* Paulusma CC et al). 2006;44:195-204
Honda A (*see* Hirayama T et al). 2006;44:602-611
— (*see* Zhang Y et al). 2006;44:612-622
Honda M, Yamashita T, Ueda T, Takatori H, Nishino R, Kaneko S. Different signaling pathways in the livers of patients with chronic hepatitis B or chronic hepatitis C. 2006;44:1122-1138
Hood BL (*see* Moon KH et al). 2006;44:1218-1230
Hoofnagle JH. The National Commission on Digestive Diseases. 2006;44:6 (This Month from the NIH)
— (*see* Fontana RJ et al). 2006;44:925-935
— (*see* LaRusso NF). 2006;44:746-764 (Special Article)
Horiguchi N (*see* Sun R et al). 2006;44:955-966
Horn PS (*see* Shire NJ et al). 2006;44:1146-1157
Hossain MA (*see* Izuishi K et al). 2006;44:573-580
Hou JL (*see* Zeng MD et al). 2006;44:108-116
Hourfar MK (*see* Chudy M et al). 2006;44:99-107
Hsi B (*see* Kneteman NM et al). 2006;44:515 (Correction)
Hsieh MY (*see* Yu ML et al). 2006;44:1086-1097
Hsu M (*see* Colonno RJ et al). 2006;44:1656-1665
Huang J (*see* Choi SS et al). 2006;44:1267-1277
Huang W (*see* Baskin-Bey ES et al). 2006;44:252-262
Hugh T (*see* Scarlett CJ et al). 2006;44:658-666
Hunt SP (*see* Lieu HT et al). 2006;44:1452-1464
Hüppe D (*see* van Bömmel F et al). 2006;44:318-325
Hussain M (*see* Antoniades CG et al). 2006;44:34-43
— (*see* Yim HJ et al). 2006;44:703-712
Hwang LY, Kramer JR, Troisi C, Bull L, Grimes CZ, Lyerla R, Alter MJ. Relationship of cosmetic procedures and drug use to hepatitis C and hepatitis B virus infections in a low-risk population. 2006;44:341-351
Hynan L (*see* Taylor RM et al). 2006;44:1589-1597
Hyodo I (*see* Zhang Y et al). 2006;44:612-622

I

Ijichi M (*see* Hasegawa K et al). 2006;44:891-895
Ikeda M, Abe K, Yamada M, Dansako H, Naka K, Kato N. Different anti-HCV profiles of statins and their potential for combination therapy with interferon. 2006;44:117-125
Ikegami T (*see* Hirayama T et al). 2006;44:602-611
— (*see* Zhang Y et al). 2006;44:612-622
Ikejima K (*see* Zheng DM et al). 2006;44:1278-1287
Ikenaka Y (*see* Kitade M et al). 2006;44:983-991
Ilyin G (*see* Bessard A et al). 2006;44:152-163
Imamura H (*see* Hasegawa K et al). 2006;44:891-895
Inaba TT (*see* Trottier J et al). 2006;44:1158-1170
Inoue K (*see* Ozasa A et al). 2006;44:326-334
Insausti R (*see* Jover R et al). 2006;44:771 (Correction)
Ishimura N (*see* Baskin-Bey ES et al). 2006;44:252-262
Isomoto H (*see* Baskin-Bey ES et al). 2006;44:252-262
Itatsu K (*see* Zen Y et al). 2006;44:1333-1343
Ito K (*see* Sugiyama M et al). 2006;44:915-924
Iwama A (*see* Chiba T et al). 2006;44:240-251
Iwan A (*see* Nattermann J et al). 2006;44:945-954
Izuishi K, Tsung A, Hossain MA, Fujiwara M, Wakabayashi H, Masaki T, Billiar TR, Maeta H. Ischemic preconditioning of the murine liver protects through the Akt kinase pathway. 2006;44:573-580
Izumi N (*see* Sugiyama M et al). 2006;44:915-924

J

Jacobs JM (*see* Diamond DL et al). 2006;44:299-308 (Science Frontier)
Jacobson JM (*see* Peters MG et al). 2006;44:1110-1116
Jacquemin E (*see* Serinet MO et al). 2006;44:75-84
Jaeschke H, Mullen K, Moradpour D. Hepatology Elsewhere. 2006;44:275-277, 502-510, 765-768, 1047-1050, 1362-1363, 1685-1693
James OFW (*see* Donaldson PT et al). 2006;44:667-674
James SP (*see* LaRusso NF). 2006;44:746-764 (Special Article)
Jankowska I (*see* Knisely AS et al). 2006;44:478-486
Janssen HLA and Leebeek FWG. JAK2 mutation: The best diagnostic tool for myeloproliferative disease in splanchnic vein thrombosis? 2006;44:1405-1407 (Editorial)
— (*see* Lisman T et al). 2006;44:53-61
— (*see* ter Borg MJ et al). 2006;44:721-727
— (*see* van der Molen RG et al). 2006;44:907-914
Jaworski M (*see* Hailfinger S et al). 2006;44:512-513 (Reply)
Jeffers LJ (*see* Fontana RJ et al). 2006;44:925-935
Jeong WI, Park O, Radaeva S, Gao B. STAT1 inhibits liver fibrosis in mice by inhibiting stellate cell proliferation and stimulating NK cell cytotoxicity. 2006;44:1441-1451
— (*see* Sun R et al). 2006;44:955-966
Ji BN (*see* Zeng MD et al). 2006;44:108-116
Ji X (*see* He XS et al). 2006;44:352-359
Jiménez W (*see* Esteva-Font C et al). 2006;44:1555-1563
Jin DY (*see* Yam JWP et al). 2006;44:881-890
Jin J (*see* Zhao J et al). 2006;44:205-215
Jinawath N, Chamgramol Y, Furukawa Y, Obama K, Tsunoda T, Sripa B, Pairojkul C, Nakamura Y. Comparison of gene expression profiles between *Opisthorchis viverr.ni* and non-*Opisthorchis viverrini* associated human intrahepatic

cholangiocarcinoma. 2006;44:1025-1038
Johnson KJ (*see* Olle EW et al). 2006;44:540-549
Johnson TC (*see* Gopal K et al). 2006;44:335-340
Johnson VA (*see* Peters MG et al). 2006;44:1110-1116
Jones D (*see* Newton JL et al). 2006;44:91-98
Jones DEJ (*see* Donaldson PT et al). 2006;44:667-674
Joseph B, Kumaran V, Berishvili E, Bhargava KK, Palestro CJ, Gupta S. Monocrotaline promotes transplanted cell engraftment and advances liver repopulation in rats via liver conditioning. 2006;44:1411-1420
— (*see* Wu YM et al). 2006;44:410-419
Jover R, Rodrigo R, Felipo V, Insausti R, Sáez-Valero J, García-Ayllón MS, Suárez I, Candela A, Compañ A, Esteban A, Cauli O, Ausó E, Rodríguez E, Gutiérrez A, Girona E, Erceg S, Berbel P, Pérez-Mateo M. Brain edema and inflammatory activation in bile duct ligated rats with diet-induced hyperammonemia: A model of hepatic encephalopathy in cirrhosis. 2006;44:771 (Correction)
Ju C (*see* You Q et al). 2006;44:1421-1431
Judah DJ (*see* Grant GR et al). 2006;44:174-185
Juran BD and Lazaridis KN. Genomics and complex liver disease: Challenges and opportunities. 2006;44:1380-1390 (Science Frontier)

K

Kaeding J (*see* Trottier J et al). 2006;44:1158-1170
— (*see* Verreault M et al). 2006;44:368-378
Kaestner KH (*see* Apte U et al). 2006;44:992-1002
Kahn JA (*see* Everson GT et al). 2006;44:1675-1684
Kaito M (*see* Sugiyama M et al). 2006;44:915-924
Kaji K (*see* Kitade M et al). 2006;44:983-991
Kakumu S (*see* Ozasa A et al). 2006;44:326-334
Kamal S, Khalifa K, Moustafa K, Koziel M, El Gohary L, Ramy A, Afdhal N. Treatment duration in acute hepatitis C: The issue is not solved yet. 2006;44:1051-1052 (Reply)
Kamal SM, Naggar KE, Chen J, Fehr J, Moneim AA, Khalifa KE, El Gohary LA, Ramy AH, Madwar MA, Rasenack J, Afdhal NH. Duration of peginterferon therapy in acute hepatitis C: A randomized trial. 2006;44:1055-1056 (Correction)
Kaneko S (*see* Honda M et al). 2006;44:1122-1138
Kang JH (*see* Ozasa A et al). 2006;44:326-334
Kao JH (*see* Liu CJ et al). 2006;44:770 (Correspondence)
Kaplan J (*see* Raychaudhuri P et al). 2006;44:1364 (Obituary)
Kaplowitz N. Hepatology Highlights. 2006;44:285-286, 1061-1062
—. Liver biology and pathobiology. 2006;44:282 (Correction)
— (*see* Andrade RJ et al). 2006;44:1581-1588
Kaposi-Novak P (*see* Coulouarn C et al). 2006;44:1003-1011
Kasashima S (*see* Zen Y et al). 2006;44:1333-1343
Katayanagi K (*see* Zen Y et al). 2006;44:1333-1343
Kato N (*see* Ikeda M et al). 2006;44:117-125
Kato T (*see* Kimata T et al). 2006;44:140-151
— (*see* Sugiyama M et al). 2006;44:915-924
Katze MG (*see* Diamond DL et al). 2006;44:299-308 (Science Frontier)
Kawabe T (*see* Tateishi R et al). 2006;44:1518-1527
Kawamura H, Govindarajan S, Aswad F, Machida K, Lai MMC, Sung VMH, Dennert G. HCV core expression in hepatocytes protects against autoimmune liver injury and promotes liver regeneration in mice. 2006;44:936-944
Kawashima A (*see* Zen Y et al). 2006;44:1333-1343
Kebede M (*see* Lieu HT et al). 2006;44:1452-1464
Kechagias S (*see* Ekstedt M et al). 2006;44:865-873
Keiding S (*see* Prytz H et al). 2006;44:1572-1580
— (*see* Sørensen M and Keiding S). 2006;44:1053-1054 (Reply)
Kemmer N (*see* Blackard JT et al). 2006;44:15-22 (Concise Review in Mechanisms of Disease)
Kennedy SM (*see* Newberry EP et al). 2006;44:1191-1205
Keryanov S (*see* Luo JH et al). 2006;44:1012-1024
Khalifa K (*see* Kamal S et al). 2006;44:1051-1052 (Reply)
Khalifa KE (*see* Kamal SM et al). 2006;44:1055-1056 (Correction)
Khuu-Duong K (*see* Doyle SE et al). 2006;44:896-906
Kim BJ (*see* Moon KH et al). 2006;44:1218-1230
Kimata T, Nagaki M, Ogiso T, Naiki T, Kato T, Moriwaki H. Actin organization and hepatocyte differentiation are regulated by extracellular matrix via PI-4,5-bisphosphate in the rat. 2006;44:140-151
Kita K (*see* Chiba T et al). 2006;44:240-251
Kitade M, Yoshiji H, Kojima H, Ikenaka Y, Noguchi R, Kaji K, Yoshii J, Yanase K, Namisaki T, Asada K, Yamazaki M, Tsujimoto T, Akahane T, Uemura M, Fukui H. Leptin-mediated neovascularization is a prerequisite for progression of nonalcoholic steatohepatitis in rats. 2006;44:983-991
Kitamura T (*see* Zheng DM et al). 2006;44:1278-1287
Klarquist J (*see* Golden-Mason L et al). 2006;44:1098-1109
Klein K (*see* Meier Y et al). 2006;44:62-74
Kleiner DE (*see* Fontana RJ et al). 2006;44:925-935
— (*see* Reshamwala PA et al). 2006;44:7-14 (Perspectives in Clinical Hepatology)
Klesczewski K (*see* Colonno RJ et al). 2006;44:1656-1665
Kline J (*see* Kneteman NM et al). 2006;44:515 (Correction)
Klucher KM (*see* Doyle SE et al). 2006;44:896-906
Kneteman NM, Weiner AJ, O'Connell J, Collett M, Gao T, Aukerman L, Kovelsky R, Ni ZJ, Hashash A, Kline J, Hsi B, Schiller D, Douglas D, Tyrrell DLJ, Mercer DF. Anti-HCV therapies in chimeric *scid*-Alb/uPA mice parallel outcomes in human clinical application. 2006;44:515 (Correction)
Knisely AS, Strautnieks SS, Meier Y, Stieger B, Byrne JA, Portmann BC, Bull LN, Pawlikowska L, Bilezikçi B, Özçay F, László A, Tiszlavicz L, Moore L, Raftos J, Arnell H, Fischler B, Németh A, Papadogiannakis N, Cielecka-Kuszyk J, Jankowska I, Pawlowska J, Melín-Aldana H, Emerick KM, Whitington PF, Mieli-Vergani G, Thompson RJ. Hepatocellular carcinoma in ten children under five years of age with bile salt export pump deficiency. 2006;44:478-486
— (*see* Paulusma CC et al). 2006;44:195-204
Knolle P (*see* Schmitz V et al). 2006;44:430-439
Ko FCF (*see* Yam JWP et al). 2006;44:881-890
Kochanek S (*see* Crettaz J et al). 2006;44:623-632
Koff RS. Fulminant hepatitis A: Disappearing, but not soon enough. 2006;44:1397-1399 (Editorial)
Koffron A, Geller D, Gamblin TC, Abecassis M. Laparoscopic liver surgery: Shifting the management of

liver tumors. 2006;44:1694-1700 (Special Article)
Kohlmann C (*see* Graf D et al). 2006;44: 1206-1217
Kojima H (*see* Kitade M et al). 2006;44: 983-991
Kokudo N (*see* Hasegawa K et al). 2006; 44:891-895
Koretsky A (*see* Landis CS et al). 2006;44: 1250-1258
Koskinas J (*see* Laras A et al). 2006;44:694-702
Kostamena A (*see* Laras A et al). 2006;44: 694-702
Kovelsky R (*see* Kneteman NM et al). 2006;44:515 (Correction)
Koziel M (*see* Kamal S et al). 2006;44: 1051-1052 (Reply)
Krajden M (*see* Grebely J et al). 2006;44: 1139-1145
Kramer JR (*see* Hwang LY et al). 2006;44: 341-351
Kramvis A (*see* Sugiyama M et al). 2006; 44:915-924
Kremer B (*see* Schafmayer C et al). 2006; 44:650-657
Kremer M, Hines IN, Milton RJ, Wheeler MD. Favored T helper 1 response in a mouse model of hepatosteatosis is associated with enhanced T cell-mediated hepatitis. 2006;44:216-227
—, Swanson KL, Frantz RP, McGoon MD, Wiesner RH. Portopulmonary hypertension: Results from a 10-year screening algorithm. 2006;44:1502-1510
Kubes P (*see* McAvoy EF and Kubes P). 2006;44:1083-1085 (Editorial)
Kuiken C, Combet C, Bukh J, Shin-I T, Deleage G, Mizokami M, Richardson R, Sablon E, Yusim K, Pawlotsky JM, Simmonds P, Los Alamos HIV database group. A comprehensive system for consistent numbering of HCV sequences, proteins and epitopes. 2006;44:1355-1361
Kulkarni S (*see* Sun R et al). 2006;44:955-966
Kumaran V (*see* Joseph B et al). 2006;44: 1411-1420
Kunne C (*see* Paulusma CC et al). 2006; 44:195-204
Kuo LM (*see* Chen CH et al). 2006;44: 1171-1181
Kuramitsu T (*see* Ozasa A et al). 2006;44: 326-334
Kurumaya H (*see* Zen Y et al). 2006;44: 1333-1343
Kusters JG (*see* van der Molen RG et al). 2006;44:907-914

L

Lachaux A (*see* Serinet MO et al). 2006;44: 75-84
Lacy AM (*see* Fernández J et al). 2006;44: 1288-1295
Lafdil F, Chobert MN, Couchie D, Brouillet A, Zafrani ES, Mavier P, Laperche Y. Induction of Gas6 protein in CCl_4-induced rat liver injury and anti-apoptotic effect on hepatic stellate cells. 2006;44:228-239
Lagging M, Romero AI, Westin J, Norkrans G, Dhillon AP, Pawlotsky JM, Zeuzem S, von Wagner M, Negro F, Schalm SW, Haagmans BL, Ferrari C, Missale G, Neumann AU, Verheij-Hart E, Hellstrand K, DITTO-HCV Study Group. IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. 2006;44:1617-1625
Lai C (*see* Grebely J et al). 2006;44:1139-1145
Lai MMC (*see* Kawamura H et al). 2006; 44:936-944
Lainé F (*see* Falize L et al). 2006;44:472-477
Lambert G (*see* Yim SH et al). 2006;44: 550-560
Lammert F (*see* Schafmayer C et al). 2006; 44:650-657
Lan RY (*see* Wakabayashi K et al). 2006; 44:1240-1249
Landis CS, Yamanouchi K, Zhou H, Mohan S, Roy-Chowdhury N, Shafritz DA, Koretsky A, Roy-Chowdhury J, Hetherington HP, Guha C. Noninvasive evaluation of liver repopulation by transplanted hepatocytes using ^{31}P MRS imaging in mice. 2006;44:1250-1258
Langhans B (*see* Nattermann J et al). 2006; 44:945-954
Lankisch TO, Moebius U, Wehmeier M, Behrens G, Manns MP, Schmidt RE, Strassburg CP. Gilbert's disease and atazanavir: From phenotype to UDP-glucuronosyltransferase haplotype. 2006;44:1324-1332
Laperche Y (*see* Lafdil F et al). 2006;44: 228-239
Laras A, Koskinas J, Dimou E, Kostamena A, Hadziyannis SJ. Intrahepatic levels and replicative activity of covalently closed circular hepatitis B virus DNA in chronically infected patients. 2006; 44:694-702
Larrea E (*see* Vilasco M et al). 2006;44: 1635-1647
Larsen FS (*see* Wendon JA and Larsen FS). 2006;44:504-506 (Hepatology Elsewhere)
Larson AM (*see* Taylor RM et al). 2006;44: 1589-1597
LaRusso NF, Shneider BL, Black D, Gores GJ, James SP, Doo E, Hoofnagle JH. Primary sclerosing cholangitis: Summary of a workshop. 2006;44: 746-764 (Special Article)
— (*see* Blechacz B et al). 2006;44:1465-1477
Lash TL (*see* Sørensen HT et al). 2006;44: 1075-1082
László A (*see* Knisely AS et al). 2006;44: 478-486
Latendresse JR (*see* Limaye PB et al). 2006; 44:379-388
Lau C (*see* Ho JWY et al). 2006;44:836-843
Lau LF (*see* Raychaudhuri P et al). 2006; 44:1364 (Obituary)
Lautt WW (*see* Ming Z et al). 2006;44: 813-822
Lavie M, Voisset C, Vu-Dac N, Zurawski V, Duverlie G, Wychowski C, Dubuisson J. Serum amyloid A has an antiviral activity against hepatitis C virus by inhibiting virus entry in a cell culture system. 2006;44:1626-1634
Lazaridis KN (*see* Juran BD and Lazaridis KN). 2006;44:1380-1390 (Science Frontier)
Le Béchec A (*see* Zindy PJ et al). 2006;44: 1296-1307
Le Couteur DG (*see* Warren A et al). 2006; 44:1182-1190
Le Gal F (*see* Castelnau C et al). 2006;44: 728-735
Lea M (*see* Hirayama T et al). 2006;44: 602-611
Lee CM (*see* Yu ML et al). 2006;44:1086-1097
Lee JS (*see* Coulouarn C et al). 2006;44: 1003-1011
— (*see* Heo J et al). 2006;44:1478-1486
Lee LP (*see* Yu ML et al). 2006;44:1086-1097
Lee WM (*see* Everson GT et al). 2006;44: 1675-1684
— (*see* Morishima C et al). 2006;44:360-367
— (*see* Taylor RM et al). 2006;44:1589-1597
Leebeek FWG (*see* Janssen HLA and Leebeek FWG). 2006;44:1391-1393 (Editorial)
— (*see* Lisman T et al). 2006;44:53-61
Léger J (*see* Zindy PJ et al). 2006;44:1296-1307
Leifeld L (*see* Nattermann J et al). 2006;44: 945-954
— (*see* Schmitz V et al). 2006;44:430-439
Lenaerts A, Codden T, Meunier JC, Henry JP, Ligny G. Effects of clonidine on diuretic response in ascitic patients with cirrhosis and activation of sympathetic nervous system. 2006;44: 844-849
Letowska M (*see* Brojer E et al). 2006;44: 1666-1674
Leung THY (*see* Yam JWP et al). 2006;44: 881-890
Levine S (*see* Colonno RJ et al). 2006;44: 1656-1665
Levitsky J. Probiotics: Application of "healthy" bacteria to liver transplant recipients. 2006;44:507-510 (Hepatology Elsewhere)

L'Helgoulc'h A (*see* Zindy PJ et al). 2006; 44:1296-1307
Li YX (*see* Choi SS et al). 2006;44:1267-1277
Lian ZX (*see* Wakabayashi K et al). 2006; 44:1240-1249
Liang TJ. Supporting the NIH before it is too late. 2006;44:1-2 (Editor's Corner)
— (*see* Barth H et al). 2006;44:527-535 (Concise Review in Mechanisms of Disease)
Liaw YF (*see* Yu ML et al). 2006;44:1086-1097
Lieb S (*see* Schafmayer C et al). 2006;44: 650-657
Liedtke C (*see* Zschemisch NH et al). 2006;44:164-173
Lieu HT, Simon MT, Nguyen-Khoa T, Kebede M, Cortes A, Tebar L, Smith AJH, Bayne R, Hunt SP, Bréchot C, Christa L. Reg2 inactivation increases sensitivity to Fas hepatotoxicity and delays liver regeneration post-hepatectomy in mice. 2006;44:1452-1464
Ligny G (*see* Lenaerts A et al). 2006;44: 844-849
Limaye PB, Bhave VS, Palkar PS, Apte UM, Sawant SP, Yu S, Latendresse JR, Reddy JK, Mehendale HM. Upregulation of calpastatin in regenerating and developing rat liver: Role in resistance against hepatotoxicity. 2006;44:379-388
Lin S (*see* Ding X et al). 2006;44:515 (Correction)
Lin SM (*see* Yu ML et al). 2006;44:1086-1097
Lin ZY (*see* Yu ML et al). 2006;44:1086-1097
Lindsay KL (*see* Morishima C et al). 2006; 44:360-367
Lisman T, Bongers TN, Adelmeijer J, Janssen HLA, de Maat, MPM, de Groot PG, Leebeek FWG. Elevated levels of von Willebrand factor in cirrhosis support platelet adhesion despite reduced functional capacity. 2006;44:53-61
— (*see* Caldwell SH et al). 2006;44:1039-1046 (Special Article)
Liszewski G (*see* Brojer E et al). 2006;44: 1666-1674
Liu CJ, Kao JH, Chen DS. Mixed hepatitis B virus genotype infections: The more, the worse?. 2006;44:770 (Correspondence)
Liu H (*see* Doyle SE et al). 2006;44:896-906
Liu T (*see* Peters MG et al). 2006;44:1110-1116
Liu Y (*see* Apte U et al). 2006;44:992-1002
— (*see* Yim HJ et al). 2006;44:703-712
Llacuna L, Marí M, Garcia-Ruiz C, Fernandez-Checa JC, Morales A. Critical role of acidic sphingomyelinase in murine hepatic ischemia-reperfusion injury. 2006;44: 561-572
Llovet JM (*see* Mazzaferro V et al). 2006; 44:1543-1554
Lockwood AH and Wack DS. The brain permeability-surface product for ammonia. 2006;44:1052-1053 (Correspondence)
Logan L (*see* Zein CO et al). 2006;44: 1564-1571
Lok ASF (*see* Everson GT et al). 2006;44: 1675-1684
— (*see* Morishima C et al). 2006;44:360-367
— (*see* Wong SN and Lok ASF). 2006;44: 309-313 (Editorial)
— (*see* Yim HJ et al). 2006;44:703-712
Lombardini S (*see* Carulli L et al). 2006;44: 278-279 (Correspondence)
Lonardo A (*see* Carulli L et al). 2006;44: 278-279 (Correspondence)
Longerich T (*see* Wursthorn K et al). 2006; 44:675-684
Lopez AR (*see* Wieckowska A et al). 2006; 44:27-33 (Rapid Communication)
Loréal O (*see* Zindy PJ et al). 2006;44: 1296-1307
Loria P (*see* Carulli L et al). 2006;44:278-279 (Correspondence)
— (*see* Valenti L). 2006;44:857-864
Los Alamos HIV database group (*see* Kuiken C et al). 2006;44:1355-1361
Lu BR (*see* Mack CL et al). 2006;44:1231-1239
Lu L (*see* Chen CH et al). 2006;44:1171-1181
Lu Y and Cederbaum AI. Enhancement by pyrazole of lipopolysaccharide-induced liver injury in mice: Role of cytochrome P450 2E1 and 2A5. 2006;44:263-274
Lucena MI, Andrade RJ, Fernández MC, Pachkoria K, Pelaez G, Durán JA, Villar M, Rodrigo L, Romero-Gomez M, Planas R, Barriocanal A, Costa J, Guarner C, Blanco S, Navarro JM, Pons F, Castiella A, Avila S, Spanish Group for the Study of Drug-Induced Liver Disease (Grupo de Estudio para las Hepatopatías Asociadas a Medicamentos (GEHAM)). Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: A prospective series from Spain. 2006;44:850-856
— (*see* Andrade RJ et al). 2006;44:1581-1588
Luo J (*see* Newberry EP et al). 2006;44: 1191-1205
Luo JH, Ren B, Keryanov S, Tseng GC, Rao UNM, Monga SP, Strom S, Demetris AJ, Nalesnik M, Yu YP, Ranganathan S, Michalopoulos GK. Transcriptomic and genomic analysis of human hepatocellular carcinomas and hepatoblastomas. 2006;44:1012-1024
Lutgehetmann M (*see* Wursthorn K et al). 2006;44:675-684
Lyerla R (*see* Hwang LY et al). 2006;44: 341-351
Lynch P (*see* Peters MG et al). 2006;44: 1110-1116

M

Ma W (*see* Choi SS et al). 2006;44:1267-1277
Ma Y (*see* Tang W et al). 2006;44:1259-1266
Machida K (*see* Kawamura H et al). 2006; 44:936-944
Macik BG (*see* Caldwell SH et al). 2006; 44:1039-1046 (Special Article)
Mack CL, Tucker RM, Lu BR, Sokol RJ, Fontenot AP, Ueno Y, Gill RG. Cellular and humoral autoimmunity directed at bile duct epithelia in murine biliary atresia. 2006;44:1231-1239
Mackay IR (*see* Wakabayashi K et al). 2006;44:1240-1249
Madden AM (*see* Morgan MY et al). 2006; 44:823-835
Madwar MA (*see* Kamal SM et al). 2006; 44:1055-1056 (Correction)
Maeta H (*see* Izuishi K et al). 2006;44:573-580
Maggioni M (*see* Valenti L). 2006;44:857-864
Majno P (*see* Mazzaferro V et al). 2006;44: 1543-1554
Major M (*see* Heo J et al). 2006;44:1478-1486
Major ME (*see* Puig M et al). 2006;44:736-745
Makuuchi M (*see* Hasegawa K et al). 2006; 44:891-895
Malagelada JR (*see* González A et al). 2006; 44:806-812
Mallet V (*see* Vallet-Pichard A et al). 2006; 44:769 (Correspondence)
Mandrekar P (*see* Szabo G et al). 2006;44: 287-298 (Concise Review in Mechanisms of Disease)
Mann DA (*see* Smart DE et al). 2006;44: 1432-1440
Mann J (*see* Smart DE et al). 2006;44: 1432-1440
Manns M (*see* Wedemeyer H et al). 2006; 44:511-512 (Reply), 1051 (Correspondence)
Manns MP (*see* Lankisch TO et al). 2006; 44:1324-1332
— (*see* Zschemisch NH et al). 2006;44: 164-173
Mannucci PM (*see* Primignani M et al). 2006;44:1528-1534
— (*see* Tripodi A et al). 2006;44:440-445
Mao YM (*see* Zeng MD et al). 2006;44: 108-116

Marcellin P (*see* Castelnau C et al). 2006; 44:728-735
— (*see* Ganne-Carrié N et al). 2006;44: 1511-1517
Marcellini M (*see* Nobili V et al). 2006;44: 458-465
Marchesini G (*see* Bugianesi E et al). 2006; 44:1648-1655
— (*see* Carulli L et al). 2006;44:278-279 (Correspondence)
Marí M (*see* Llacuna L et al). 2006;44:561-572
Mariani L (*see* Mazzaferro V et al). 2006; 44:1543-1554
Marrone A (*see* Niro GA et al). 2006;44: 713-720
Martinot-Peignoux M (*see* Castelnau C et al). 2006;44:728-735
Mas A (*see* Fernández J et al). 2006;44: 1288-1295
Masaki T (*see* Izuishi K et al). 2006;44: 573-580
Mason AL. An autoimmune biliary disease mouse model for primary biliary cirrhosis: Something for everyone. 2006;44:1047-1050 (Hepatology Elsewhere)
Masuda S (*see* Zen Y et al). 2006;44:1333-1343
Matei V, Rodríguez-Vilarrupla A, Deulofeu R, Colomer D, Fernández M, Bosch J, Garcia-Pagán JC. The eNOS cofactor tetrahydrobiopterin improves endothelial dysfunction in livers of rats with CCl_4 cirrhosis. 2006;44:44-52
Mathiesen UL (*see* Ekstedt M et al). 2006; 44:865-873
Matsuyama Y (*see* Hasegawa K et al). 2006; 44:891-895
Matsuzaki Y (*see* Hirayama T et al). 2006; 44:602-611
— (*see* Zhang Y et al). 2006;44:612-622
Mauleón I (*see* Crettaz J et al). 2006;44: 623-632
Mavier P (*see* Lafdil F et al). 2006;44:228-239
Maylin S (*see* Castelnau C et al). 2006;44: 728-735
Mazzaferro V, Romito R, Schiavo M, Mariani L, Camerini T, Bhoori S, Capussotti L, Callise F, Pellicci R, Belli G, Tagger A, Colombo M, Bonino F, Majno P, Llovet JM, HCC Italian Task Force. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. 2006;44: 1543-1554
Mazzucco C (*see* Colonno RJ et al). 2006; 44:1656-1665
McAvoy EF and Kubes P. Holey endothelium: Gateways for naïve T cell activation. 2006;44:1083-1085 (Editorial)
McCaughan GW (*see* Warren A et al). 2006;44:1182-1190
McClintock SD (*see* Olle EW et al). 2006; 44:540-549
McCullough AJ (*see* Wieckowska A et al). 2006;44:27-33 (Rapid Communication)
— (*see* Zein CO et al). 2006;44:1564-1571
McGee M (*see* Bergasa NV et al). 2006;44: 1317-1323
McGoon MD (*see* Krowka MJ et al). 2006; 44:1502-1510
McGuire B (*see* Taylor RM et al). 2006;44: 1589-1597
McHutchison JG (*see* Muir AJ and McHutchison JG). 2006;44:1400-1403 (Editorial)
Mehendale HM (*see* Limaye PB et al). 2006;44:379-388
Meier PJ (*see* Meier Y et al). 2006;44:62-74
— (*see* Pauli-Magnus C and Meier PJ). 2006;44:778-787
Meier Y, Pauli-Magnus C, Zanger UM, Klein K, Schaeffeler E, Nussler AK, Nussler N, Eichelbaum M, Meier PJ, Stieger B. Interindividual variability of canalicular ATP-binding-cassette (ABC)-transporter expression in human liver. 2006;44:62-74
— (*see* Knisely AS et al). 2006;44:478-486
Melín-Aldana H (*see* Knisely AS et al). 2006;44:478-486
Mendoza M and Younossi Z. Diabetic hepatosclerosis: A novel entity or a rare form of nonalcoholic fatty liver disease?. 2006;44:1362-1363 (Hepatology Elsewhere)
Mercer DF (*see* Kneteman NM et al). 2006;44:515 (Correction)
Merchlinsky M (*see* Puig M et al). 2006;44: 736-745
Merriman RB, Ferrell LD, Patti MG, Weston SR, Pabst MS, Aouizerat BE, Bass NM. Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease. 2006;44.874-880
Metzler F (*see* Wursthorn K et al). 2006; 44:675-684
Meunier JC (*see* Lenaerts A et al). 2006;44: 844-849
Meurs EF (*see* Vilasco M et al). 2006;44: 1635-1647
Mhamdi M (*see* Funk A et al). 2006;44: 685-693
Michalopoulos GK (*see* Bell AW and Michalopoulos GK). 2006;44:186-194
— (*see* Luo JH et al). 2006;44:1012-1024
Micsenyi A (*see* Apte U et al). 2006;44: 992-1002
Mieli-Vergani G (*see* Knisely AS et al). 2006;44:478-486
Mihalik K (*see* Puig M et al). 2006;44:736-745
Mihm S (*see* Doyle SE et al). 2006;44:896-906
Mikulska M (*see* Brojer E et al). 2006;44: 1666-1674
Millward-Sadler H (*see* Smart DE et al). 2006;44:1432-1440
Milton RJ (*see* Kremer M et al). 2006;44: 216-227
Min AD (*see* Gopal K et al). 2006;44:335-340
Minato H (*see* Zen Y et al). 2006;44:1333-1343
Ming Z, Fan YJ, Yang X, Lautt WW. Contribution of hepatic adenosine A_1 receptors to renal dysfunction associated with acute liver injury in rats. 2006;44:813-822
Missale G (*see* Lagging M et al). 2006;44: 1617-1625
— (*see* Urbani S et al). 2006;44:126-139
Mitsui T (*see* Zen Y et al). 2006;44:1333-1343
Miura S (*see* Zen Y et al). 2006;44:1333-1343
Miyakawa Y (*see* Ozasa A et al). 2006;44: 326-334
— (*see* Sugiyama M et al). 2006;44:915-924
Miyazaki T (*see* Hirayama T et al). 2006; 44:602-611
— (*see* Zhang Y et al). 2006;44:612-622
Mizokami M (*see* Kuiken C et al). 2006;44: 1355-1361
— (*see* Ozasa A et al). 2006;44:326-334
— (*see* Sugiyama M et al). 2006;44:915-924
Moebius U (*see* Lankisch TO et al). 2006; 44:1324-1332
Mohan S (*see* Landis CS et al). 2006;44: 1250-1258
Moneim AA (*see* Kamal SM et al). 2006; 44:1055-1056 (Correction)
Monga SP (*see* Luo JH et al). 2006;44: 1012-1024
Monga SPS (*see* Apte U et al). 2006;44: 992-1002
Monté D (*see* Trottier J et al). 2006;44: 1158-1170
Moon KH, Hood BL, Kim BJ, Hardwick JP, Conrads TP, Veenstra TD, Song BJ. Inactivation of oxidized and S-nitrosylated mitochondrial proteins in alcoholic fatty liver of rats. 2006;44: 1218-1230
Moore DD (*see* Baskin-Bey ES et al). 2006; 44:252-262
Moore L (*see* Knisely AS et al). 2006;44: 478-486
Moradpour D (*see* Bellecave P and Moradpour D). 2006;44:1687-1689 (Hepatology Elsewhere)
— (*see* Gouttenoire J et al). 2006;44:1690-1693 (Hepatology Elsewhere)
— (*see* Jaeschke H et al). 2006;44:275-277, 502-510, 765-768, 1047-1050, 1362-1363, 1685-1693
Morales A (*see* Llacuna L et al). 2006;44: 561-572
Morgan MY, Madden AM, Soulsby CT, Morris RW. Derivation and validation of a new global method for

assessing nutritional status in patients with cirrhosis. 2006;44:823-835
Morgan TR (*see* Morishima C et al). 2006; 44:360-367
Mori C (*see* Urbani S et al). 2006;44:126-139
Morishima C, Morgan TR, Everhart JE, Wright EC, Shiffman ML, Everson GT, Lindsay KL, Lok ASF, Bonkovsky HL, Di Bisceglie AM, Lee WM, Dienstag JL, Ghany MG, Gretch DR, HALT-C Trial Group. HCV RNA detection by TMA during the Hepatitis C Antiviral Long-term Treatment against Cirrhosis (Halt-C) Trial. 2006;44:360-367
— (*see* Everson GT et al). 2006;44:1675-1684
Moritoki Y (*see* Wakabayashi K et al). 2006;44:1240-1249
Moriwaki H (*see* Kimata T et al). 2006;44: 140-151
Morris HD (*see* Yim SH et al). 2006;44: 550-560
Morris RW (*see* Morgan MY et al). 2006; 44:823-835
Mosebach M (*see* Chudy M et al). 2006;44: 99-107
Moustafa K (*see* Kamal S et al). 2006;44: 1051-1052 (Reply)
Muir AJ and McHutchison JG. Growth factors during HCV therapy may be "cost-effective," but are they "effective"?. 2006;44:1400-1403 (Editorial)
Mullen K (*see* Jaeschke H et al). 2006;44: 275-277, 502-510, 765-768, 1047-1050, 1362-1363, 1685-1693
Muller P (*see* Apte U et al). 2006;44:992-1002
Multicenter Hemophilia Cohort HCV Study Group (*see* Shire NJ et al). 2006;44:1146-1157
Munk OL (*see* Prytz H et al). 2006;44: 1572-1580
Muñoz C (*see* Guarner C et al). 2006;44: 633-639
Munoz S (*see* Taylor RM et al). 2006;44: 1589-1597
Muñoz-Yagüe T (*see* Andrade RJ et al). 2006;44:1581-1588
— (*see* García-Ruiz I et al). 2006;44:581-591
Murawaki Y (*see* Ozasa A et al). 2006;44: 326-334
Murray JM, Purcell RH, Wieland SF. The half-life of hepatitis B virus. 2006;44: 1117-1121 (Concise Communication)
Musardo S (*see* Grizzi F et al). 2006;44: 1701-1702 (Correspondence)
Musso O (*see* Zindy PJ et al). 2006;44: 1296-1307
Myers R (*see* Blechacz B et al). 2006;44: 1465-1477

N

Nagaki M (*see* Kimata T et al). 2006;44: 140-151
Naggar KE (*see* Kamal SM et al). 2006;44: 1055-1056 (Correction)
Naiki T (*see* Kimata T et al). 2006;44:140-151
Naishadham D (*see* Everson GT et al). 2006;44:1675-1684
Naka K (*see* Ikeda M et al). 2006;44:117-125
Nakamura K (*see* Zen Y et al). 2006;44: 1333-1343
Nakamura Y (*see* Jinawath N et al). 2006; 44:1025-1038
Nakanuma Y (*see* Zen Y et al). 2006;44: 1333-1343
Nakauchi H (*see* Chiba T et al). 2006;44: 240-251
Nalesnik M (*see* Luo JH et al). 2006;44: 1012-1024
Namisaki T (*see* Kitade M et al). 2006;44: 983-991
Nattermann J, Zimmermann H, Iwan A, von Lilienfeld-Toal M, Leifeld L, Nischalke HD, Langhans B, Sauerbruch T, Spengler U. Hepatitis C virus E2 and CD81 interaction may be associated with altered trafficking of dendritic cells in chronic hepatitis C. 2006;44:945-954
Navarro JM (*see* Lucena MI et al). 2006; 44:850-856
Navasa M (*see* Fernández J et al). 2006;44: 1288-1295
Negro F (*see* Lagging M et al). 2006;44: 1617-1625
Németh A (*see* Knisely AS et al). 2006;44: 478-486
Neumann AU (*see* Lagging M et al). 2006; 44:1617-1625
Nevzorova YA (*see* Zschemisch NH et al). 2006;44:164-173
Newberry EP, Xie Y, Kennedy SM, Luo J, Davidson NO. Protection against Western diet–induced obesity and hepatic steatosis in liver fatty acid–binding protein knockout mice. 2006; 44:1191-1205
Newton JL, Gibson GJ, Tomlinson M, Wilton K, Jones D. Fatigue in primary biliary cirrhosis is associated with excessive daytime somnolence. 2006;44:91-98
Ng IOL (*see* Yam JWP et al). 2006;44:881-890
Nguyen-Khoa T (*see* Lieu HT et al). 2006; 44:1452-1464
Ni H (*see* Zhao J et al). 2006;44:205-215
Ni ZJ (*see* Kneteman NM et al). 2006;44: 515 (Correction)
Nick S (*see* Chudy M et al). 2006;44:99-107
Nielsen AQ (*see* Scarlett CJ et al). 2006;44: 658-666
Nieto N. Oxidative-stress and IL-6 mediate the fibrogenic effects of rodent Kupffer cells on stellate cells. 2006;44: 1487-1501
Niro GA, Ciancio A, Battista Gaeta G, Smedile A, Marrone A, Olivero A, Stanzione M, David E, Brancaccio G, Fontana R, Perri F, Andriulli A, Rizzetto M. Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. 2006;44:713-720
Nischalke HD (*see* Nattermann J et al). 2006;44:945-954
Nishino R (*see* Honda M et al). 2006;44: 1122-1138
Niwa H (*see* Zen Y et al). 2006;44:1333-1343
Nobili V, Marcellini M, Devito R, Ciampalini P, Piemonte F, Comparcola D, Sartorelli MR, Angulo P. NAFLD in children: A prospective clinical-pathological study and effect of lifestyle advice. 2006;44: 458-465
Noguchi R (*see* Kitade M et al). 2006;44: 983-991
Nolan GP (*see* He XS et al). 2006;44:352-359
Norenberg MD (*see* Albrecht J and Norenberg MD). 2006;44:788-794
Norkrans G (*see* Lagging M et al). 2006;44: 1617-1625
Northup PG (*see* Caldwell SH et al). 2006; 44:1039-1046 (Special Article)
Nübling CM (*see* Chudy M et al). 2006; 44:99-107
Nussler AK (*see* Meier Y et al). 2006;44:62-74
Nussler N (*see* Meier Y et al). 2006;44:62-74

O

Oakley F (*see* Smart DE et al). 2006;44: 1432-1440
Obama K (*see* Jinawath N et al). 2006;44: 1025-1038
Obi S (*see* Tateishi R et al). 2006;44:1518-1527
Ochoa L (*see* Crettaz J et al). 2006;44:623-632
O'Connell J (*see* Kneteman NM et al). 2006;44:515 (Correction)
Ogiso T (*see* Kimata T et al). 2006;44:140-151
Ohta T (*see* Zen Y et al). 2006;44:1333-1343
Okada S (*see* Ozasa A et al). 2006;44:326-334
Okanoue T (*see* Ozasa A et al). 2006;44: 326-334
Olivero A (*see* Niro GA et al). 2006;44: 713-720
Olle EW, Ren X, McClintock SD, Warner RL, Deogracias MP, Johnson KJ, Colletti LM. Matrix

metalloproteinase-9 is an important factor in hepatic regeneration after partial hepatectomy in mice. 2006;44: 540-549
Omata M (*see* Tateishi R et al). 2006;44: 1518-1527
Onishchenko GE (*see* Coulouarn C et al). 2006;44:1003-1011
Onji M (*see* Ozasa A et al). 2006;44:326-334
Opolon P (*see* Descamps D et al). 2006;44: 399-409
Orito E (*see* Ozasa A et al). 2006;44:326-334
— (*see* Sugiyama M et al). 2006;44:915-924
Orlandini A (*see* Urbani S et al). 2006;44: 126-139
Ozasa A, Tanaka Y, Orito E, Sugiyama M, Kang JH, Hige S, Kuramitsu T, Suzuki K, Tanaka E, Okada S, Tokita H, Asahina Y, Inoue K, Kakumu S, Okanoue T, Murawaki Y, Hino K, Onji M, Yatsuhashi H, Sakugawa H, Miyakawa Y, Ueda R, Mizokami M. Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection. 2006;44:326-334
Özçay F (*see* Knisely AS et al). 2006;44: 478-486

P

Pabst MS (*see* Merriman RB). 2006;44: 874-880
Pachkoria K (*see* Andrade RJ et al). 2006; 44:1581-1588
— (*see* Lucena MI et al). 2006;44:850-856
Pairojkul C (*see* Jinawath N et al). 2006;44: 1025-1038
Palestro CJ (*see* Joseph B et al). 2006;44: 1411-1420
Palkar PS (*see* Limaye PB et al). 2006;44: 379-388
Pang M (*see* Cantarini MC et al). 2006;44: 446-457
Pang RWC (*see* Ho JWY et al). 2006;44: 836-843
Papadogiannakis N (*see* Knisely AS et al). 2006;44:478-486
Paragh G (*see* Fülöp P et al). 2006;44:592-601
Park O (*see* Jeong WI et al). 2006;44:1441-1451
— (*see* Sun R et al). 2006;44:955-966
Pascual S (*see* Guarner C et al). 2006;44: 633-639
Patti MG (*see* Merriman RB). 2006;44: 874-880
Pauli-Magnus C and Meier PJ. Hepatobiliary transporters and drug-induced cholestasis. 2006;44: 778-787
— (*see* Meier Y et al). 2006;44:62-74
Paulusma CC, Groen A, Kunne C, Ho-Mok KS, Spijkerboer AL, de Waart DR, Hoek FJ, Vreeling H, Hoeben KA, van Marle J, Pawlikowska L, Bull LN, Hofmann AF, Knisely AS, Elferink RPJO. Atp8b1 deficiency in mice reduces resistance of the canalicular membrane to hydrophobic bile salts and impairs bile salt transport. 2006;44:195-204
Pawlikowska L (*see* Knisely AS et al). 2006; 44:478-486
— (*see* Paulusma CC et al). 2006;44:195-204
Pawlotsky JM (*see* Kuiken C et al). 2006; 44:1355-1361
— (*see* Lagging M et al). 2006;44:1617-1625
Pawlowska J (*see* Knisely AS et al). 2006; 44:478-486
Pelaez G (*see* Andrade RJ et al). 2006;44: 1581-1588
— (*see* Lucena MI et al). 2006;44:850-856
Pellicci R (*see* Mazzaferro V et al). 2006;44: 1543-1554
Pena-Sahdala HN (*see* Gopal K et al). 2006;44:335-340
Peng KW (*see* Blechacz B et al). 2006;44: 1465-1477
Penin F (*see* Gouttenoire J et al). 2006;44: 1690-1693 (Hepatology Elsewhere)
Pérez M (*see* González A et al). 2006;44: 806-812
Pérez-Mateo M (*see* Guarner C et al). 2006;44:633-639
— (*see* Jover R et al). 2006;44:771 (Correction)
Perri F (*see* Niro GA et al). 2006;44:713-720
Perricaudet M (*see* Descamps D et al). 2006;44:399-409
Perrin M (*see* Falize L et al). 2006;44:472-477
Peters MG, Andersen J, Lynch P, Liu T, Alston-Smith B, Brosgart CL, Jacobson JM, Johnson VA, Pollard RB, Rooney JF, Sherman KE, Swindells S, Polsky B, ACTG Protocol A5127 Team. Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. 2006;44:1110-1116
Petersen J (*see* Wursthorn K et al). 2006; 44:675-684
Pfeffer LM (*see* He XS et al). 2006;44:352-359
Pham BN (*see* Castelnau C et al). 2006;44: 728-735
Piemonte F (*see* Nobili V et al). 2006;44: 458-465
Piperno A (*see* Valenti L). 2006;44:857-864
Planas R (*see* Andrade RJ et al). 2006;44: 1581-1588
— (*see* Lucena MI et al). 2006;44:850-856
Plessier A, Sibert A, Consigny Y, Hakime A, Zappa M, Denninger MH, Condat B, Farges O, Chagneau C, de Ledinghen V, Francoz C, Sauvanet A, Vilgrain V, Belghiti J, Durand F, Valla D. Aiming at minimal invasiveness as a therapeutic strategy for Budd-Chiari syndrome. 2006;44: 1308-1316
Plym M (*see* Colonno RJ et al). 2006;44: 1656-1665
Pokornowski K (*see* Colonno RJ et al). 2006;44:1656-1665
Pol S (*see* Abel M et al). 2006;44:1607-1616
— (*see* Vallet-Pichard A et al). 2006;44:769 (Correspondence)
Polish Blood Transfusion Service Viral Study Group (*see* Brojer E et al). 2006;44:1666-1674
Pollard RB (*see* Peters MG et al). 2006;44: 1110-1116
Polsky B (*see* Peters MG et al). 2006;44: 1110-1116
Pons F (*see* Lucena MI et al). 2006;44:850-856
Poon RTP (*see* Ho JWY et al). 2006;44: 836-843
Portmann BC (*see* Knisely AS et al). 2006; 44:478-486
Post AB (*see* Del Rio RA et al). 2006;44: 1598-1606
— (*see* Zein CO et al). 2006;44:1564-1571
Poupon R, Chazouilleres O, Corpechot C, Chrétien Y. Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis. 2006; 44:85-90
— (*see* Corpechot C et al). 2006;44:513-514 (Correspondence)
Poynard T (*see* Abel M et al). 2006;44: 1607-1616
— (*see* Ratzu V and Poynard T). 2006;44: 802-805 (Editorial)
Prieto J (*see* Crettaz J et al). 2006;44:623-632
— (*see* Schmitz V et al). 2006;44:430-439
— (*see* Vilasco M et al). 2006;44:1635-1647
Primignani M, Barosi G, Bergamaschi G, Gianelli U, Fabris F, Reati R, Dell'Era A, Bucciarelli P, Mannucci PM. Role of the *JAK2* mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. 2006;44:1528-1534
— (*see* Tripodi A et al). 2006;44:440-445
Proll SC (*see* Diamond DL et al). 2006;44: 299-308 (Science Frontier)
Prytz H, Keiding S, Björnsson E, Broomé U, Almer S, Castedal M, Munk OL, The Swedish Internal Medicine Liver Club. Dynamic FDG-PET is useful for detection of cholangiocarcinoma in patients with PSC listed for liver transplantation. 2006;44:1572-1580
Puig M, Mihalik K, Tilton JC, Williams O, Merchlinsky M, Connors M, Feinstone SM, Major ME. CD4+ immune escape and subsequent T-cell

failure following chimpanzee immunization against hepatitis C virus. 2006;44:736-745
Purcell RH (*see* Murray JM et al). 2006;44: 1117-1121 (Concise Communication)
Pusl T (*see* Beuers U et al). 2006;44:280-281 (Correspondence)

Q

Qi Y (*see* Choi SS et al). 2006;44:1267-1277
Qian C (*see* Crettaz J et al). 2006;44:623-632
— (*see* Schmitz V et al). 2006;44:430-439
Qian S (*see* Chen CH et al). 2006;44:1171-1181

R

Radaeva S (*see* Jeong WI et al). 2006;44: 1441-1451
— (*see* Sun R et al). 2006;44:955-966
Raffa JD (*see* Grebely J et al). 2006;44: 1139-1145
Raftos J (*see* Knisely AS et al). 2006;44: 478-486
Ramcharran D (*see* Fontana RJ et al). 2006;44:925-935
Rametta R (*see* Valenti L). 2006;44:857-864
Ramy A (*see* Kamal S et al). 2006;44:1051-1052 (Reply)
Ramy AH (*see* Kamal SM et al). 2006;44: 1055-1056 (Correction)
Ranganathan S (*see* Luo JH et al). 2006;44: 1012-1024
Rao UNM (*see* Luo JH et al). 2006;44: 1012-1024
Rasenack J (*see* Kamal SM et al). 2006;44: 1055-1056 (Correction)
Ratzu V and Poynard T. Assessing the outcome of nonalcoholic steatohepatitis? It's time to get serious. 2006;44:802-805 (Editorial)
Raychaudhuri P, Lau LF, Grayson D, Kaplan J. Robert H. Costa: 1957-2006. 2006;44:1364 (Obituary)
Reati R (*see* Primignani M et al). 2006;44: 1528-1534
Reddy JK (*see* Limaye PB et al). 2006;44: 379-388
Reddy KR (*see* Caldwell SH et al). 2006; 44:1039-1046 (Special Article)
Regnault B (*see* Vilasco M et al). 2006;44: 1635-1647
Reilly TP (*see* You Q et al). 2006;44:1421-1431
Remondini E (*see* Valenti L). 2006;44:857-864
Ren B (*see* Luo JH et al). 2006;44:1012-1024
Ren X (*see* Olle EW et al). 2006;44:540-549
Rescan C (*see* Bessard A et al). 2006;44: 152-163
Reshamwala PA, Kleiner DE, Heller T. Nodular regenerative hyperplasia: Not all nodules are created equal. 2006;44: 7-14 (Perspectives in Clinical Hepatology)
Resnick MB (*see* Fülöp P et al). 2006;44: 592-601
Reuben A. Landmarks in Hepatology: A postscript. 2006;44:1703 (Landmarks in Hepatology)
—. Seeing purple. 2006;44:515 (Correction)
—. Splendid isolation. 2006;44:1365-1370 (Landmarks in Hepatology)
Reynolds G (*see* Smart DE et al). 2006;44: 1432-1440
Richardson R (*see* Kuiken C et al). 2006; 44:1355-1361
Ridgway W (*see* Wakabayashi K et al). 2006;44:1240-1249
Riezu JI (*see* Vilasco M et al). 2006;44: 1635-1647
Ripault MP (*see* Castelnau C et al). 2006; 44:728-735
Risch N (*see* He XS et al). 2006;44:352-359
Rizzetto M (*see* Bugianesi E et al). 2006;44: 1648-1655
— (*see* Niro GA et al). 2006;44:713-720
Roberts EA (*see* Shneider BL et al). 2006; 44:1344-1354 (Meeting Report)
Robinson SW (*see* Grant GR et al). 2006; 44:174-185
Rodrigo L (*see* Andrade RJ et al). 2006;44: 1581-1588
— (*see* Lucena MI et al). 2006;44:850-856
Rodrigo R (*see* Jover R et al). 2006;44:771 (Correction)
Rodrigues CMP and Steer CJ. Fooling the Fas ligand in death. 2006;44:314-317 (Editorial)
Rodríguez E (*see* Jover R et al). 2006;44: 771 (Correction)
Rodríguez-Juan C (*see* García-Ruiz I et al). 2006;44:581-591
Rodríguez-Vilarrupla A (*see* Matei V et al). 2006;44:44-52
Rojkind M (*see* Zhang Y et al). 2006;44: 612-622
Romero AI (*see* Lagging M et al). 2006;44: 1617-1625
Romero-Gomez M (*see* Andrade RJ et al). 2006;44:1581-1588
— (*see* Lucena MI et al). 2006;44:850-856
Romito R (*see* Mazzaferro V et al). 2006; 44:1543-1554
Rooney JF (*see* Peters MG et al). 2006;44: 1110-1116
Rose R (*see* Colonno RJ et al). 2006;44: 1656-1665
Rosen HR (*see* Golden-Mason L et al). 2006;44:1098-1109
Rosler R (*see* Doyle SE et al). 2006;44:896-906
Ross MA (*see* Chen CH et al). 2006;44: 1171-1181
Roth WK (*see* Chudy M et al). 2006;44: 99-107
Rothman KJ (*see* Sørensen HT et al). 2006; 44:1075-1082
Rouster SD (*see* Shire NJ et al). 2006;44: 1146-1157
Roy-Chowdhury J (*see* Landis CS et al). 2006;44:1250-1258
Roy-Chowdhury N (*see* Landis CS et al). 2006;44:1250-1258
Rudnick DA, Shikapwashya O, Blomenkamp K, Teckman JH. Indomethacin increases liver damage in a murine model of liver injury from alpha-1-antitrypsin deficiency. 2006; 44:976-982
Russell SJ (*see* Blechacz B et al). 2006;44: 1465-1477

S

Sablon E (*see* Kuiken C et al). 2006;44: 1355-1361
Sabo E (*see* Fülöp P et al). 2006;44:592-601
Saboorian MH (*see* Browning JD et al). 2006;44:487-488 (Concise Communication)
Sacchelli L (*see* Urbani S et al). 2006;44: 126-139
Sáez-Valero J (*see* Jover R et al). 2006;44: 771 (Correction)
Saisho H (*see* Chiba T et al). 2006;44:240-251
Sakugawa H (*see* Ozasa A et al). 2006;44: 326-334
Salen G (*see* Hirayama T et al). 2006;44: 602-611
Salerno F (*see* Tripodi A et al). 2006;44: 440-445
Salmerón J (*see* Andrade RJ et al). 2006;44: 1581-1588
Samra JS (*see* Scarlett CJ et al). 2006;44: 658-666
Sánchez E (*see* Guarner C et al). 2006;44: 633-639
Sano K (*see* Hasegawa K et al). 2006;44: 891-895
Sans L (*see* Esteva-Font C et al). 2006;44: 1555-1563
Sanyal AJ (*see* Caldwell SH et al). 2006;44: 1039-1046 (Special Article)
Saperas E (*see* González A et al). 2006;44: 806-812
Sarles J (*see* Serinet MO et al). 2006;44:75-84
Sarrazin C (*see* van Bömmel F et al). 2006; 44:318-325
Sartorelli MR (*see* Nobili V et al). 2006;44: 458-465
Sato N (*see* Zheng DM et al). 2006;44: 1278-1287
Sauerbruch T (*see* Nattermann J et al). 2006;44:945-954
— (*see* Schmitz V et al). 2006;44:430-439
Sauvanet A (*see* Plessier A et al). 2006;44: 1308-1316

Sawant SP (*see* Limaye PB et al). 2006;44:379-388
Saxby AJ (*see* Scarlett CJ et al). 2006;44:658-666
Saxena NK (*see* Ding X et al). 2006;44:515 (Correction)
Scarlett CJ, Saxby AJ, Nielsen AQ, Bell C, Samra JS, Hugh T, Baxter RC, Smith RC. Proteomic profiling of cholangiocarcinoma: Diagnostic potential of SELDI-TOF MS in malignant bile duct stricture. 2006;44:658-666
Schaeffeler E (*see* Meier Y et al). 2006;44:62-74
Schafmayer C, Tepel J, Franke A, Buch S, Lieb S, Seeger M, Lammert F, Kremer B, Fölsch UR, Fändrich F, Schreiber S, Hampe J. Investigation of the Lith1 candidate genes *ABCB11* and *LXRA* in human gallstone disease. 2006;44:650-657
Schalm SW (*see* Lagging M et al). 2006;44:1617-1625
— (*see* ter Borg MJ et al). 2006;44:721-727
Scheiblauer H (*see* Chudy M et al). 2006;44:99-107
Schiavo M (*see* Mazzaferro V et al). 2006;44:1543-1554
Schiller D (*see* Kneteman NM et al). 2006;44:515 (Correction)
Schirmacher P (*see* Wursthorn K et al). 2006;44:675-684
Schmidt M (*see* Chudy M et al). 2006;44:99-107
Schmidt RE (*see* Lankisch TO et al). 2006;44:1324-1332
Schmitz V, Dombrowski F, Prieto J, Qian C, Diehl L, Knolle P, Sauerbruch T, Caselmann WH, Spengler U, Leifeld L. Induction of murine liver damage by overexpression of CD40 ligand provides an experimental model to study fulminant hepatic failure. 2006;44:430-439
Schreckhise H (*see* Doyle SE et al). 2006;44:896-906
Schreiber S (*see* Schafmayer C et al). 2006;44:650-657
Schwarz M (*see* Hailfinger S et al). 2006;44:512-513 (Reply)
Seeff LB (*see* Everson GT et al). 2006;44:1675-1684
Seeger M (*see* Schafmayer C et al). 2006;44:650-657
Segarra A (*see* González A et al). 2006;44:806-812
Seifried E (*see* Chudy M et al). 2006;44:99-107
Seki E (*see* Uchinami H et al). 2006;44:420-429
Sène D (*see* Abel M et al). 2006;44:1607-1616
Senekeo-Effenberger K (*see* Verreault M et al). 2006;44:368-378
Senturk H (*see* ter Borg MJ et al). 2006;44:721-727
Serinet MO, Broué P, Jacquemin E, Lachaux A, Sarles J, Gottrand F, Gauthier F, Chardot C. Management of patients with biliary atresia in France: Results of a decentralized policy 1986-2002. 2006;44:75-84
Shafritz DA (*see* Landis CS et al). 2006;44:1250-1258
Shah Y (*see* Yim SH et al). 2006;44:550-560
Shankar V (*see* Crettaz J et al). 2006;44:623-632
Sheets A (*see* Fülöp P et al). 2006;44:592-601
Sherman KE (*see* Blackard JT et al). 2006;44:15-22 (Concise Review in Mechanisms of Disease)
— (*see* Peters MG et al). 2006;44:1110-1116
— (*see* Shire NJ et al). 2006;44:1146-1157
Shi M (*see* Zhao J et al). 2006;44:205-215
Shiffman ML (*see* Everson GT et al). 2006;44:1675-1684
— (*see* Morishima C et al). 2006;44:360-367
Shiina S (*see* Tateishi R et al). 2006;44:1518-1527
Shikapwashya O (*see* Rudnick DA et al). 2006;44:976-982
Shimada T (*see* Sugiyama M et al). 2006;44:915-924
Shin-I T (*see* Kuiken C et al). 2006;44:1355-1361
Shire NJ, Horn PS, Rouster SD, Stanford S, Eyster ME, Sherman KE, Multicenter Hemophilia Cohort HCV Study Group. HCV kinetics, quasispecies, and clearance in treated HCV-infected and HCV/HIV-1-coinfected patients with hemophilia. 2006;44:1146-1157
Shneider BL, González-Peralta R, Roberts EA. Controversies in the management of pediatric liver disease: Hepatitis B, C and NAFLD: Summary of a single topic conference. 2006;44:1344-1354 (Meeting Report)
— (*see* LaRusso NF). 2006;44:746-764 (Special Article)
Sibert A (*see* Plessier A et al). 2006;44:1308-1316
Sicklick JK (*see* Choi SS et al). 2006;44:1267-1277
Simmonds P (*see* Kuiken C et al). 2006;44:1355-1361
Simon C (*see* ter Borg MJ et al). 2006;44:721-727
Simon MT (*see* Lieu HT et al). 2006;44:1452-1464
Singer ME (*see* Del Rio RA et al). 2006;44:1598-1606
Sirma H (*see* Funk A et al). 2006;44:685-693
Sivakumar P (*see* Doyle SE et al). 2006;44:896-906
Smart DE, Green K, Oakley F, Weitzman JB, Yaniv M, Reynolds G, Mann J, Millward-Sadler H, Mann DA. JunD is a profibrogenic transcription factor regulated by Jun N-terminal kinase-independent phosphorylation. 2006;44:1432-1440
Smedile A (*see* Niro GA et al). 2006;44:713-720
Smith AG (*see* Grant GR et al). 2006;44:174-185
Smith AJH (*see* Lieu HT et al). 2006;44:1452-1464
Smith RC (*see* Scarlett CJ et al). 2006;44:658-666
Smith RD (*see* Diamond DL et al). 2006;44:299-308 (Science Frontier)
Sokol RJ (*see* Mack CL et al). 2006;44:1231-1239
Solís-Herruzo JA (*see* García-Ruiz I et al). 2006;44:581-591
Song BJ (*see* Moon KH et al). 2006;44:1218-1230
Sørensen HT, Lash TL, Rothman KJ. Beyond randomized controlled trials: A critical comparison with nonrandomized studies. 2006;44:1075-1082
Sørensen M and Keiding S. The brain permeability-surface product for ammonia. 2006;44:1053-1054 (Reply)
Soriando G (*see* Guarner C et al). 2006;44:633-639
Soulsby CT (*see* Morgan MY et al). 2006;44:823-835
Spanish Group for the Study of Drug-Induced Liver Disease (Grupo de Estudio para las Hepatopatías Asociadas a Medicamentos (GEHAM)) (*see* Lucena MI et al). 2006;44:850-856
Spengler U (*see* Nattermann J et al). 2006;44:945-954
— (*see* Schmitz V et al). 2006;44:430-439
— (*see* van Bömmel F et al). 2006;44:318-325
Spijkerboer AL (*see* Paulusma CC et al). 2006;44:195-204
Splinter PL (*see* Blechacz B et al). 2006;44:1465-1477
Sprengers D (*see* van der Molen RG et al). 2006;44:907-914
Sripa B (*see* Jinawath N et al). 2006;44:1025-1038
Staels B (*see* Verreault M et al). 2006;44:368-378
Stanford S (*see* Shire NJ et al). 2006;44:1146-1157
Stanzione M (*see* Niro GA et al). 2006;44:713-720
Steer CJ (*see* Rodrigues CMP and Steer CJ). 2006;44:314-317 (Editorial)
Sterling RK. FIB-4: A simple, inexpensive and accurate marker of fibrosis in HCV-infected patients. 2006;44:769-770 (Reply)

Stieger B (*see* Knisely AS et al). 2006;44:478-486
— (*see* Meier Y et al). 2006;44:62-74
Stolz DB (*see* Chen CH et al). 2006;44:1171-1181
Storey H (*see* Doyle SE et al). 2006;44:896-906
Strassburg CP (*see* Lankisch TO et al). 2006;44:1324-1332
Strautnieks SS (*see* Knisely AS et al). 2006;44:478-486
Strom S (*see* Luo JH et al). 2006;44:1012-1024
Suárez I (*see* Jover R et al). 2006;44:771 (Correction)
Such J (*see* Guarner C et al). 2006;44:633-639
Sugawara Y (*see* Hasegawa K et al). 2006;44:891-895
Sugiyama M, Tanaka Y, Kato T, Orito E, Ito K, Acharya SK, Gish RG, Kramvis A, Shimada T, Izumi N, Kaito M, Miyakawa Y, Mizokami M. Influence of hepatitis B virus genotypes on the intra- and extracellular expression of viral DNA and antigens. 2006;44:915-924
— (*see* Ozasa A et al). 2006;44:326-334
Suigo E (*see* Valenti L). 2006;44:857-864
Sun CK (*see* Ho JWY et al). 2006;44:836-843
Sun HY (*see* Sun R et al). 2006;44:955-966
Sun R, Park O, Horiguchi N, Kulkarni S, Jeong WI, Sun HY, Radaeva S, Gao B. STAT1 contributes to dsRNA inhibition of liver regeneration after partial hepatectomy in mice. 2006;44:955-966
Sung VMH (*see* Kawamura H et al). 2006;44:936-944
Suwandhi P (*see* Gopal K et al). 2006;44:335-340
Suzuki K (*see* Ozasa A et al). 2006;44:326-334
Suzuki S (*see* Zheng DM et al). 2006;44:1278-1287
Swanson KL (*see* Krowka MJ et al). 2006;44:1502-1510
The Swedish Internal Medicine Liver Club (*see* Prytz H et al). 2006;44:1572-1580
Swindells S (*see* Peters MG et al). 2006;44:1110-1116
Szabo G, Dolganiuc A, Mandrekar P. Pattern recognition receptors: A contemporary view on liver diseases. 2006;44:287-298 (Concise Review in Mechanisms of Disease)

T

Tagger A (*see* Mazzaferro V et al). 2006;44:1543-1554
Takahama Y (*see* Heo J et al). 2006;44:1478-1486
Takatori H (*see* Honda M et al). 2006;44:1122-1138
Takayama T (*see* Hasegawa K et al). 2006;44:891-895
Takei Y (*see* Zheng DM et al). 2006;44:1278-1287
Tan X (*see* Apte U et al). 2006;44:992-1002
Tanaka E (*see* Ozasa A et al). 2006;44:326-334
Tanaka Y (*see* Ozasa A et al). 2006;44:326-334
— (*see* Sugiyama M et al). 2006;44:915-924
Tang W, Ma Y, Yu L. Plasma cholesterol is hyperresponsive to statin in ABCG5/ABCG8 transgenic mice. 2006;44:1259-1266
Taniguchi H (*see* Chiba T et al). 2006;44:240-251
Tateishi R, Shiina S, Yoshida H, Teratani T, Obi S, Yamashiki N, Yoshida H, Akamatsu M, Kawabe T, Omata M. Prediction of recurrence of hepatocellular carcinoma after curative ablation using three tumor markers. 2006;44:1518-1527
Taylor RM, Davern T, Munoz S, Han SH, McGuire B, Larson AM, Hynan L, Lee WM, Fontana RJ, U.S. Acute Liver Failure Study Group. Fulminant hepatitis A virus infection in the United States: Incidence, prognosis, and outcomes. 2006;44:1589-1597
Tebar L (*see* Lieu HT et al). 2006;44:1452-1464
Teckman JH (*see* Rudnick DA et al). 2006;44:976-982
Tenney DJ (*see* Colonno RJ et al). 2006;44:1656-1665
Tepel J (*see* Schafmayer C et al). 2006;44:650-657
ter Borg MJ, van Zonneveld M, Zeuzem S, Senturk H, Akarca US, Simon C, Hansen BE, Haagmans BL, de Man RA, Schalm SW, Janssen HLA, HBV 99-01 Study Group. Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: Relation to treatment response. 2006;44:721-727
Teratani T (*see* Tateishi R et al). 2006;44:1518-1527
Terrault N (*see* Fontana RJ et al). 2006;44:925-935
Therapondos G, Hol L, Benjaminov F, Wong F. The effect of single oral low-dose losartan on posture-related sodium handling in post-TIPS ascites-free cirrhosis. 2006;44:640-649
Théret N (*see* Zindy PJ et al). 2006;44:1296-1307
Thirunavukkarasu C, Watkins SC, Gandhi CR. Mechanisms of endotoxin-induced NO, IL-6, and TNF-α production in activated rat hepatic stellate cells: Role of p38 MAPK. 2006;44:389-398
Thompson RJ (*see* Knisely AS et al). 2006;44:478-486
Thorelius L (*see* Ekstedt M et al). 2006;44:865-873
Thorgeirsson SS (*see* Coulouarn C et al). 2006;44:1003-1011
— (*see* Heo J et al). 2006;44:1478-1486
Tibshirani R (*see* He XS et al). 2006;44:352-359
Tiegs G. Lack of chemokine receptor CCR5 promotes murine fulminant liver failure. 2006;44:275-277 (Hepatology Elsewhere)
Tilton JC (*see* Puig M et al). 2006;44:736-745
Tiszlavicz L (*see* Knisely AS et al). 2006;44:478-486
Tokita H (*see* Ozasa A et al). 2006;44:326-334
Tola D (*see* Urbani S et al). 2006;44:126-139
Tomasello A (*see* González A et al). 2006;44:806-812
Tomita S (*see* Yim SH et al). 2006;44:550-560
Tomlinson M (*see* Newton JL et al). 2006;44:91-98
Tong M (*see* Cantarini MC et al). 2006;44:446-457
Trautwein C (*see* Zschemisch NH et al). 2006;44:164-173
Trevisani F (*see* Cantarini MC et al). 2006;44:446-457
Trinchet JC (*see* Ganne-Carrié N et al). 2006;44:1511-1517
Tripodi A, Primignani M, Chantarangkul V, Clerici M, Dell'Era A, Fabris F, Salerno F, Mannucci PM. Thrombin generation in patients with cirrhosis: The role of platelets. 2006;44:440-445
— (*see* Caldwell SH et al). 2006;44:1039-1046 (Special Article)
Troisi C (*see* Hwang LY et al). 2006;44:341-351
Trombini P (*see* Valenti L). 2006;44:857-864
Trottier J, Verreault M, Grepper S, Monté D, Bélanger J, Kaeding J, Caron P, Inaba TT, Barbier O. Human UDP-glucuronosyltransferase (UGT)1A3 enzyme conjugates chenodeoxycholic acid in the liver. 2006;44:1158-1170
— (*see* Verreault M et al). 2006;44:368-378
Tseng GC (*see* Luo JH et al). 2006;44:1012-1024
Tsujimoto T (*see* Kitade M et al). 2006;44:983-991
Tsuneyama K (*see* Wakabayashi K et al). 2006;44:1240-1249
Tsung A (*see* Izuishi K et al). 2006;44:573-580
Tsunoda T (*see* Jinawath N et al). 2006;44:1025-1038
Tucker RM (*see* Mack CL et al). 2006;44:1231-1239

Tukey RH (*see* Verreault M et al). 2006; 44:368-378
Tung EKK (*see* Yam JWP et al). 2006;44: 881-890
Turlin B (*see* Falize L et al). 2006;44:472-477
— (*see* Zindy PJ et al). 2006;44:1296-1307
Tyndall M (*see* Grebely J et al). 2006;44: 1139-1145
Tyrrell DLJ (*see* Kneteman NM et al). 2006;44:515 (Correction)

U

Uchinami H, Seki E, Brenner DA, D'Armiento J. Loss of MMP 13 attenuates murine hepatic injury and fibrosis during cholestasis. 2006;44: 420-429
Ueberham E (*see* Gebhardt R and Ueberham E). 2006;44:512 (Correspondence)
Ueda R (*see* Ozasa A et al). 2006;44:326-334
Ueda T (*see* Honda M et al). 2006;44: 1122-1138
Uemura M (*see* Kitade M et al). 2006;44: 983-991
Ueno Y (*see* Mack CL et al). 2006;44: 1231-1239
— (*see* Wakabayashi K et al). 2006;44: 1240-1249
Underhill JA (*see* Donaldson PT et al). 2006;44:667-674
Urbani S, Amadei B, Fisicaro P, Tola D, Orlandini A, Sacchelli L, Mori C, Missale G, Ferrari C. Outcome of acute hepatitis C is related to virus-specific CD4 function and maturation of antiviral memory CD8 responses. 2006;44:126-139
Uren T (*see* Heo J et al). 2006;44:1478-1486
U.S. Acute Liver Failure Study Group (*see* Taylor RM et al). 2006;44:1589-1597

V

Valenti L, Dongiovanni P, Piperno A, Fracanzani AL, Maggioni M, Rametta R, Loria P, Casiraghi MA, Suigo E, Ceriani R, Remondini E, Trombini P, Fargion S. *α1-Antitrypsin* mutations in NAFLD: High prevalence and association with altered iron metabolism but not with liver damage. 2006;44:857-864
Valla D (*see* Plessier A et al). 2006;44: 1308-1316
Vallet-Pichard A, Mallet V, Pol S. FIB-4: A simple, inexpensive and accurate marker of fibrosis in HCV-infected patients. 2006;44:769 (Correspondence)
van Bömmel F, Zöllner B, Sarrazin C, Spengler U, Hüppe D, Böller B, Feucht HH, Wiedenmann B, Berg T. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. 2006; 44:318-325
van der Molen RG, Sprengers D, Biesta PJ, Kusters JG, Janssen HLA. Favorable effect of adefovir on the number and functionality of myeloid dendritic cells of patients with chronic HBV. 2006;44:907-914
van Marle J (*see* Paulusma CC et al). 2006; 44:195-204
van Rooijen N (*see* Crettaz J et al). 2006; 44:623-632
van Zonneveld M (*see* ter Borg MJ et al). 2006;44:721-727
Vanni E (*see* Bugianesi E et al). 2006;44: 1648-1655
Vaquero J, Belanger M, Blei AT, Butterworth RF. Lack of assessment of body temperature in mice with acetaminophen toxicity. 2006;44:279-280 (Correspondence)
Veenstra TD (*see* Moon KH et al). 2006; 44:1218-1230
Venturi C (*see* Donaldson PT et al). 2006; 44:667-674
Vergani D (*see* Antoniades CG et al). 2006; 44:34-43
Verheij-Hart E (*see* Lagging M et al). 2006; 44:1617-1625
Verreault M, Senekeo-Effenberger K, Trottier J, Bonzo JA, Bélanger J, Kaeding J, Staels B, Caron P, Tukey RH, Barbier O. The liver X-receptor alpha controls hepatic expression of the human bile acid–glucuronidating UGT1A3 enzyme in human cells and transgenic mice. 2006;44:368-378
— (*see* Trottier J et al). 2006;44:1158-1170
Vigant F (*see* Descamps D et al). 2006;44: 399-409
Vilasco M, Larrea E, Vitour D, Dabo S, Breiman A, Regnault B, Riezu JI, Eid P, Prieto J, Meurs EF. The protein kinase IKKε can inhibit HCV expression independently of IFN and its own expression is downregulated in HCV-infected livers. 2006;44:1635-1647
Vilgrain V (*see* Plessier A et al). 2006;44: 1308-1316
Villar M (*see* Lucena MI et al). 2006;44: 850-856
Virahep-C Study Group (*see* Fontana RJ et al). 2006;44:925-935
Vitour D (*see* Vilasco M et al). 2006;44: 1635-1647
Voisset C (*see* Lavie M et al). 2006;44: 1626-1634
Volz T (*see* Wursthorn K et al). 2006;44: 675-684
von Lilienfeld-Toal M (*see* Nattermann J et al). 2006;44:945-954
von Wagner M (*see* Lagging M et al). 2006; 44:1617-1625
Vreeling H (*see* Paulusma CC et al). 2006; 44:195-204
Vu-Dac N (*see* Lavie M et al). 2006;44: 1626-1634

W

Wack DS (*see* Lockwood AH and Wack DS). 2006;44:1052-1053 (Correspondence)
Wakabayashi H (*see* Izuishi K et al). 2006; 44:573-580
Wakabayashi K, Lian ZX, Moritoki Y, Lan RY, Tsuneyama K, Chuang YH, Yang GX, Ridgway W, Ueno Y, Ansari AA, Coppel RL, Mackay IR, Gershwin ME. IL-2 receptor $\alpha^{-/-}$ mice and the development of primary biliary cirrhosis. 2006;44:1240-1249
Walfish A (*see* Gopal K et al). 2006;44: 335-340
Walsh A (*see* Colonno RJ et al). 2006;44: 1656-1665
Wands JR (*see* Cantarini MC et al). 2006; 44:446-457
— (*see* Fülöp P et al). 2006;44:592-601
Wang C (*see* Golden-Mason L et al). 2006; 44:1098-1109
Wang H (*see* Zeng MD et al). 2006;44: 108-116
Wang LY (*see* Yu ML et al). 2006;44:1086-1097
Wang YZ (*see* Zeng MD et al). 2006;44: 108-116
Ward JM (*see* Yim SH et al). 2006;44:550-560
Warner RL (*see* Olle EW et al). 2006;44: 540-549
Warren A, Le Couteur DG, Fraser R, Bowen DG, McCaughan GW, Bertolino P. T lymphocytes interact with hepatocytes through fenestrations in murine liver sinusoidal endothelial cells. 2006;44: 1182-1190
Watkins SC (*see* Thirunavukkarasu C et al). 2006;44:389-398
Watson H (*see* Angeli P et al). 2006;44: 1535-1542
Wedemeyer H, Cornberg M, Wiegand J, Manns M. Treatment duration in acute hepatitis C: The issue is not solved yet. 2006;44:1051 (Correspondence)
—, Wiegand J, Cornberg M, Manns M. Acute hepatitis C: Dosage and compliance. 2006;44:511-512 (Reply)
Wegmann D (*see* You Q et al). 2006;44: 1421-1431
Wehmeier M (*see* Lankisch TO et al). 2006;44:1324-1332
Weiner AJ (*see* Kneteman NM et al). 2006; 44:515 (Correction)
Weitzman JB (*see* Smart DE et al). 2006; 44:1432-1440

Wendon J (*see* Antoniades CG et al). 2006; 44:34-43
Wendon JA and Larsen FS. Intracranial pressure monitoring in acute liver failure. A procedure with clear indications. 2006;44:504-506 (Hepatology Elsewhere)
Werth M, Gebhardt R, Gaunitz F. Hepatic expression of glutamine synthetase in rats is controlled by STAT5 and TCF transcription factors. 2006;44:967-975
Westin J (*see* Lagging M et al). 2006;44: 1617-1625
Weston SR (*see* Merriman RB). 2006;44: 874-880
Wheeler MD (*see* Kremer M et al). 2006; 44:216-227
Whitington PF (*see* Knisely AS et al). 2006; 44:478-486
Wieckowska A, Zein NN, Yerian LM, Lopez AR, McCullough AJ, Feldstein AE. *In vivo* assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. 2006;44:27-33 (Rapid Communication)
Wiedenmann B (*see* van Bömmel F et al). 2006;44:318-325
Wiegand J (*see* Wedemeyer H et al). 2006; 44:511-512 (Reply), 1051 (Correspondence)
Wieland SF (*see* Murray JM et al). 2006; 44:1117-1121 (Concise Communication)
Wiesner RH (*see* Krowka MJ et al). 2006; 44:1502-1510
Wietzke-Braun P (*see* Doyle SE et al). 2006;44:896-906
Will H (*see* Funk A et al). 2006;44:685-693
Williams O (*see* Puig M et al). 2006;44: 736-745
Williams R. Global challenges in liver disease. 2006;44:521-526 (Perspectives in Clinical Hepatology)
Wilton K (*see* Newton JL et al). 2006;44: 91-98
Wong F (*see* Angeli P et al). 2006;44:1535-1542
— (*see* Therapondos G et al). 2006;44: 640-649
Wong SN and Lok ASF. Tenofovir disoproxil fumarate: Role in hepatitis B treatment. 2006;44:309-313 (Editorial)
— (*see* Yim HJ et al). 2006;44:703-712
Wright EC (*see* Morishima C et al). 2006; 44:360-367
Wright TL (*see* He XS et al). 2006;44:352-359
Wu M (*see* Zhao J et al). 2006;44:205-215
Wu W (*see* Chen CH et al). 2006;44:1171-1181
Wu YM, Joseph B, Gupta S. Immunosuppression using the mTOR inhibition mechanism affects replacement of rat liver with transplanted cells. 2006;44:410-419
Wursthorn K, Lutgehetmann M, Dandri M, Volz T, Buggisch P, Zollner B, Longerich T, Schirmacher P, Metzler F, Zankel M, Fischer C, Currie G, Brosgart C, Petersen J. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. 2006;44:675-684
Wüstefeld T (*see* Zschemisch NH et al). 2006;44:164-173
Wychowski C (*see* Lavie M et al). 2006;44: 1626-1634

X

Xhang CX (*see* Zindy PJ et al). 2006;44: 1296-1307
Xie Y (*see* Newberry EP et al). 2006;44: 1191-1205
Xu G (*see* Hirayama T et al). 2006;44:602-611
Xu H (*see* Zhao J et al). 2006;44:205-215

Y

Yam JWP, Ko FCF, Chan CY, Yau TO, Tung EKK, Leung THY, Jin DY, Ng IOL. Tensin2 variant 3 is associated with aggressive tumor behavior in human hepatocellular carcinoma. 2006;44:881-890
Yamada M (*see* Ikeda M et al). 2006;44: 117-125
Yamanouchi K (*see* Landis CS et al). 2006; 44:1250-1258
Yamashiki N (*see* Tateishi R et al). 2006; 44:1518-1527
Yamashina S (*see* Zheng DM et al). 2006; 44:1278-1287
Yamashita T (*see* Honda M et al). 2006;44: 1122-1138
Yamazaki M (*see* Kitade M et al). 2006;44: 983-991
Yanase K (*see* Kitade M et al). 2006;44: 983-991
Yang GX (*see* Wakabayashi K et al). 2006; 44:1240-1249
Yang L (*see* Choi SS et al). 2006;44:1267-1277
Yang S (*see* Zhao J et al). 2006;44:205-215
Yang X (*see* Ming Z et al). 2006;44:813-822
Yaniv M (*see* Smart DE et al). 2006;44: 1432-1440
Yao GB (*see* Zeng MD et al). 2006;44:108-116
Yao L (*see* Doyle SE et al). 2006;44:896-906
Yatsuhashi H (*see* Ozasa A et al). 2006;44: 326-334
Yau TO (*see* Yam JWP et al). 2006;44:881-890
Yerian LM (*see* Wieckowska A et al). 2006; 44:27-33 (Rapid Communication)
Yim HJ, Hussain M, Liu Y, Wong SN, Fung SK, Lok ASF. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. 2006;44: 703-712
Yim SH, Shah Y, Tomita S, Morris HD, Gavrilova O, Lambert G, Ward JM, Gonzalez FJ. Disruption of the *Arnt* gene in endothelial cells causes hepatic vascular defects and partial embryonic lethality in mice. 2006;44:550-560
Yokosuka O (*see* Chiba T et al). 2006;44: 240-251
Yoshida H (*see* Tateishi R et al). 2006;44: 1518-1527
Yoshii J (*see* Kitade M et al). 2006;44:983-991
Yoshiji H (*see* Kitade M et al). 2006;44: 983-991
You Q, Cheng L, Reilly TP, Wegmann D, Ju C. Role of neutrophils in a mouse model of halothane-induced liver injury. 2006;44:1421-1431
Younossi Z (*see* Mendoza M and Younossi Z). 2006;44:1362-1363 (Hepatology Elsewhere)
Yu CF (*see* Colonno RJ et al). 2006;44: 1656-1665
Yu L (*see* Tang W et al). 2006;44:1259-1266
Yu ML, Lin SM, Lee CM, Dai CY, Chang WY, Chen SC, Lee LP, Lin ZY, Hsieh MY, Wang LY, Chuang WL, Liaw YF. A simple noninvasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapy. 2006;44:1086-1097
Yu S (*see* Limaye PB et al). 2006;44:379-388
Yu WC (*see* Ho JWY et al). 2006;44:836-843
Yu YP (*see* Luo JH et al). 2006;44:1012-1024
Yusim K (*see* Kuiken C et al). 2006;44: 1355-1361

Z

Zabalza M (*see* Fernández J et al). 2006;44: 1288-1295
Zafrani ES (*see* Lafdil F et al). 2006;44: 228-239
Zanger UM (*see* Meier Y et al). 2006;44: 62-74
Zankel M (*see* Wursthorn K et al). 2006; 44:675-684
Zapater P (*see* Guarner C et al). 2006;44: 633-639
Zappa M (*see* Plessier A et al). 2006;44: 1308-1316
Zein CO, Beatty K, Post AB, Logan L, Debanne S, McCullough AJ. Smoking and increased severity of hepatic fibrosis in primary biliary cirrhosis: A cross validated retrospective assessment. 2006;44: 1564-1571

Zein NN (*see* Wieckowska A et al). 2006; 44:27-33 (Rapid Communication)
Zen Y, Fujii T, Itatsu K, Nakamura K, Minato H, Kasashima S, Kurumaya H, Katayanagi K, Kawashima A, Masuda S, Niwa H, Mitsui T, Asada Y, Miura S, Ohta T, Nakanuma Y. Biliary papillary tumors share pathological features with intraductal papillary mucinous neoplasm of the pancreas. 2006;44:1333-1343
Zeng G (*see* Apte U et al). 2006;44:992-1002
Zeng MD, Mao YM, Yao GB, Wang H, Hou JL, Wang YZ, Ji BN, Chang CNP, Barker KF. A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B. 2006;44: 108-116
Zeuzem S (*see* Lagging M et al). 2006;44: 1617-1625
— (*see* ter Borg MJ et al). 2006;44:721-727
Zhang S (*see* Colonno RJ et al). 2006;44: 1656-1665
Zhang X (*see* Zhao J et al). 2006;44:205-215
Zhang Y, Ikegami T, Honda A, Miyazaki T, Bouscarel B, Rojkind M, Hyodo I, Matsuzaki Y. Involvement of integrin-linked kinase in carbon tetrachloride–induced hepatic fibrosis in rats. 2006; 44:612-622
Zhao J, Zhang X, Shi M, Xu H, Jin J, Ni H, Yang S, Dai J, Wu M, Guo Y. TIP30 inhibits growth of HCC cell lines and inhibits HCC xenografts in mice in combination with 5-FU. 2006;44:205-215
Zheng DM, Kitamura T, Ikejima K, Enomoto N, Yamashina S, Suzuki S, Takei Y, Sato N. Sphingosine 1-phosphate protects rat liver sinusoidal endothelial cells from ethanol-induced apoptosis: Role of intracellular calcium and nitric oxide. 2006;44: 1278-1287
Zheng YW (*see* Chiba T et al). 2006;44: 240-251
Zhou H (*see* Landis CS et al). 2006;44: 1250-1258
Zimmermann H (*see* Nattermann J et al). 2006;44:945-954
Zindy PJ, L'Helgoulc'h A, Bonnier D, Le Béchec A, Bourd-Boitin K, Xhang CX, Musso O, Glaise D, Bérangère Troadec M, Loréal O, Turlin B, Léger J, Clément B, Théret N. Upregulation of the tumor suppressor gene menin in hepatocellular carcinomaa and its significance in fibrogenesis. 2006; 44:1296-1307
Ziol M (*see* Ganne-Carrié N et al). 2006; 44:1511-1517
Zöllner B (*see* van Bömmel F et al). 2006; 44:318-325
— (*see* Wursthorn K et al). 2006;44:675-684
Zoulim F. Hepatitis B virus resistance to entecavir in nucleoside-naïve patients: Does it exist? 2006;44:1404-1407 (Editorial)
Zschemisch NH, Liedtke C, Dierssen U, Nevzorova YA, Wüstefeld T, Borlak J, Manns MP, Trautwein C. Expression of a cyclin E1 isoform in mice is correlated with the quiescent cell cycle status of hepatocytes *in vivo*. 2006;44: 164-173
Zurawski V (*see* Lavie M et al). 2006;44: 1626-1634

Subject Index to Volume 44*

A

AASLD 2006 Distinguished Achievement Award
AASLD 2006 Distinguished Achievement Award to Neil Kaplowitz. 2006;44:1378-1379

AASLD 2006 Distinguished Service Award
AASLD 2006 Distinguished Service Award to Allan W. Wolkoff (Cohen). 2006;44:1376-1377

***ABCB11* gene**
Interindividual variability of canalicular ATP-binding-cassette (ABC)–transporter expression in human liver (Meier et al). 2006;44: 62-74
Investigation of the *Lith1* candidate genes *ABCB11* and *LXRA* in human gallstone disease (Schafmayer et al). 2006;44:650-657

Acetaminophen
Hepatology Highlights (Kaplowitz). 2006;44:285-286
Lack of assessment of body temperature in mice with acetaminophen toxicity (Vaquero et al). 2006;44:279-280 (Correspondence)
Reduced monocyte HLA-DR expression: A novel biomarker of disease severity and outcome in acetaminophen-induced acute liver failure (Antoniades et al). 2006;44:34-43

Acidic sphingomyelinase
Critical role of acidic sphingomyelinase in murine hepatic ischemia-reperfusion injury (Llacuna et al). 2006;44:561-572

ACTG A5127 trial
Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127 (Peters et al). 2006; 44:1110-1116

Actin
Actin organization and hepatocyte differentiation are regulated by extracellular matrix via PI-4,5-bisphosphate in the rat (Kimata et al). 2006;44:140-151

Acute hepatitis B
Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection (Ozasa et al). 2006;44: 326-334

Acute hepatitis C
Acute hepatitis C: Dosage and compliance (De Rosa et al). 2006; 44:511 (Correspondence)
Acute hepatitis C: Dosage and compliance (Wedemeyer et al). 2006;44:511-512 (Reply)
Duration of peginterferon therapy in acute hepatitis C: A randomized trial (Kamal et al). 2006;44:1055-1056 (Correction) (Rapid Communication)
Loss of IL-7 receptor alpha-chain (CD127) expression in acute HCV infection associated with viral persistence (Golden-Mason et al). 2006;44:1098-1109
Outcome of acute hepatitis C is related to virus-specific CD4 function and maturation of antiviral memory CD8 responses (Urbani et al). 2006; 44:126-139
Treatment duration in acute hepatitis C: The issue is not solved yet (Kamal et al). 2006;44:1051-1052 (Reply)
Treatment duration in acute hepatitis C: The issue is not solved yet (Wedemeyer et al). 2006;44:1051 (Correspondence)

Acute idiosyncratic drug-induced liver injury
Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry (Andrade et al). 2006;44: 1581-1588

Acute liver failure
Indeterminate acute liver failure: A riddle wrapped in a mystery inside an enigma (Davern). 2006;44:765-768 (Hepatology *Elsewhere*)
Intracranial pressure monitoring in acute liver failure. A procedure with clear indications (Wendon and Larsen). 2006;44:504-506 (Hepatology *Elsewhere*)
Intracranial pressure monitoring in patients with acute liver failure: A questionable invasive surveillance (Bernuau and Durand). 2006;44: 502-504 (Hepatology *Elsewhere*)
Reduced monocyte HLA-DR expression: A novel biomarker of disease severity and outcome in acetaminophen-induced acute liver failure (Antoniades et al). 2006;44:34-43

Acute liver injury
Contribution of hepatic adenosine A_1 receptors to renal dysfunction associated with acute liver injury in rats (Ming et al). 2006;44:813-822

Adefovir
A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B (Zeng et al). 2006;44:108-116
Favorable effect of adefovir on the number and functionality of myeloid dendritic cells of patients with chronic HBV (van der Molen et al). 2006;44:907-914
Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B (Wursthorn et al). 2006;44:675-684
Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127 (Peters et al). 2006; 44:1110-1116
Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy (van Bömmel et al). 2006;44:318-325

Adenosine A_1 receptors
Contribution of hepatic adenosine A_1 receptors to renal dysfunction associated with acute liver injury in rats (Ming et al). 2006;44:813-822
Hepatology Highlights (Elias). 2006;44: 1374-1375

Adenovirus
Intrahepatic injection of adenovirus reduces inflammation and increases gene transfer and therapeutic effect in mice (Crettaz et al). 2006;44: 623-632

Adrenal insufficiency
Adrenal insufficiency in patients with cirrhosis and septic shock: Effect of treatment with hydrocortisone on survival (Fernández et al). 2006;44: 1288-1295

African Americans
Modeling hepatic fibrosis in African American and Caucasian American patients with chronic hepatitis C virus infection (Fontana et al). 2006;44:925-935

Akt
Hepatology Highlights (Kaplowitz). 2006;44:1061-1062

Akt kinase
Ischemic preconditioning of the murine liver protects through the Akt kinase pathway (Izuishi et al). 2006;44: 573-580

Allograft dysfunction
Liver biopsy interpretation for causes of late liver allograft dysfunction (Banff Working Group). 2006;44:489-501 (Special Article)

Alpha-fetoprotein

*July, 1-284; August, 285-518; September, 519-774; October, 775-1060; November, 1061-1372, December 1373-1752

Prediction of recurrence of hepatocellular carcinoma after curative ablation using three tumor markers (Tateishi et al). 2006;44:1518-1527

Amino acid

HLA class II alleles, genotypes, haplotypes, and amino acids in primary biliary cirrhosis: A large-scale study (Donaldson et al). 2006; 44:667-674

Ammonia

The brain permeability-surface product for ammonia (Lockwood and Wack). 2006;44:1052-1053 (Correspondence)

The brain permeability-surface product for ammonia (Sørensen and Keiding). 2006;44:1053-1054 (Reply)

Glutamine: A trojan horse in ammonia neurotoxicity (Albrecht and Norenberg). 2006;44:788-794

Amoxicillin-clavulanate hepatotoxicity

Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: A prospective series from Spain (Lucena et al). 2006;44: 850-856

Anemia

Cost-effectiveness of hematologic growth factors for anemia occurring during hepatitis C combination therapy (Del Rio et al). 2006;44:1598-1606

Animal models

Actin organization and hepatocyte differentiation are regulated by extracellular matrix via PI-4,5-bisphosphate in the rat (Kimata et al). 2006;44:140-151

Activation of Wnt/β-catenin pathway during hepatocyte growth factor–induced hepatomegaly in mice (Apte et al). 2006;44:992-1002

Anti-HCV therapies in chimeric *scid*-Alb/uPA mice parallel outcomes in human clinical application (Kneteman et al). 2006;44:515 (Correction)

Atp8b1 deficiency in mice reduces resistance of the canalicular membrane to hydrophobic bile salts and impairs bile salt transport (Paulusma et al). 2006;44:195-204

An autoimmune biliary disease mouse model for primary biliary cirrhosis: Something for everyone (Mason). 2006;44:1047-1050 (Hepatology *Elsewhere*)

Bile acids inhibit interleukin-6 signaling via gp130 receptor-dependent and -independent pathways in rat liver (Graf et al). 2006;44:1206-1217

Brain edema and inflammatory activation in bile duct ligated rats with diet-induced hyperammonemia: A model of hepatic encephalopathy in cirrhosis (Jover et al). 2006;44:771 (Correction)

CD4+ immune escape and subsequent T-cell failure following chimpanzee immunization against hepatitis C virus (Puig et al). 2006;44:736-745

Cellular and humoral autoimmunity directed at bile duct epithelia in murine biliary atresia (Mack et al). 2006;44:1231-1239

Constitutive androstane receptor (CAR) ligand, TCPOBOP, attenuates Fas-induced murine liver injury by altering Bcl-2 proteins (Baskin-Bey et al). 2006;44:252-262

Contribution of hepatic adenosine A_1 receptors to renal dysfunction associated with acute liver injury in rats (Ming et al). 2006;44:813-822

Critical role of acidic sphingomyelinase in murine hepatic ischemia-reperfusion injury (Llacuna et al). 2006;44:561-572

The detection of bacterial DNA in blood of rats with CCl_4-induced cirrhosis with ascites represents episodes of bacterial translocation (Guarner et al). 2006;44:633-639

Disruption of the *Arnt* gene in endothelial cells causes hepatic vascular defects and partial embryonic lethality in mice (Yim et al). 2006;44:550-560

Enhancement by pyrazole of lipopolysaccharide-induced liver injury in mice: Role of cytochrome P450 2E1 and 2A5 (Lu and Cederbaum). 2006;44:263-274

The eNOS cofactor tetrahydrobiopterin improves endothelial dysfunction in livers of rats with CCl_4 cirrhosis (Matei et al). 2006;44:44-52

Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice (Ding et al). 2006;44:515 (Correction)

Expression of a cyclin E1 isoform in mice is correlated with the quiescent cell cycle status of hepatocytes *in vivo* (Zschemisch et al). 2006;44: 164-173

Expression of non-signaling membrane-anchored death receptors protects murine livers in different models of hepatitis (Descamps et al). 2006;44: 399-409

Favored T helper 1 response in a mouse model of hepatosteatosis is associated with enhanced T cell–mediated hepatitis (Kremer et al). 2006;44:216-227

HCV core expression in hepatocytes protects against autoimmune liver injury and promotes liver regeneration in mice (Kawamura et al). 2006;44:936-944

Hepatic expression of glutamine synthetase in rats is controlled by STAT5 and TCF transcription factors (Werth et al). 2006;44:967-975

Hepatic precursors derived from murine embryonic stem cells contribute to regeneration of injured liver (Heo et al). 2006;44:1478-1486

Hepatology Highlights (Alter). 2006;44: 3-6

Hepatology Highlights (Kaplowitz). 2006;44:285-286

Hypercholesterolemia in rats with hepatomas: Increased oxysterols accelerate efflux but do not inhibit biosynthesis of cholesterol (Hirayama et al). 2006;44:602-611

IL-2 receptor $\alpha^{-/-}$ mice and the development of primary biliary cirrhosis (Wakabayashi et al). 2006; 44:1240-1249

Immunosuppression using the mTOR inhibition mechanism affects replacement of rat liver with transplanted cells (Wu et al). 2006; 44:410-419

In vivo immune modulatory activity of hepatic stellate cells in mice (Chen et al). 2006;44:1171-1181

Inactivation of oxidized and S-nitrosylated mitochondrial proteins in alcoholic fatty liver of rats (Moon et al). 2006;44:1218-1230

Indomethacin increases liver damage in a murine model of liver injury from alpha-1-antitrypsin deficiency (Rudnick et al). 2006;44:976-982

Induction of Gas6 protein in CCl_4-induced rat liver injury and anti-apoptotic effect on hepatic stellate cells (Lafdil et al). 2006;44:228-239

Induction of murine liver damage by overexpression of CD40 ligand provides an experimental model to study fulminant hepatic failure (Schmitz et al). 2006;44:430-439

Intrahepatic injection of adenovirus reduces inflammation and increases gene transfer and therapeutic effect in mice (Crettaz et al). 2006;44: 623-632

Involvement of integrin-linked kinase in carbon tetrachloride–induced hepatic fibrosis in rats (Zhang et al). 2006;44:612-622

Ischemic preconditioning of the murine liver protects through the Akt kinase pathway (Izuishi et al). 2006;44: 573-580

Lack of assessment of body temperature in mice with acetaminophen toxicity (Vaquero et al). 2006;44:279-280 (Correspondence)

Lack of chemokine receptor CCR5 promotes murine fulminant liver

failure (Tiegs). 2006;44:275-277 (Hepatology *Elsewhere*)
Lack of UCP2 reduces Fas-mediated liver injury in *ob/ob* mice and reveals importance of cell-specific UCP2 expression (Fülöp et al). 2006;44: 592-601
Leptin-mediated neovascularization is a prerequisite for progression of nonalcoholic steatohepatitis in rats (Kitade et al). 2006;44:983-991
The liver X-receptor alpha controls hepatic expression of the human bile acid–glucuronidating UGT1A3 enzyme in human cells and transgenic mice (Verreault et al). 2006;44:368-378
Loss of MMP 13 attenuates murine hepatic injury and fibrosis during cholestasis (Uchinami et al). 2006; 44:420-429
Matrix metalloproteinase-9 is an important factor in hepatic regeneration after partial hepatectomy in mice (Olle et al). 2006;44:540-549
Mechanisms of endotoxin-induced NO, IL-6, and TNF-α production in activated rat hepatic stellate cells: Role of p38 MAPK (Thirunavukkarasu et al). 2006;44: 389-398
Monocrotaline promotes transplanted cell engraftment and advances liver repopulation in rats via liver conditioning (Joseph et al). 2006; 44:1411-1420
Multiple polymorphic loci determine basal hepatic and splenic iron status in mice (Grant et al). 2006;44:174-185
Oncogene-specific gene expression signatures at preneoplastic stage in mice define distinct mechanisms of hepatocarcinogenesis (Coulouarn et al). 2006;44:1003-1011
Phenobarbital regulates nuclear expression of HNF-4α in mouse and rat hepatocytes independent of CAR and PXR (Bell and Michalopoulos). 2006;44:186-194
pH-Independent entry and sequential endosomal sorting are major determinants of hepadnaviral infection in primary hepatocytes (Funk et al). 2006;44:685-693
Plasma cholesterol is hyperresponsive to statin in ABCG5/ABCG8 transgenic mice (Tang et al). 2006; 44:1259-1266
Protection against Western diet–induced obesity and hepatic steatosis in liver fatty acid–binding protein knockout mice (Newberry et al). 2006;44: 1191-1205
Role of neutrophils in a mouse model of halothane-induced liver injury (You et al). 2006;44:1421-1431
Sphingosine 1-phosphate protects rat liver sinusoidal endothelial cells from ethanol-induced apoptosis: Role of intracellular calcium and nitric oxide (Zheng et al). 2006;44: 1278-1287
STAT1 contributes to dsRNA inhibition of liver regeneration after partial hepatectomy in mice (Sun et al). 2006;44:955-966
STAT1 inhibits liver fibrosis in mice by inhibiting stellate cell proliferation and stimulating NK cell cytotoxicity (Jeong et al). 2006;44:1441-1451
Sustained activation of Rac1 in hepatic stellate cells promotes liver injury and fibrosis in mice (Choi et al). 2006;44:1267-1277
T lymphocytes interact with hepatocytes through fenestrations in murine liver sinusoidal endothelial cells (Warren et al). 2006;44:1182-1190
TIP30 inhibits growth of HCC cell lines and inhibits HCC xenografts in mice in combination with 5-FU (Zhao et al). 2006;44:205-215
Upregulation of calpastatin in regenerating and developing rat liver: Role in resistance against hepatotoxicity (Limaye et al). 2006; 44:379-388
Uric acid and anti-TNF antibody improve mitochondrial dysfunction in ob/ob mice (García-Ruiz et al). 2006;44:581-591
Zonal gene expression in murine liver: Are tumors helping us to solve the mystery? (Gebhardt and Ueberham). 2006;44:512 (Correspondence)
Zonal gene expression in murine liver: Are tumors helping us to solve the mystery? (Hailfinger et al). 2006;44: 512-513 (Reply)

alpha-1-Antitrypsin deficiency
Hepatology Highlights (Kaplowitz). 2006;44:1061-1062
Indomethacin increases liver damage in a murine model of liver injury from alpha-1-antitrypsin deficiency (Rudnick et al). 2006;44:976-982

α1-Antitrypsin gene
α1-Antitrypsin mutations in NAFLD: High prevalence and association with altered iron metabolism but not with liver damage (Valenti et al). 2006;44:857-864

Antiviral therapy
Anti-HCV therapies in chimeric *scid*-Alb/uPA mice parallel outcomes in human clinical application (Kneteman et al). 2006;44:515 (Correction)
Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C Trial (Everson et al). 2006;44:1675-1684

Apoptosis
In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease (Wieckowska et al). 2006;44: 27-33 (Rapid Communication)
Sphingosine 1-phosphate protects rat liver sinusoidal endothelial cells from ethanol-induced apoptosis: Role of intracellular calcium and nitric oxide (Zheng et al). 2006;44: 1278-1287

Aquaporin-1
Aquaporin-1 and aquaporin-2 urinary excretion in cirrhosis: Relationship with ascites and hepatorenal syndrome (Esteva-Font et al). 2006; 44:1555-1563

Aquaporin-2
Aquaporin-1 and aquaporin-2 urinary excretion in cirrhosis: Relationship with ascites and hepatorenal syndrome (Esteva-Font et al). 2006; 44:1555-1563
Hepatology Highlights (Elias). 2006;44: 1374-1375

***Arnt* gene**
Disruption of the *Arnt* gene in endothelial cells causes hepatic vascular defects and partial embryonic lethality in mice (Yim et al). 2006;44:550-560

Ascites
Aquaporin-1 and aquaporin-2 urinary excretion in cirrhosis: Relationship with ascites and hepatorenal syndrome (Esteva-Font et al). 2006; 44:1555-1563
The detection of bacterial DNA in blood of rats with CCl_4-induced cirrhosis with ascites represents episodes of bacterial translocation (Guarner et al). 2006;44:633-639
Effects of clonidine on diuretic response in ascitic patients with cirrhosis and activation of sympathetic nervous system (Lenaerts et al). 2006;44: 844-849

Aspartyl-asparagyl β hydroxylase
Aspartyl-asparagyl β hydroxylase overexpression in human hepatoma is linked to activation of insulin-like growth factor and Notch signaling mechanisms (Cantarini et al). 2006; 44:446-457

Atazanavir
Gilbert's disease and atazanavir: From phenotype to UDP-glucuronosyltransferase haplotype (Lankisch et al). 2006;44:1324-1332

***ATP8B1* gene**
Atp8b1 deficiency in mice reduces resistance of the canalicular membrane to hydrophobic bile salts

and impairs bile salt transport (Paulusma et al). 2006;44:195-204
Hepatology Highlights (Kaplowitz). 2006;44:285-286

ATP-binding-cassette (ABC) transporter
Interindividual variability of canalicular ATP-binding-cassette (ABC)–transporter expression in human liver (Meier et al). 2006;44: 62-74
Plasma cholesterol is hyperresponsive to statin in ABCG5/ABCG8 transgenic mice (Tang et al). 2006; 44:1259-1266

Autoimmune biliary disease
An autoimmune biliary disease mouse model for primary biliary cirrhosis: Something for everyone (Mason). 2006;44:1047-1050 (Hepatology *Elsewhere*)
Cellular and humoral autoimmunity directed at bile duct epithelia in murine biliary atresia (Mack et al). 2006;44:1231-1239

Autoimmune hepatitis
Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis (Poupon et al). 2006;44:85-90

Autoimmune liver injury
HCV core expression in hepatocytes protects against autoimmune liver injury and promotes liver regeneration in mice (Kawamura et al). 2006;44:936-944

B

Bcl-2 protein
Constitutive androstane receptor (CAR) ligand, TCPOBOP, attenuates Fas-induced murine liver injury by altering Bcl-2 proteins (Baskin-Bey et al). 2006;44:252-262

Beta-lipoprotein
Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment (Gopal et al). 2006;44: 335-340

Bile acids
Bile acids inhibit interleukin-6 signaling via gp130 receptor-dependent and -independent pathways in rat liver (Graf et al). 2006;44:1206-1217

Bile duct ligation
Brain edema and inflammatory activation in bile duct ligated rats with diet-induced hyperammonemia: A model of hepatic encephalopathy in cirrhosis (Jover et al). 2006;44:771 (Correction)

Bile duct strictures
Proteomic profiling of cholangiocarcinoma: Diagnostic potential of SELDI-TOF MS in malignant bile duct stricture (Scarlett et al). 2006;44:658-666

Bile ducts
Cellular and humoral autoimmunity directed at bile duct epithelia in murine biliary atresia (Mack et al). 2006;44:1231-1239

Bile salt export pump (BSEP, *ABCB11*)
Interindividual variability of canalicular ATP-binding-cassette (ABC)–transporter expression in human liver (Meier et al). 2006;44: 62-74
Investigation of the *Lith1* candidate genes *ABCB11* and *LXRA* in human gallstone disease (Schafmayer et al). 2006;44:650-657

Bile salt export pump deficiency
Hepatocellular carcinoma in ten children under five years of age with bile salt export pump deficiency (Knisely AS). 2006;44:478-486

Bile salt transport
Atp8b1 deficiency in mice reduces resistance of the canalicular membrane to hydrophobic bile salts and impairs bile salt transport (Paulusma et al). 2006;44:195-204

Biliary atresia
Cellular and humoral autoimmunity directed at bile duct epithelia in murine biliary atresia (Mack et al). 2006;44:1231-1239
Management of patients with biliary atresia in France: Results of a decentralized policy 1986-2002 (Serinet et al). 2006;44:75-84

Biliary cirrhosis, primary
An autoimmune biliary disease mouse model for primary biliary cirrhosis: Something for everyone (Mason). 2006;44:1047-1050 (Hepatology *Elsewhere*)
Biliary drainage transiently relieves intractable pruritus in primary biliary cirrhosis (Beuers et al). 2006; 44:280-281 (Correspondence)
Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis (Poupon et al). 2006;44:85-90
Fatigue in primary biliary cirrhosis is associated with excessive daytime somnolence (Newton et al). 2006; 44:91-98
Hepatology Highlights (Elias). 2006;44: 1374-1375
HLA class II alleles, genotypes, haplotypes, and amino acids in primary biliary cirrhosis: A large-scale study (Donaldson et al). 2006; 44:667-674
IL-2 receptor $\alpha^{-/-}$ mice and the development of primary biliary cirrhosis (Wakabayashi et al). 2006; 44:1240-1249
Smoking and increased severity of hepatic fibrosis in primary biliary cirrhosis: A cross validated retrospective assessment (Zein et al). 2006;44:1564-1571

Biliary disease, autoimmune
An autoimmune biliary disease mouse model for primary biliary cirrhosis: Something for everyone (Mason). 2006;44:1047-1050 (Hepatology *Elsewhere*)

Biliary drainage
Biliary drainage transiently relieves intractable pruritus in primary biliary cirrhosis (Beuers et al). 2006; 44:280-281 (Correspondence)

Biliary papillary tumors
Biliary papillary tumors share pathological features with intraductal papillary mucinous neoplasm of the pancreas (Zen et al). 2006;44:1333-1343

Biology
Liver biology and pathobiology (Kaplowitz). 2006;44:282 (Correction)

1.4-Bis[2,3-(3,5-dichloropyridyloxy)] benzene (TCPOBOP)
Constitutive androstane receptor (CAR) ligand, TCPOBOP, attenuates Fas-induced murine liver injury by altering Bcl-2 proteins (Baskin-Bey et al). 2006;44:252-262

Blood components
Hepatitis B virus genotype G monoinfection and its transmission by blood components (Chudy et al). 2006;44:99-107

Blood donors
Characterization of HBV DNA^{+}/$HBsAg^{-}$ blood donors in Poland identified by triplex NAT (Brojer et al). 2006;44:1666-1674

Blood-brain barrier
The brain permeability-surface product for ammonia (Lockwood and Wack). 2006;44:1052-1053 (Correspondence)
The brain permeability-surface product for ammonia (Sørensen and Keiding). 2006;44:1053-1054 (Reply)

Body temperature
Lack of assessment of body temperature in mice with acetaminophen toxicity (Vaquero et al). 2006;44:279-280 (Correspondence)

Brain edema
Brain edema and inflammatory activation in bile duct ligated rats with diet-induced hyperammonemia: A model of hepatic encephalopathy in cirrhosis (Jover et al). 2006;44:771 (Correction)

Budd-Chiari syndrome
Aiming at minimal invasiveness as a therapeutic strategy for Budd-Chiari

syndrome (Plessier et al). 2006;44: 1308-1316

Byler disease
Atp8b1 deficiency in mice reduces resistance of the canalicular membrane to hydrophobic bile salts and impairs bile salt transport (Paulusma et al). 2006;44:195-204

C

Calcium, intracellular
Sphingosine 1-phosphate protects rat liver sinusoidal endothelial cells from ethanol-induced apoptosis: Role of intracellular calcium and nitric oxide (Zheng et al). 2006;44: 1278-1287

Calpastatin
Hepatology Highlights (Kaplowitz). 2006;44:285-286
Upregulation of calpastatin in regenerating and developing rat liver: Role in resistance against hepatotoxicity (Limaye et al). 2006; 44:379-388

Canalicular membrane
Atp8b1 deficiency in mice reduces resistance of the canalicular membrane to hydrophobic bile salts and impairs bile salt transport (Paulusma et al). 2006;44:195-204

Carbohydrates
A low-carbohydrate diet rapidly and dramatically reduces intrahepatic triglyceride content (Browning et al). 2006;44:487-488 (Concise Communication)

Carbon tetrachloride (CCl_4)
The detection of bacterial DNA in blood of rats with CCl_4-induced cirrhosis with ascites represents episodes of bacterial translocation (Guarner et al). 2006;44:633-639
The eNOS cofactor tetrahydrobiopterin improves endothelial dysfunction in livers of rats with CCl_4 cirrhosis (Matei et al). 2006;44:44-52
Induction of Gas6 protein in CCl_4-induced rat liver injury and anti-apoptotic effect on hepatic stellate cells (Lafdil et al). 2006;44:228-239
Involvement of integrin-linked kinase in carbon tetrachloride–induced hepatic fibrosis in rats (Zhang et al). 2006;44:612-622

β-Catenin
Activation of Wnt/β-catenin pathway during hepatocyte growth factor–induced hepatomegaly in mice (Apte et al). 2006;44:992-1002

Caucasian Americans
Modeling hepatic fibrosis in African American and Caucasian American patients with chronic hepatitis C virus infection (Fontana et al). 2006;44:925-935

CD4
CD4+ immune escape and subsequent T-cell failure following chimpanzee immunization against hepatitis C virus (Puig et al). 2006;44:736-745

CD8
Intrahepatic virus-specific IL-10-producing CD8 T cells prevent liver damage during chronic hepatitis C virus infection (Abel et al). 2006;44: 1607-1616
Outcome of acute hepatitis C is related to virus-specific CD4 function and maturation of antiviral memory CD8 responses (Urbani et al). 2006; 44:126-139

CD40 ligand
Induction of murine liver damage by overexpression of CD40 ligand provides an experimental model to study fulminant hepatic failure (Schmitz et al). 2006;44:430-439

CD81
Hepatitis C virus E2 and CD81 interaction may be associated with altered trafficking of dendritic cells in chronic hepatitis C (Nattermann et al). 2006;44:945-954

CD127
Loss of IL-7 receptor alpha-chain (CD127) expression in acute HCV infection associated with viral persistence (Golden-Mason et al). 2006;44:1098-1109

Cell cycle
Expression of a cyclin E1 isoform in mice is correlated with the quiescent cell cycle status of hepatocytes *in vivo* (Zschemisch et al). 2006;44: 164-173
An MLCK-dependent window in late G1 controls S phase entry of proliferating rodent hepatocytes via ERK-p70S6K pathway (Bessard et al). 2006;44:152-163

Cell death
Fooling the Fas ligand in death (Rodrigues and Steer). 2006;44:314-317 (Editorial)

Cell differentiation
Actin organization and hepatocyte differentiation are regulated by extracellular matrix via PI-4,5-bisphosphate in the rat (Kimata et al). 2006;44:140-151

Cell growth
TIP30 inhibits growth of HCC cell lines and inhibits HCC xenografts in mice in combination with 5-FU (Zhao et al). 2006;44:205-215

Cell proliferation
An MLCK-dependent window in late G1 controls S phase entry of proliferating rodent hepatocytes via ERK-p70S6K pathway (Bessard et al). 2006;44:152-163

Cerebral edema
Brain edema and inflammatory activation in bile duct ligated rats with diet-induced hyperammonemia: A model of hepatic encephalopathy in cirrhosis (Jover et al). 2006;44:771 (Correction)

Chemokine receptor CCR5
Lack of chemokine receptor CCR5 promotes murine fulminant liver failure (Tiegs). 2006;44:275-277 (Hepatology *Elsewhere*)

Chenodeoxycholic acid
Human UDP-glucuronosyltransferase (UGT)1A3 enzyme conjugates chenodeoxycholic acid in the liver (Trottier et al). 2006;44:1158-1170

Children
Hepatocellular carcinoma in ten children under five years of age with bile salt export pump deficiency (Knisely AS). 2006;44:478-486
NAFLD in children: A prospective clinical-pathological study and effect of lifestyle advice (Nobili et al). 2006;44:458-465

Chinese
A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B (Zeng et al). 2006;44:108-116

Cholangiocarcinoma
Dynamic FDG-PET is useful for detection of cholangiocarcinoma in patients with PSC listed for liver transplantation (Prytz et al). 2006; 44:1572-1580
Hepatology Highlights (Elias). 2006;44: 1374-1375
Proteomic profiling of cholangiocarcinoma: Diagnostic potential of SELDI-TOF MS in malignant bile duct stricture (Scarlett et al). 2006;44:658-666

Cholangiocarcinoma, intrahepatic
Comparison of gene expression profiles between *Opisthorchis viverrini* and non-*Opisthorchis viverrini* associated human intrahepatic cholangiocarcinoma (Jinawath et al). 2006;44:1025-1038

Cholangitis, sclerosing
Dynamic FDG-PET is useful for detection of cholangiocarcinoma in patients with PSC listed for liver transplantation (Prytz et al). 2006; 44:1572-1580
Hepatology Highlights (Elias). 2006;44: 1374-1375
Primary sclerosing cholangitis: Summary of a workshop (LaRusso et al). 2006; 44:746-764 (Special Article)
Sclerosing cholangitis: A focus on secondary causes (Abdalian and Heathcote). 2006;44:1063-1074

(Perspectives in Clinical Hepatology)

Cholestasis

Gabapentin in patients with the pruritus of cholestasis: A double-blind, randomized, placebo-controlled trial (Bergasa et al). 2006;44:1317-1323

Hepatobiliary transporters and drug-induced cholestasis (Pauli-Magnus and Meier). 2006;44:778-787

Loss of MMP 13 attenuates murine hepatic injury and fibrosis during cholestasis (Uchinami et al). 2006; 44:420-429

Cholesterol

Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment (Gopal et al). 2006;44: 335-340

Hypercholesterolemia in rats with hepatomas: Increased oxysterols accelerate efflux but do not inhibit biosynthesis of cholesterol (Hirayama et al). 2006;44:602-611

Plasma cholesterol is hyperresponsive to statin in ABCG5/ABCG8 transgenic mice (Tang et al). 2006; 44:1259-1266

Chronic hepatitis

A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B (Zeng et al). 2006;44:108-116

Chronic hepatitis B

Different signaling pathways in the livers of patients with chronic hepatitis B or chronic hepatitis C (Honda et al). 2006;44:1122-1138

Favorable effect of adefovir on the number and functionality of myeloid dendritic cells of patients with chronic HBV (van der Molen et al). 2006;44:907-914

Intrahepatic levels and replicative activity of covalently closed circular hepatitis B virus DNA in chronically infected patients (Laras et al). 2006;44:694-702

Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: Relation to treatment response (ter Borg et al). 2006;44:721-727

Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B (Wursthorn et al). 2006;44:675-684

Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127 (Peters et al). 2006; 44:1110-1116

Chronic hepatitis C

Different signaling pathways in the livers of patients with chronic hepatitis B or chronic hepatitis C (Honda et al). 2006;44:1122-1138

Hepatitis C virus E2 and CD81 interaction may be associated with altered trafficking of dendritic cells in chronic hepatitis C (Nattermann et al). 2006;44:945-954

Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C Trial (Everson et al). 2006;44:1675-1684

Intrahepatic virus-specific IL-10-producing CD8 T cells prevent liver damage during chronic hepatitis C virus infection (Abel et al). 2006;44: 1607-1616

Modeling hepatic fibrosis in African American and Caucasian American patients with chronic hepatitis C virus infection (Fontana et al). 2006;44:925-935

A simple noninvasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapy (Yu et al). 2006;44: 1086-1097

Chronic hepatitis C, genotype 3

Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis (Bugianesi et al). 2006;44:1648-1655

Chronic hepatitis D

Treatment of chronic hepatitis D: New advances, old challenges (Farci). 2006;44:536-539 (Editorial)

Chronic hepatitis delta

Efficacy of peginterferon alpha-2b in chronic hepatitis delta: Relevance of quantitative RT-PCR for follow-up (Castelnau et al). 2006;44:728-735

Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta (Niro et al). 2006;44:713-720

Chronic liver disease

Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases (Ganne-Carrié et al). 2006;44:1511-1517

Time to ban smoking in patients with chronic liver disease (Bataller). 2006;44:1408-1410 (Editorial)

Chronic myeloproliferative disorders

Role of the *JAK2* mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis (Primignani et al). 2006;44:1528-1534

Cirrhosis. *See also* Primary biliary cirrhosis

Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases (Ganne-Carrié et al). 2006;44:1511-1517

Adrenal insufficiency in patients with cirrhosis and septic shock: Effect of treatment with hydrocortisone on survival (Fernández et al). 2006;44: 1288-1295

Aquaporin-1 and aquaporin-2 urinary excretion in cirrhosis: Relationship with ascites and hepatorenal syndrome (Esteva-Font et al). 2006; 44:1555-1563

Brain edema and inflammatory activation in bile duct ligated rats with diet-induced hyperammonemia: A model of hepatic encephalopathy in cirrhosis (Jover et al). 2006;44:771 (Correction)

Derivation and validation of a new global method for assessing nutritional status in patients with cirrhosis (Morgan et al). 2006;44: 823-835

The detection of bacterial DNA in blood of rats with CCl_4-induced cirrhosis with ascites represents episodes of bacterial translocation (Guarner et al). 2006;44:633-639

The effect of single oral low-dose losartan on posture-related sodium handling in post-TIPS ascites-free cirrhosis (Therapondos et al). 2006; 44:640-649

Effects of clonidine on diuretic response in ascitic patients with cirrhosis and activation of sympathetic nervous system (Lenaerts et al). 2006;44: 844-849

Elevated levels of von Willebrand factor in cirrhosis support platelet adhesion despite reduced functional capacity (Lisman et al). 2006;44:53-61

The eNOS cofactor tetrahydrobiopterin improves endothelial dysfunction in livers of rats with CCl_4 cirrhosis (Matei et al). 2006;44:44-52

HCV RNA detection by TMA during the Hepatitis C Antiviral Long-term Treatment against Cirrhosis (Halt-C) Trial (Morishima et al). 2006;44: 360-367

Hepatology Highlights (Alter). 2006;44: 3-6

Hepatology Highlights (Elias). 2006;44: 519-520, 1374-1375

Hyponatremia in cirrhosis: Results of the Cirrhotic Ascites Patient Population Survey (Angeli et al). 2006;44:1535-1542

Impaired 11β-hydroxysteroid dehydrogenase contributes to renal sodium avidity in cirrhosis: Hypothesis or fact? (Frey). 2006;44: 795-801

Prevention of hepatocellular carcinoma recurrence with alpha-interferon

after liver resection in HCV cirrhosis (Mazzaferro et al). 2006; 44:1543-1554
Thrombin generation in patients with cirrhosis: The role of platelets (Tripodi et al). 2006;44:440-445
Cirrhotic Ascites Patient Population Survey
Hyponatremia in cirrhosis: Results of a patient population survey (Angeli et al). 2006;44:1535-1542
Clavulanate
Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: A prospective series from Spain (Lucena et al). 2006;44: 850-856
Clinical trials
Beyond randomized controlled trials: A critical comparison of trials with nonrandomized studies (Sørensen et al). 2006;44:1075-1082
Clonidine
Effects of clonidine on diuretic response in ascitic patients with cirrhosis and activation of sympathetic nervous system (Lenaerts et al). 2006;44: 844-849
Coagulation disorders
Coagulation disorders and hemostasis in liver disease: Pathophysiology and critical assessment of current management (Caldwell et al). 2006; 44:1039-1046 (Special Article)
Con A
Hepatology Highlights (Kaplowitz). 2006;44:285-286
Cosmetic procedures
Relationship of cosmetic procedures and drug use to hepatitis C and hepatitis B virus infections in a low-risk population (Hwang et al). 2006;44: 341-351
Costa, Robert H.
Robert H. Costa: 1957-2006 (Raychaudhuri et al). 2006;44:1364 (Obituary)
Cyclin E1
Expression of a cyclin E1 isoform in mice is correlated with the quiescent cell cycle status of hepatocytes *in vivo* (Zschemisch et al). 2006;44: 164-173
Cytochrome P450 2A5
Enhancement by pyrazole of lipopolysaccharide-induced liver injury in mice: Role of cytochrome P450 2E1 and 2A5 (Lu and Cederbaum). 2006;44:263-274
Cytochrome P450 2E1
Enhancement by pyrazole of lipopolysaccharide-induced liver injury in mice: Role of cytochrome P450 2E1 and 2A5 (Lu and Cederbaum). 2006;44:263-274
Hepatology Highlights (Kaplowitz). 2006;44:285-286

D

Dallas Heart Study
Statins and hepatic steatosis: Perspectives from the Dallas Heart Study (Browning). 2006;44:466-471
Darbepoietin alpha
Cost-effectiveness of hematologic growth factors for anemia occurring during hepatitis C combination therapy (Del Rio et al). 2006;44:1598-1606
Daytime somnolence
Fatigue in primary biliary cirrhosis is associated with excessive daytime somnolence (Newton et al). 2006; 44:91-98
Death receptors
Expression of non-signaling membrane-anchored death receptors protects murine livers in different models of hepatitis (Descamps et al). 2006;44: 399-409
Dendritic cells
Favorable effect of adefovir on the number and functionality of myeloid dendritic cells of patients with chronic HBV (van der Molen et al). 2006;44:907-914
Hepatitis C virus E2 and CD81 interaction may be associated with altered trafficking of dendritic cells in chronic hepatitis C (Nattermann et al). 2006;44:945-954
Hepatology Highlights (Alter). 2006;44: 775-777
Des-gamma-carboxy prothrombin
Prediction of recurrence of hepatocellular carcinoma after curative ablation using three tumor markers (Tateishi et al). 2006;44:1518-1527
Diabetes
Diabetes and hepatocellular carcinoma (Beasley). 2006;44:1408-1410 (Editorial)
Diabetic hepatosclerosis
Diabetic hepatosclerosis: A novel entity or a rare form of nonalcoholic fatty liver disease? (Mendoza and Younossi). 2006;44:1362-1363 (Hepatology *Elsewhere*)
Diet
Brain edema and inflammatory activation in bile duct ligated rats with diet-induced hyperammonemia: A model of hepatic encephalopathy in cirrhosis (Jover et al). 2006;44:771 (Correction)
A low-carbohydrate diet rapidly and dramatically reduces intrahepatic triglyceride content (Browning et al). 2006;44:487-488 (Concise Communication)
Protection against Western diet–induced obesity and hepatic steatosis in liver fatty acid–binding protein knockout mice (Newberry et al). 2006;44: 1191-1205
Diuresis
Effects of clonidine on diuretic response in ascitic patients with cirrhosis and activation of sympathetic nervous system (Lenaerts et al). 2006;44: 844-849
DNA, covalently closed circular (cccDNA)
Hepatology Highlights (Alter). 2006;44: 775-777
Intrahepatic levels and replicative activity of covalently closed circular hepatitis B virus DNA in chronically infected patients (Laras et al). 2006;44:694-702
Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B (Wursthorn et al). 2006;44:675-684
Drug use
Relationship of cosmetic procedures and drug use to hepatitis C and hepatitis B virus infections in a low-risk population (Hwang et al). 2006;44: 341-351
Drug-induced cholestasis
Hepatobiliary transporters and drug-induced cholestasis (Pauli-Magnus and Meier). 2006;44:778-787
Drug-induced liver injury
Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry (Andrade et al). 2006;44: 1581-1588
Duck hepatitis B virus (DHBV)
pH-Independent entry and sequential endosomal sorting are major determinants of hepadnaviral infection in primary hepatocytes (Funk et al). 2006;44:685-693

E

Embryonic stem cells
Hepatic precursors derived from murine embryonic stem cells contribute to regeneration of injured liver (Heo et al). 2006;44:1478-1486
Endothelial cells
Disruption of the *Arnt* gene in endothelial cells causes hepatic vascular defects and partial embryonic lethality in mice (Yim et al). 2006;44:550-560
Endothelial cells, sinusoidal
Hepatology Highlights (Kaplowitz). 2006;44:1061-1062
Sphingosine 1-phosphate protects rat liver sinusoidal endothelial cells from ethanol-induced apoptosis: Role of intracellular calcium and nitric oxide (Zheng et al). 2006;44: 1278-1287
T lymphocytes interact with hepatocytes

through fenestrations in murine liver sinusoidal endothelial cells (Warren et al). 2006;44:1182-1190

Endothelial progenitor cells, circulating
Significance of circulating endothelial progenitor cells in hepatocellular carcinoma (Ho et al). 2006;44:836-843

Endothelium
The eNOS cofactor tetrahydrobiopterin improves endothelial dysfunction in livers of rats with CCl_4 cirrhosis (Matei et al). 2006;44:44-52
Holey endothelium: Gateways for naïve T cell activation (McAvoy and Kubes). 2006;44:1083-1085 (Editorial)

Endotoxins
Mechanisms of endotoxin-induced NO, IL-6, and TNF-α production in activated rat hepatic stellate cells: Role of p38 MAPK (Thirunavukkarasu et al). 2006;44:389-398

Entecavir
Entecavir resistance is rare in nucleoside naïve patients with hepatitis B (Colonno et al). 2006;44:1656-1665
Hepatitis B virus resistance to entecavir in nucleoside-naïve patients: Does it exist? (Zoulim). 2006;44:1404-1407 (Editorial)

Enzymes, elevated
Long-term follow-up of patients with NAFLD and elevated liver enzymes (Ekstedt et al). 2006;44:865-873

Epoetin alpha
Cost-effectiveness of hematologic growth factors for anemia occurring during hepatitis C combination therapy (Del Rio et al). 2006;44:1598-1606

Ethanol
Sphingosine 1-phosphate protects rat liver sinusoidal endothelial cells from ethanol-induced apoptosis: Role of intracellular calcium and nitric oxide (Zheng et al). 2006;44:1278-1287

Exendin-4
Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice (Ding et al). 2006;44:515 (Correction)

Extracellular matrix
Actin organization and hepatocyte differentiation are regulated by extracellular matrix via PI-4,5-bisphosphate in the rat (Kimata et al). 2006;44:140-151

Extracellular signal-regulated kinase
An MLCK-dependent window in late G1 controls S phase entry of proliferating rodent hepatocytes via ERK-p70S6K pathway (Bessard et al). 2006;44:152-163

F

Fas
Constitutive androstane receptor (CAR) ligand, TCPOBOP, attenuates Fas-induced murine liver injury by altering Bcl-2 proteins (Baskin-Bey et al). 2006;44:252-262
Lack of UCP2 reduces Fas-mediated liver injury in ob/ob mice and reveals importance of cell-specific UCP2 expression (Fülöp et al). 2006;44:592-601
Reg2 inactivation increases sensitivity to Fas hepatotoxicity and delays liver regeneration post-hepatectomy in mice (Lieu et al). 2006;44:1452-1464

Fas ligand
Fooling the Fas ligand in death (Rodrigues and Steer). 2006;44:314-317 (Editorial)

Fatigue
Fatigue in primary biliary cirrhosis is associated with excessive daytime somnolence (Newton et al). 2006;44:91-98

Fatty liver
Gender, fatty liver and GGT (Carulli et al). 2006;44:278-279 (Correspondence)
Inactivation of oxidized and S-nitrosylated mitochondrial proteins in alcoholic fatty liver of rats (Moon et al). 2006;44:1218-1230
Lack of UCP2 reduces Fas-mediated liver injury in ob/ob mice and reveals importance of cell-specific UCP2 expression (Fülöp et al). 2006;44:592-601

Fatty liver disease, nonalcoholic
α1-Antitrypsin mutations in NAFLD: High prevalence and association with altered iron metabolism but not with liver damage (Valenti et al). 2006;44:857-864
Controversies in the management of pediatric liver disease: Hepatitis B, C and NAFLD: Summary of a single topic conference (Shneider et al). 2006;44:1344-1354 (Meeting Report)
Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease (Merriman et al). 2006;44:874-880
Diabetic hepatosclerosis: A novel entity or a rare form of nonalcoholic fatty liver disease? (Mendoza and Younossi). 2006;44:1362-1363 (Hepatology *Elsewhere*)
Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis (Bugianesi et al). 2006;44:1648-1655
In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease (Wieckowska et al). 2006;44:27-33 (Rapid Communication)
Long-term follow-up of patients with NAFLD and elevated liver enzymes (Ekstedt et al). 2006;44:865-873
NAFLD in children: A prospective clinical-pathological study and effect of lifestyle advice (Nobili et al). 2006;44:458-465

FIB-4
FIB-4: A simple, inexpensive and accurate marker of fibrosis in HCV-infected patients (Sterling). 2006;44:769-770 (Reply)
FIB-4: A simple, inexpensive and accurate marker of fibrosis in HCV-infected patients (Vallet-Pichard et al). 2006;44:769 (Correspondence)

Fibrogenesis
Oxidative-stress and IL-6 mediate the fibrogenic effects of rodent Kupffer cells on stellate cells (Nieto). 2006;44:1487-1501
Upregulation of the tumor suppressor gene menin in hepatocellular carcinomaa and its significance in fibrogenesis (Zindy et al). 2006;44:1296-1307

Fibrosis
FIB-4: A simple, inexpensive and accurate marker of fibrosis in HCV-infected patients (Sterling). 2006;44:769-770 (Reply)
FIB-4: A simple, inexpensive and accurate marker of fibrosis in HCV-infected patients (Vallet-Pichard et al). 2006;44:769 (Correspondence)
Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis (Bugianesi et al). 2006;44:1648-1655
Loss of MMP 13 attenuates murine hepatic injury and fibrosis during cholestasis (Uchinami et al). 2006;44:420-429
Modeling hepatic fibrosis in African American and Caucasian American patients with chronic hepatitis C virus infection (Fontana et al). 2006;44:925-935
Reversibility of hepatic fibrosis in treated genetic hemochromatosis: A study of 36 cases (Falize et al). 2006;44:472-477
Smoking and increased severity of hepatic fibrosis in primary biliary cirrhosis: A cross validated retrospective assessment (Zein et al). 2006;44:1564-1571
STAT1 inhibits liver fibrosis in mice by inhibiting stellate cell proliferation and stimulating NK cell cytotoxicity (Jeong et al). 2006;44:1441-1451

Sustained activation of Rac1 in hepatic stellate cells promotes liver injury and fibrosis in mice (Choi et al). 2006;44:1267-1277

Fluorodeoxyglucose-positron emission tomography (FDG-PET), dynamic
Dynamic FDG-PET is useful for detection of cholangiocarcinoma in patients with PSC listed for liver transplantation (Prytz et al). 2006; 44:1572-1580

5-Fluorouracil
TIP30 inhibits growth of HCC cell lines and inhibits HCC xenografts in mice in combination with 5-FU (Zhao et al). 2006;44:205-215

France
Management of patients with biliary atresia in France: Results of a decentralized policy 1986-2002 (Serinet et al). 2006;44:75-84

Fulminant hepatitis A
Fulminant hepatitis A: Disappearing, but not soon enough (Koff). 2006;44: 1397-1399 (Editorial)
Fulminant hepatitis A virus infection in the United States: Incidence, prognosis, and outcomes (Taylor et al). 2006;44:1589-1597

Fulminant liver failure
Induction of murine liver damage by overexpression of CD40 ligand provides an experimental model to study fulminant hepatic failure (Schmitz et al). 2006;44:430-439
Lack of chemokine receptor CCR5 promotes murine fulminant liver failure (Tiegs). 2006;44:275-277 (Hepatology *Elsewhere*)

G

Gabapentin
Gabapentin in patients with the pruritus of cholestasis: A double-blind, randomized, placebo-controlled trial (Bergasa et al). 2006;44:1317-1323

Gallstone disease
Investigation of the *Lith1* candidate genes *ABCB11* and *LXRA* in human gallstone disease (Schafmayer et al). 2006;44:650-657

Gamma-glutamyl transferase (GGT)
Gender, fatty liver and GGT (Carulli et al). 2006;44:278-279 (Correspondence)

Gas6 protein
Induction of Gas6 protein in CCl_4-induced rat liver injury and anti-apoptotic effect on hepatic stellate cells (Lafdil et al). 2006;44:228-239

Gender differences
Gender, fatty liver and GGT (Carulli et al). 2006;44:278-279 (Correspondence)
Gender and liver: Is the liver stiffness weaker in weaker sex? (Corpechot et al). 2006;44:513-514 (Correspondence)

Gene expression
Oncogene-specific gene expression signatures at preneoplastic stage in mice define distinct mechanisms of hepatocarcinogenesis (Coulouarn et al). 2006;44:1003-1011
Zonal gene expression in murine liver: Are tumors helping us to solve the mystery? (Gebhardt and Ueberham). 2006;44:512 (Correspondence)
Zonal gene expression in murine liver: Are tumors helping us to solve the mystery? (Hailfinger et al). 2006;44: 512-513 (Reply)

Gene expression profiles
Comparison of gene expression profiles between *Opisthorchis viverrini* and non-*Opisthorchis viverrini* associated human intrahepatic cholangiocarcinoma (Jinawath et al). 2006;44:1025-1038

Gene polymorphisms
Hepatology Highlights (Elias). 2006;44: 519-520
Multiple polymorphic loci determine basal hepatic and splenic iron status in mice (Grant et al). 2006;44:174-185

Gene therapy
Intrahepatic injection of adenovirus reduces inflammation and increases gene transfer and therapeutic effect in mice (Crettaz et al). 2006;44: 623-632

Gene transfer
Intrahepatic injection of adenovirus reduces inflammation and increases gene transfer and therapeutic effect in mice (Crettaz et al). 2006;44: 623-632

Genomics
Genomics and complex liver disease: Challenges and opportunities (Juran and Lazaridis). 2006;44:1380-1390 (Science Frontier)
Transcriptomic and genomic analysis of human hepatocellular carcinomas and hepatoblastomas (Luo et al). 2006;44:1012-1024

Genotype
Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis (Bugianesi et al). 2006;44:1648-1655
Hepatitis B virus genotype G monoinfection and its transmission by blood components (Chudy et al). 2006;44:99-107
Hepatology Highlights (Alter). 2006;44: 775-777
HLA class II alleles, genotypes, haplotypes, and amino acids in primary biliary cirrhosis: A large-scale study (Donaldson et al). 2006; 44:667-674
Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection (Ozasa et al). 2006;44: 326-334
Influence of hepatitis B virus genotypes on the intra- and extracellular expression of viral DNA and antigens (Sugiyama et al). 2006;44: 915-924
IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection (Lagging et al). 2006;44: 1617-1625
Mixed hepatitis B virus genotype infections: The more, the worse? (Liu et al). 2006;44:770 (Correspondence)

Gilbert's disease
Gilbert's disease and atazanavir: From phenotype to UDP-glucuronosyltransferase haplotype (Lankisch et al). 2006;44:1324-1332

Globalization
Global challenges in liver disease (Williams). 2006;44:521-526 (Perspectives in Clinical Hepatology)

Glutamine
Glutamine: A trojan horse in ammonia neurotoxicity (Albrecht and Norenberg). 2006;44:788-794

Glutamine synthetase
Hepatic expression of glutamine synthetase in rats is controlled by STAT5 and TCF transcription factors (Werth et al). 2006;44:967-975

gp130 receptor
Bile acids inhibit interleukin-6 signaling via gp130 receptor-dependent and -independent pathways in rat liver (Graf et al). 2006;44:1206-1217

Growth factors
Cost-effectiveness of hematologic growth factors for anemia occurring during hepatitis C combination therapy (Del Rio et al). 2006;44:1598-1606
Growth factors during HCV therapy may be "cost-effective," but are they "effective"? (Muir and McHutchison). 2006;44:1400-1403 (Editorial)

H

Halothane
Role of neutrophils in a mouse model of halothane-induced liver injury (You et al). 2006;44:1421-1431

Haplotype
Gilbert's disease and atazanavir: From phenotype to UDP-

glucuronosyltransferase haplotype (Lankisch et al). 2006;44:1324-1332
HLA class II alleles, genotypes, haplotypes, and amino acids in primary biliary cirrhosis: A large-scale study (Donaldson et al). 2006;44:667-674

Helicobacter pylori
H. pylori and platelet counts (Arnold and Harrison). 2006;44:1685-1686 (Hepatology _Elsewhere_)

Hematologic growth factors
Cost-effectiveness of hematologic growth factors for anemia occurring during hepatitis C combination therapy (Del Rio et al). 2006;44:1598-1606

Hemochromatosis
Reversibility of hepatic fibrosis in treated genetic hemochromatosis: A study of 36 cases (Falize et al). 2006;44:472-477

Hemodynamic response–guided therapy
Hemodynamic response–guided therapy for prevention of variceal rebleeding: An uncontrolled pilot study (González et al). 2006;44:806-812

Hemophilia
HCV kinetics, quasispecies, and clearance in treated HCV-infected and HCV/HIV-1-coinfected patients with hemophilia (Shire et al). 2006;44:1146-1157

Hemostasis
Coagulation disorders and hemostasis in liver disease: Pathophysiology and critical assessment of current management (Caldwell et al). 2006;44:1039-1046 (Special Article)
Elevated levels of von Willebrand factor in cirrhosis support platelet adhesion despite reduced functional capacity (Lisman et al). 2006;44:53-61

Hepadnaviral infection
pH-Independent entry and sequential endosomal sorting are major determinants of hepadnaviral infection in primary hepatocytes (Funk et al). 2006;44:685-693

Hepatectomy
Reg2 inactivation increases sensitivity to Fas hepatotoxicity and delays liver regeneration post-hepatectomy in mice (Lieu et al). 2006;44:1452-1464

Hepatectomy, partial
Matrix metalloproteinase-9 is an important factor in hepatic regeneration after partial hepatectomy in mice (Olle et al). 2006;44:540-549
STAT1 contributes to dsRNA inhibition of liver regeneration after partial hepatectomy in mice (Sun et al). 2006;44:955-966

Hepatic encephalopathy
Brain edema and inflammatory activation in bile duct ligated rats with diet-induced hyperammonemia: A model of hepatic encephalopathy in cirrhosis (Jover et al). 2006;44:771 (Correction)

Hepatic steatosis
Statins and hepatic steatosis: Perspectives from the Dallas Heart Study (Browning). 2006;44:466-471

Hepatitis
Expression of non-signaling membrane-anchored death receptors protects murine livers in different models of hepatitis (Descamps et al). 2006;44:399-409
Favored T helper 1 response in a mouse model of hepatosteatosis is associated with enhanced T cell–mediated hepatitis (Kremer et al). 2006;44:216-227
Hepatology Highlights (Alter). 2006;44:775-777

Hepatitis, autoimmune
Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis (Poupon et al). 2006;44:85-90

Hepatitis, chronic
A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B (Zeng et al). 2006;44:108-116

Hepatitis A, fulminant
Fulminant hepatitis A: Disappearing, but not soon enough (Koff). 2006;44:1397-1399 (Editorial)
Fulminant hepatitis A virus infection in the United States: Incidence, prognosis, and outcomes (Taylor et al). 2006;44:1589-1597

Hepatitis B
Controversies in the management of pediatric liver disease: Hepatitis B, C and NAFLD: Summary of a single topic conference (Shneider et al). 2006;44:1344-1354 (Meeting Report)
Entecavir resistance is rare in nucleoside naïve patients with hepatitis B (Colonno et al). 2006;44:1656-1665
Global challenges in liver disease (Williams). 2006;44:521-526 (Perspectives in Clinical Hepatology)
Mixed hepatitis B virus genotype infections: The more, the worse? (Liu et al). 2006;44:770 (Correspondence)
Relationship of cosmetic procedures and drug use to hepatitis C and hepatitis B virus infections in a low-risk population (Hwang et al). 2006;44:341-351
Tenofovir disoproxil fumarate: Role in hepatitis B treatment (Wong and Lok). 2006;44:309-313 (Editorial)
Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy (van Bömmel et al). 2006;44:318-325

Hepatitis B, acute
Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection (Ozasa et al). 2006;44:326-334

Hepatitis B, chronic
Different signaling pathways in the livers of patients with chronic hepatitis B or chronic hepatitis C (Honda et al). 2006;44:1122-1138
Favorable effect of adefovir on the number and functionality of myeloid dendritic cells of patients with chronic HBV (van der Molen et al). 2006;44:907-914
Intrahepatic levels and replicative activity of covalently closed circular hepatitis B virus DNA in chronically infected patients (Laras et al). 2006;44:694-702
Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: Relation to treatment response (ter Borg et al). 2006;44:721-727
Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B (Wursthorn et al). 2006;44:675-684
Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127 (Peters et al). 2006;44:1110-1116

Hepatitis B e antigen (HBeAg)
A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B (Zeng et al). 2006;44:108-116
Hepatology Highlights (Alter). 2006;44:775-777
Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: Relation to treatment response (ter Borg et al). 2006;44:721-727

Hepatitis B s antigen (HBsAg)
Characterization of HBV $DNA^+/HBsAg^-$ blood donors in Poland identified by triplex NAT (Brojer et al). 2006;44:1666-1674
Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B (Wursthorn et al). 2006;44:675-684

Hepatitis B virus

Characterization of HBV $DNA^+/HBsAg^-$ blood donors in Poland identified by triplex NAT (Brojer et al). 2006;44:1666-1674
Evolution of multi-drug resistant hepatitis B virus during sequential therapy (Yim et al). 2006;44:703-712
The half-life of hepatitis B virus (Murray et al). 2006;44:1117-1121 (Concise Communication)
Hepatitis B virus resistance to entecavir in nucleoside-naïve patients: Does it exist? (Zoulim). 2006;44:1404-1407 (Editorial)
Hepatology Highlights (Alter). 2006;44:775-777
Influence of hepatitis B virus genotypes on the intra- and extracellular expression of viral DNA and antigens (Sugiyama et al). 2006;44:915-924
Intrahepatic levels and replicative activity of covalently closed circular hepatitis B virus DNA in chronically infected patients (Laras et al). 2006;44:694-702
Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: Relation to treatment response (ter Borg et al). 2006;44:721-727

Hepatitis B virus genotype G
Hepatitis B virus genotype G monoinfection and its transmission by blood components (Chudy et al). 2006;44:99-107

Hepatitis C
Controversies in the management of pediatric liver disease: Hepatitis B, C and NAFLD: Summary of a single topic conference (Shneider et al). 2006;44:1344-1354 (Meeting Report)
Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment (Gopal et al). 2006;44:335-340
Cost-effectiveness of hematologic growth factors for anemia occurring during hepatitis C combination therapy (Del Rio et al). 2006;44:1598-1606
FIB-4: A simple, inexpensive and accurate marker of fibrosis in HCV-infected patients (Sterling). 2006;44:769-770 (Reply)
FIB-4: A simple, inexpensive and accurate marker of fibrosis in HCV-infected patients (Vallet-Pichard et al). 2006;44:769 (Correspondence)
Global challenges in liver disease (Williams). 2006;44:521-526 (Perspectives in Clinical Hepatology)
Growth factors during HCV therapy may be "cost-effective," but are they "effective"? (Muir and McHutchison). 2006;44:1400-1407 (Editorial)
HCV kinetics, quasispecies, and clearance in treated HCV-infected and HCV/HIV-1-coinfected patients with hemophilia (Shire et al). 2006;44:1146-1157
Hepatitis C virus entry: Molecular biology and clinical implications (Barth et al). 2006;44:527-535 (Concise Review in Mechanisms of Disease)
Hepatitis C virus reinfection in injection drug users (Grebely et al). 2006;44:1139-1145
Relationship of cosmetic procedures and drug use to hepatitis C and hepatitis B virus infections in a low-risk population (Hwang et al). 2006;44:341-351

Hepatitis C, acute
Acute hepatitis C: Dosage and compliance (De Rosa et al). 2006;44:511 (Correspondence)
Acute hepatitis C: Dosage and compliance (Wedemeyer et al). 2006;44:511-512 (Reply)
Duration of peginterferon therapy in acute hepatitis C: A randomized trial (Kamal et al). 2006;44:1055-1056 (Correction) (Rapid Communication)
Loss of IL-7 receptor alpha-chain (CD127) expression in acute HCV infection associated with viral persistence (Golden-Mason et al). 2006;44:1098-1109
Outcome of acute hepatitis C is related to virus-specific CD4 function and maturation of antiviral memory CD8 responses (Urbani et al). 2006;44:126-139
Treatment duration in acute hepatitis C: The issue is not solved yet (Kamal et al). 2006;44:1051-1052 (Reply)
Treatment duration in acute hepatitis C: The issue is not solved yet (Wedemeyer et al). 2006;44:1051 (Correspondence)

Hepatitis C, chronic
Different signaling pathways in the livers of patients with chronic hepatitis B or chronic hepatitis C (Honda et al). 2006;44:1122-1138
Hepatitis C virus E2 and CD81 interaction may be associated with altered trafficking of dendritic cells in chronic hepatitis C (Nattermann et al). 2006;44:945-954
Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C Trial (Everson et al). 2006;44:1675-1684
Intrahepatic virus-specific IL-10-producing CD8 T cells prevent liver damage during chronic hepatitis C virus infection (Abel et al). 2006;44:1607-1616
Modeling hepatic fibrosis in African American and Caucasian American patients with chronic hepatitis C virus infection (Fontana et al). 2006;44:925-935
A simple noninvasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapy (Yu et al). 2006;44:1086-1097

Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) Trial
HCV RNA detection by TMA during the Hepatitis C Antiviral Long-term Treatment against Cirrhosis (Halt-C) Trial (Morishima et al). 2006;44:360-367
Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C Trial (Everson et al). 2006;44:1675-1684

Hepatitis C virus
Anti-HCV therapies in chimeric *scid*-Alb/uPA mice parallel outcomes in human clinical application (Kneteman et al). 2006;44:515 (Correction)
CD4+ immune escape and subsequent T-cell failure following chimpanzee immunization against hepatitis C virus (Puig et al). 2006;44:736-745
A comprehensive system for consistent numbering of HCV sequences, proteins and epitopes (Kuiken et al). 2006;44:1355-1361
Extrahepatic replication of HCV: Insights into clinical manifestations and biological consequences (Blackard et al). 2006;44:15-22 (Concise Review in Mechanisms of Disease)
HCV core expression in hepatocytes protects against autoimmune liver injury and promotes liver regeneration in mice (Kawamura et al). 2006;44:936-944
HCV kinetics, quasispecies, and clearance in treated HCV-infected and HCV/HIV-1-coinfected patients with hemophilia (Shire et al). 2006;44:1146-1157
HCV RNA detection by TMA during the Hepatitis C Antiviral Long-term Treatment against Cirrhosis (Halt-C) Trial (Morishima et al). 2006;44:360-367
Hepatitis C virus entry: Molecular biology and clinical implications (Barth et al). 2006;44:527-535 (Concise Review in Mechanisms of Disease)
Hepatology Highlights (Alter). 2006;44:3-6, 775-777
Loss of IL-7 receptor alpha-chain

(CD127) expression in acute HCV infection associated with viral persistence (Golden-Mason et al). 2006;44:1098-1109
A picture says more than a thousand words: Structural insights into hepatitis C virus translation initiation (Bellecave and Moradpour). 2006;44:1687-1689 (Hepatology *Elsewhere*)
Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis (Mazzaferro et al). 2006; 44:1543-1554
The protein kinase IKKε can inhibit HCV expression independently of IFN and its own expression is downregulated in HCV-infected livers (Vilasco et al). 2006;44:1635-1647
Serum amyloid A has antiviral activity against hepatitis C virus by inhibiting virus entry in a cell culture system (Lavie et al). 2006; 44:1626-1634

Hepatitis C virus E2
Hepatitis C virus E2 and CD81 interaction may be associated with altered trafficking of dendritic cells in chronic hepatitis C (Nattermann et al). 2006;44:945-954

Hepatitis C virus genotype 1
IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection (Lagging et al). 2006;44: 1617-1625

Hepatitis C virus genotype 3
Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis (Bugianesi et al). 2006;44:1648-1655

Hepatitis C virus NS2-3 protease
Surprises from the crystal structure of the hepatitis C virus NS2-3 protease (Gouttenoire et al). 2006;44:1690-1693 (Hepatology *Elsewhere*)

Hepatitis C virus therapy
Global transcriptional response to interferon is a determinant of HCV treatment outcome and is modified by race (He et al). 2006;44:352-359
Hepatology Highlights (Alter). 2006;44: 3-6

Hepatitis C virus vaccine
Hepatology Highlights (Alter). 2006;44: 775-777

Hepatitis D, chronic
Treatment of chronic hepatitis D: New advances, old challenges (Farci). 2006;44:536-539 (Editorial)

Hepatitis delta, chronic
Efficacy of peginterferon alpha-2b in chronic hepatitis delta: Relevance of quantitative RT-PCR for follow-up (Castelnau et al). 2006;44:728-735
Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta (Niro et al). 2006;44:713-720

Hepatobiliary transporters
Hepatobiliary transporters and drug-induced cholestasis (Pauli-Magnus and Meier). 2006;44:778-787

Hepatoblastoma
Transcriptomic and genomic analysis of human hepatocellular carcinomas and hepatoblastomas (Luo et al). 2006;44:1012-1024

Hepatocarcinogenesis
Oncogene-specific gene expression signatures at preneoplastic stage in mice define distinct mechanisms of hepatocarcinogenesis (Coulouarn et al). 2006;44:1003-1011

Hepatocellular carcinoma
Diabetes and hepatocellular carcinoma (Beasley). 2006;44:1408-1410 (Editorial)
Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma (Blechacz et al). 2006;44:1465-1477
Hepatocellular carcinoma in ten children under five years of age with bile salt export pump deficiency (Knisely AS). 2006;44:478-486
Prediction of recurrence of hepatocellular carcinoma after curative ablation using three tumor markers (Tateishi et al). 2006;44:1518-1527
Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis (Mazzaferro et al). 2006; 44:1543-1554
Side population (SP) cells: Taking center stage in regeneration and liver cancer? (Forbes and Alison). 2006; 44:23-26 (Editorial)
Side population purified from hepatocellular carcinoma cells harbors cancer stem cell–like properties (Chiba et al). 2006;44: 240-251
Significance of circulating endothelial progenitor cells in hepatocellular carcinoma (Ho et al). 2006;44:836-843
Tensin2 variant 3 is associated with aggressive tumor behavior in human hepatocellular carcinoma (Yam et al). 2006;44:881-890
TIP30 inhibits growth of HCC cell lines and inhibits HCC xenografts in mice in combination with 5-FU (Zhao et al). 2006;44:205-215
Transcriptomic and genomic analysis of human hepatocellular carcinomas and hepatoblastomas (Luo et al). 2006;44:1012-1024
Upregulation of the tumor suppressor gene menin in hepatocellular carcinomaa and its significance in fibrogenesis (Zindy et al). 2006;44: 1296-1307
Uracil-tegafur as an adjuvant for hepatocellular carcinoma: A randomized trial (Hasegawa et al). 2006;44:891-895

Hepatocyte growth factor
Activation of Wnt/β-catenin pathway during hepatocyte growth factor–induced hepatomegaly in mice (Apte et al). 2006;44:992-1002

Hepatocyte nuclear factor 4α
Phenobarbital regulates nuclear expression of HNF-4α in mouse and rat hepatocytes independent of CAR and PXR (Bell and Michalopoulos). 2006;44:186-194

Hepatocyte transplantation
Noninvasive evaluation of liver repopulation by transplanted hepatocytes using ^{31}P MRS imaging (Landis et al). 2006;44:1250-1258

Hepatocytes
Actin organization and hepatocyte differentiation are regulated by extracellular matrix via PI-4,5-bisphosphate in the rat (Kimata et al). 2006;44:140-151
Expression of a cyclin E1 isoform in mice is correlated with the quiescent cell cycle status of hepatocytes *in vivo* (Zschemisch et al). 2006;44: 164-173
HCV core expression in hepatocytes protects against autoimmune liver injury and promotes liver regeneration in mice (Kawamura et al). 2006;44:936-944
Hepatology Highlights (Alter). 2006;44: 3-6
Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes (Doyle et al). 2006;44:896-906
An MLCK-dependent window in late G1 controls S phase entry of proliferating rodent hepatocytes via ERK-p70S6K pathway (Bessard et al). 2006;44:152-163
Phenobarbital regulates nuclear expression of HNF-4α in mouse and rat hepatocytes independent of CAR and PXR (Bell and Michalopoulos). 2006;44:186-194
pH-Independent entry and sequential endosomal sorting are major determinants of hepadnaviral infection in primary hepatocytes (Funk et al). 2006;44:685-693
Splendid isolation (Reuben). 2006;44: 1365-1370 (Landmarks in Hepatology)
T lymphocytes interact with hepatocytes through fenestrations in murine

liver sinusoidal endothelial cells (Warren et al). 2006;44:1182-1190

Hepatocytes, killer
Hepatology Highlights (Kaplowitz). 2006;44:285-286

Hepatology
Innovations in Hepatology (Blei). 2006;44:1373 (Editor's Corner)
Intermezzo (Blei). 2006;44:2 (Editor's Corner)
Landmarks in Hepatology: A postscript (Reuben). 2006;44:1703 (Landmarks in Hepatology)

Hepatoma
Aspartyl-asparagyl β hydroxylase overexpression in human hepatoma is linked to activation of insulin-like growth factor and Notch signaling mechanisms (Cantarini et al). 2006; 44:446-457
Hypercholesterolemia in rats with hepatomas: Increased oxysterols accelerate efflux but do not inhibit biosynthesis of cholesterol (Hirayama et al). 2006;44:602-611

Hepatomegaly
Activation of Wnt/β-catenin pathway during hepatocyte growth factor–induced hepatomegaly in mice (Apte et al). 2006;44:992-1002

Hepatoproteomics
HepatoProteomics: Applying proteomic technologies to the study of liver function and disease (Diamond et al). 2006;44:299-308 (Science Frontier)

Hepatorenal syndrome
Aquaporin-1 and aquaporin-2 urinary excretion in cirrhosis: Relationship with ascites and hepatorenal syndrome (Esteva-Font et al). 2006; 44:1555-1563
Hepatology Highlights (E!ias). 2006;44: 1374-1375

Hepatosclerosis, diabetic
Diabetic hepatosclerosis: A novel entity or a rare form of nonalcoholic fatty liver disease? (Mendoza and Younossi). 2006;44:1362-1363 (Hepatology *Elsewhere*)

Hepatosteatosis
Favored T helper 1 response in a mouse model of hepatosteatosis is associated with enhanced T cell–mediated hepatitis (Kremer et al). 2006;44:216-227

Hepatotoxicity
Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: A prospective series from Spain (Lucena et al). 2006;44: 850-856
Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry (Andrade et al). 2006;44: 1581-1588
Reg2 inactivation increases sensitivity to Fas hepatotoxicity and delays liver regeneration post-hepatectomy in mice (Lieu et al). 2006;44:1452-1464
Upregulation of calpastatin in regenerating and developing rat liver: Role in resistance against hepatotoxicity (Limaye et al). 2006; 44:379-388

Human immunodeficiency virus infection
HCV kinetics, quasispecies, and clearance in treated HCV-infected and HCV/HIV-1-coinfected patients with hemophilia (Shire et al). 2006;44:1146-1157
Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127 (Peters et al). 2006; 44:1110-1116

Human leukocyte antigen class II
HLA class II alleles, genotypes, haplotypes, and amino acids in primary biliary cirrhosis: A large-scale study (Donaldson et al). 2006; 44:667-674

Human leukocyte antigen DR
Reduced monocyte HLA-DR expression: A novel biomarker of disease severity and outcome in acetaminophen-induced acute liver failure (Antoniades et al). 2006;44:34-43

Hydrocortisone
Adrenal insufficiency in patients with cirrhosis and septic shock: Effect of treatment with hydrocortisone on survival (Fernández et al). 2006;44: 1288-1295

11β-Hydroxysteroid dehydrogenase
Impaired 11β-hydroxysteroid dehydrogenase contributes to renal sodium avidity in cirrhosis: Hypothesis or fact? (Frey). 2006;44: 795-801

Hyperammonemia
Brain edema and inflammatory activation in bile duct ligated rats with diet-induced hyperammonemia: A model of hepatic encephalopathy in cirrhosis (Jover et al). 2006;44:771 (Correction)

Hypercholesterolemia
Hypercholesterolemia in rats with hepatomas: Increased oxysterols accelerate efflux but do not inhibit biosynthesis of cholesterol (Hirayama et al). 2006;44:602-611

Hypertension, portopulmonary
Hepatology Highlights (Elias). 2006;44: 1374-1375
Portopulmonary hypertension: Results from a 10-year screening algorithm (Krowka et al). 2006;44:1502-1510

Hyponatremia
Hyponatremia in cirrhosis: Results of a patient population survey (Angeli et al). 2006;44:1535-1542

I

IKKρ
The protein kinase IKKε can inhibit HCV expression independently of IFN and its own expression is downregulated in HCV-infected livers (Vilasco et al). 2006;44:1635-1647

Immunization
CD4+ immune escape and subsequent T-cell failure following chimpanzee immunization against hepatitis C virus (Puig et al). 2006;44:736-745

Immunomodulation
In vivo immune modulatory activity of hepatic stellate cells in mice (Chen et al). 2006;44:1171-1181

Immunosuppression
Immunosuppression using the mTOR inhibition mechanism affects replacement of rat liver with transplanted cells (Wu et al). 2006; 44:410-419

Indomethacin
Hepatology Highlights (Kaplowitz). 2006;44:1061-1062
Indomethacin increases liver damage in a murine model of liver injury from alpha-1-antitrypsin deficiency (Rudnick et al). 2006;44:976-982

Injection drug users
Hepatitis C virus reinfection in injection drug users (Grebely et al). 2006;44: 1139-1145

Insulin resistance
Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis (Bugianesi et al). 2006;44:1648-1655

Insulin-like growth factor
Aspartyl-asparagyl β hydroxylase overexpression in human hepatoma is linked to activation of insulin-like growth factor and Notch signaling mechanisms (Cantarini et al). 2006; 44:446-457

Integrin-linked kinase
Involvement of integrin-linked kinase in carbon tetrachloride–induced hepatic fibrosis in rats (Zhang et al). 2006;44:612-622

Interferon
Acute hepatitis C: Dosage and compliance (De Rosa et al). 2006; 44:511 (Correspondence)
Acute hepatitis C: Dosage and compliance (Wedemeyer et al). 2006;44:511-512 (Reply)
Different anti-HCV profiles of statins and their potential for combination therapy with interferon (Ikeda et al). 2006;44:117-125

Global transcriptional response to interferon is a determinant of HCV treatment outcome and is modified by race (He et al). 2006;44:352-359
Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis (Mazzaferro et al). 2006; 44:1543-1554
A simple noninvasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapy (Yu et al). 2006;44: 1086-1097

Interferon α
Hepatology Highlights (Alter). 2006;44: 3-6
Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes (Doyle et al). 2006;44:896-906

Interferon α-2b
Duration of peginterferon therapy in acute hepatitis C: A randomized trial (Kamal et al). 2006;44:1055-1056 (Correction) (Rapid Communication)
Efficacy of peginterferon alpha-2b in chronic hepatitis delta: Relevance of quantitative RT-PCR for follow-up (Castelnau et al). 2006;44:728-735
Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: Relation to treatment response (ter Borg et al). 2006;44:721-727
Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B (Wursthorn et al). 2006;44:675-684
Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta (Niro et al). 2006;44:713-720

Interferon γ inducible protein 10 kDa (IP-10 or CXCL10)
IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection (Lagging et al). 2006;44: 1617-1625

Interleukin 2 receptor α
IL-2 receptor $\alpha^{-/-}$ mice and the development of primary biliary cirrhosis (Wakabayashi et al). 2006; 44:1240-1249

Interleukin 6
Bile acids inhibit interleukin-6 signaling via gp130 receptor-dependent and -independent pathways in rat liver (Graf et al). 2006;44:1206-1217
Mechanisms of endotoxin-induced NO, IL-6, and TNF-α production in activated rat hepatic stellate cells: Role of p38 MAPK (Thirunavukkarasu et al). 2006;44: 389-398
Oxidative-stress and IL-6 mediate the fibrogenic effects of rodent Kupffer cells on stellate cells (Nieto). 2006; 44:1487-1501

Interleukin 7 receptor alpha-chain (CD127)
Loss of IL-7 receptor alpha-chain (CD127) expression in acute HCV infection associated with viral persistence (Golden-Mason et al). 2006;44:1098-1109

Interleukin 10
Intrahepatic virus-specific IL-10-producing CD8 T cells prevent liver damage during chronic hepatitis C virus infection (Abel et al). 2006;44: 1607-1616

Interleukin 15
Hepatology Highlights (Kaplowitz). 2006;44:285-286

Interleukin 29
Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes (Doyle et al). 2006;44:896-906

Intracranial pressure monitoring
Intracranial pressure monitoring in acute liver failure. A procedure with clear indications (Wendon and Larsen). 2006;44:504-506 (Hepatology *Elsewhere*)
Intracranial pressure monitoring in patients with acute liver failure: A questionable invasive surveillance (Bernuau and Durand). 2006;44: 502-504 (Hepatology *Elsewhere*)

Intraductal papillary mucinous neoplasms
Biliary papillary tumors share pathological features with intraductal papillary mucinous neoplasm of the pancreas (Zen et al). 2006;44:1333-1343

Intrahepatic cholangiocarcinoma
Comparison of gene expression profiles between *Opisthorchis viverrini* and non-*Opisthorchis viverrini* associated human intrahepatic cholangiocarcinoma (Jinawath et al). 2006;44:1025-1038

Invasiveness
Aiming at minimal invasiveness as a therapeutic strategy for Budd-Chiari syndrome (Plessier et al). 2006;44: 1308-1316

Iron metabolism
α1-Antitrypsin mutations in NAFLD: High prevalence and association with altered iron metabolism but not with liver damage (Valenti et al). 2006;44:857-864

Iron status
Multiple polymorphic loci determine basal hepatic and splenic iron status in mice (Grant et al). 2006;44:174-185

Ischemia-reperfusion injury
Critical role of acidic sphingomyelinase in murine hepatic ischemia-reperfusion injury (Llacuna et al). 2006;44:561-572
Ischemic preconditioning of the murine liver protects through the Akt kinase pathway (Izuishi et al). 2006;44: 573-580

Isolation
Splendid isolation (Reuben). 2006;44: 1365-1370 (Landmarks in Hepatology)

J

JAK2 gene
JAK2 mutation: The best diagnostic tool for myeloproliferative disease in splanchnic vein thrombosis? (Janssen and Leebeek). 2006;44: 1391-1393 (Editorial)
Role of the *JAK2* mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis (Primignani et al). 2006;44:1528-1534

JunD
JunD is a profibrogenic transcription factor regulated by Jun N-terminal kinase-independent phosphorylation (Smart et al). 2006;44:1432-1440

K

Kaplowitz, Neil
AASLD 2006 Distinguished Achievement Award to Neil Kaplowitz. 2006;44:1378-1379

Killer hepatocytes
Hepatology Highlights (Kaplowitz). 2006;44:285-286

Kupffer cells
Oxidative-stress and IL-6 mediate the fibrogenic effects of rodent Kupffer cells on stellate cells (Nieto). 2006; 44:1487-1501

L

Lamivudine resistance
Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy (van Bömmel et al). 2006;44:318-325

Laparoscopic liver surgery
Laparoscopic liver surgery: Shifting the management of liver tumors (Koffron et al). 2006;44:1694-1700 (Special Article)

Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein
Prediction of recurrence of hepatocellular carcinoma after curative ablation

using three tumor markers (Tateishi et al). 2006;44:1518-1527

Leptin
Leptin-mediated neovascularization is a prerequisite for progression of nonalcoholic steatohepatitis in rats (Kitade et al). 2006;44:983-991

Lifestyle advice
NAFLD in children: A prospective clinical-pathological study and effect of lifestyle advice (Nobili et al). 2006;44:458-465

Lipopolysaccharide
Enhancement by pyrazole of lipopolysaccharide-induced liver injury in mice: Role of cytochrome P450 2E1 and 2A5 (Lu and Cederbaum). 2006;44:263-274
Hepatology Highlights (Kaplowitz). 2006;44:285-286

Lipoprotein
Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment (Gopal et al). 2006;44:335-340

***Lith1* candidate genes**
Investigation of the *Lith1* candidate genes *ABCB11* and *LXRA* in human gallstone disease (Schafmayer et al). 2006;44:650-657

Liver
Different signaling pathways in the livers of patients with chronic hepatitis B or chronic hepatitis C (Honda et al). 2006;44:1122-1138
Gender and liver: Is the liver stiffness weaker in weaker sex? (Corpechot et al). 2006;44:513-514 (Correspondence)
Human UDP-glucuronosyltransferase (UGT)1A3 enzyme conjugates chenodeoxycholic acid in the liver (Trottier et al). 2006;44:1158-1170
Liver biology and pathobiology (Kaplowitz). 2006;44:282 (Correction)
Pituitary tumor transforming gene 1 in the liver (Grizzi et al). 2006;44:1701-1702 (Correspondence)

Liver, fatty
Gender, fatty liver and GGT (Carulli et al). 2006;44:278-279 (Correspondence)
Inactivation of oxidized and S-nitrosylated mitochondrial proteins in alcoholic fatty liver of rats (Moon et al). 2006;44:1218-1230

Liver biopsy
Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease (Merriman et al). 2006;44:874-880
Liver biopsy interpretation for causes of late liver allograft dysfunction (Banff Working Group). 2006;44:489-501 (Special Article)

Liver conditioning
Monocrotaline promotes transplanted cell engraftment and advances liver repopulation in rats via liver conditioning (Joseph et al). 2006;44:1411-1420

Liver disease
Coagulation disorders and hemostasis in liver disease: Pathophysiology and critical assessment of current management (Caldwell et al). 2006;44:1039-1046 (Special Article)
Global challenges in liver disease (Williams). 2006;44:521-526 (Perspectives in Clinical Hepatology)
Hepatology Highlights (Kaplowitz). 2006;44:1061-1062
Pattern recognition receptors: A contemporary view on liver diseases (Szabo et al). 2006;44:287-298 (Concise Review in Mechanisms of Disease)

Liver disease, chronic
Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases (Ganne-Carrié et al). 2006;44:1511-1517
Time to ban smoking in patients with chronic liver disease (Bataller). 2006;44:1394-1396 (Editorial)

Liver disease, complex
Genomics and complex liver disease: Challenges and opportunities (Juran and Lazaridis). 2006;44:1380-1390 (Science Frontier)

Liver disease, fatty
α1-Antitrypsin mutations in NAFLD: High prevalence and association with altered iron metabolism but not with liver damage (Valenti et al). 2006;44:857-864
Controversies in the management of pediatric liver disease: Hepatitis B, C and NAFLD: Summary of a single topic conference (Shneider et al). 2006;44:1344-1354 (Meeting Report)
Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease (Merriman et al). 2006;44:874-880
Diabetic hepatosclerosis: A novel entity or a rare form of nonalcoholic fatty liver disease? (Mendoza and Younossi). 2006;44:1362-1363 (Hepatology *Elsewhere*)
Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis (Bugianesi et al). 2006;44:1648-1655
In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease (Wieckowska et al). 2006;44:27-33 (Rapid Communication)
Long-term follow-up of patients with NAFLD and elevated liver enzymes (Ekstedt et al). 2006;44:865-873
NAFLD in children: A prospective clinical-pathological study and effect of lifestyle advice (Nobili et al). 2006;44:458-465

Liver disease, pediatric
Controversies in the management of pediatric liver disease: Hepatitis B, C and NAFLD: Summary of a single topic conference (Shneider et al). 2006;44:1344-1354 (Meeting Report)

Liver enzymes, elevated
Long-term follow-up of patients with NAFLD and elevated liver enzymes (Ekstedt et al). 2006;44:865-873

Liver failure, acute
Indeterminate acute liver failure: A riddle wrapped in a mystery inside an enigma (Davern). 2006;44:765-768 (Hepatology *Elsewhere*)
Intracranial pressure monitoring in acute liver failure. A procedure with clear indications (Wendon and Larsen). 2006;44:504-506 (Hepatology *Elsewhere*)
Intracranial pressure monitoring in patients with acute liver failure: A questionable invasive surveillance (Bernuau and Durand). 2006;44:502-504 (Hepatology *Elsewhere*)
Reduced monocyte HLA-DR expression: A novel biomarker of disease severity and outcome in acetaminophen-induced acute liver failure (Antoniades et al). 2006;44:34-43

Liver failure, fulminant
Induction of murine liver damage by overexpression of CD40 ligand provides an experimental model to study fulminant hepatic failure (Schmitz et al). 2006;44:430-439
Lack of chemokine receptor CCR5 promotes murine fulminant liver failure (Tiegs). 2006;44:275-277 (Hepatology *Elsewhere*)

Liver fatty acid-binding protein
Protection against Western diet–induced obesity and hepatic steatosis in liver fatty acid–binding protein knockout mice (Newberry et al). 2006;44:1191-1205

Liver injury
Constitutive androstane receptor (CAR) ligand, TCPOBOP, attenuates Fas-induced murine liver injury by altering Bcl-2 proteins (Baskin-Bey et al). 2006;44:252-262
Enhancement by pyrazole of lipopolysaccharide-induced liver injury in mice: Role of cytochrome P450 2E1 and 2A5 (Lu and Cederbaum). 2006;44:263-274

Indomethacin increases liver damage in a murine model of liver injury from alpha-1-antitrypsin deficiency (Rudnick et al). 2006;44:976-982
Induction of Gas6 protein in CCl_4-induced rat liver injury and anti-apoptotic effect on hepatic stellate cells (Lafdil et al). 2006;44:228-239
Lack of UCP2 reduces Fas-mediated liver injury in *ob/ob* mice and reveals importance of cell-specific UCP2 expression (Fülöp et al). 2006;44:592-601
Loss of MMP 13 attenuates murine hepatic injury and fibrosis during cholestasis (Uchinami et al). 2006;44:420-429
Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry (Andrade et al). 2006;44:1581-1588
Role of neutrophils in a mouse model of halothane-induced liver injury (You et al). 2006;44:1421-1431
Sustained activation of Rac1 in hepatic stellate cells promotes liver injury and fibrosis in mice (Choi et al). 2006;44:1267-1277

Liver injury, acute
Contribution of hepatic adenosine A_1 receptors to renal dysfunction associated with acute liver injury in rats (Ming et al). 2006;44:813-822

Liver injury, autoimmune
HCV core expression in hepatocytes protects against autoimmune liver injury and promotes liver regeneration in mice (Kawamura et al). 2006;44:936-944

Liver regeneration
HCV core expression in hepatocytes protects against autoimmune liver injury and promotes liver regeneration in mice (Kawamura et al). 2006;44:936-944
Hepatic precursors derived from murine embryonic stem cells contribute to regeneration of injured liver (Heo et al). 2006;44:1478-1486
Matrix metalloproteinase-9 is an important factor in hepatic regeneration after partial hepatectomy in mice (Olle et al). 2006;44:540-549
Reg2 inactivation increases sensitivity to Fas hepatotoxicity and delays liver regeneration post-hepatectomy in mice (Lieu et al). 2006;44:1452-1464
Side population (SP) cells: Taking center stage in regeneration and liver cancer? (Forbes and Alison). 2006;44:23-26 (Editorial)
STAT1 contributes to dsRNA inhibition of liver regeneration after partial hepatectomy in mice (Sun et al). 2006;44:955-966

Liver repopulation
Hepatic precursors derived from murine embryonic stem cells contribute to regeneration of injured liver (Heo et al). 2006;44:1478-1486
Monocrotaline promotes transplanted cell engraftment and advances liver repopulation in rats via liver conditioning (Joseph et al). 2006;44:1411-1420
Noninvasive evaluation of liver repopulation by transplanted hepatocytes using ^{31}P MRS imaging (Landis et al). 2006;44:1250-1258

Liver stiffness measurement
Accuracy of the measurement of liver stiffness for the diagnosis of cirrhosis in patients with chronic liver diseases (Ganne-Carrié et al). 2006;44:1511-1517

Liver surgery
Hepatology Highlights (Elias). 2006;44:519-520
Laparoscopic liver surgery: Shifting the management of liver tumors (Koffron et al). 2006;44:1694-1700 (Special Article)

Liver transplantation
Dynamic FDG-PET is useful for detection of cholangiocarcinoma in patients with PSC listed for liver transplantation (Prytz et al). 2006;44:1572-1580
Liver biopsy interpretation for causes of late liver allograft dysfunction (Banff Working Group). 2006;44:489-501 (Special Article)
Probiotics: Application of "healthy" bacteria to liver transplant recipients (Levitsky). 2006;44:507-510 (Hepatology *Elsewhere*)

Liver tumors
Laparoscopic liver surgery – Shifting the management of liver tumors (Koffron et al). 2006;44:1694-1700 (Special Article)

Liver X-receptor alpha (LXRα)
The liver X-receptor alpha controls hepatic expression of the human bile acid–glucuronidating UGT1A3 enzyme in human cells and transgenic mice (Verreault et al). 2006;44:368-378

Losartan
The effect of single oral low-dose losartan on posture-related sodium handling in post-TIPS ascites-free cirrhosis (Therapondos et al). 2006;44:640-649

Low-density lipoprotein
Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment (Gopal et al). 2006;44:335-340

***LXRA* gene**
Investigation of the *Lith1* candidate genes *ABCB11* and *LXRA* in human gallstone disease (Schafmayer et al). 2006;44:650-657

M

Magnetic resonance spectroscopy
Noninvasive evaluation of liver repopulation by transplanted hepatocytes using ^{31}P MRS imaging (Landis et al). 2006;44:1250-1258

Malignant bile duct strictures
Proteomic profiling of cholangiocarcinoma: Diagnostic potential of SELDI-TOF MS in malignant bile duct stricture (Scarlett et al). 2006;44:658-666

Mammalian target of rapamycin (mTOR)
Immunosuppression using the mTOR inhibition mechanism affects replacement of rat liver with transplanted cells (Wu et al). 2006;44:410-419

Mass spectrometry
Proteomic profiling of cholangiocarcinoma: Diagnostic potential of SELDI-TOF MS in malignant bile duct stricture (Scarlett et al). 2006;44:658-666

Matrix metalloproteinase 9
Matrix metalloproteinase-9 is an important factor in hepatic regeneration after partial hepatectomy in mice (Olle et al). 2006;44:540-549

Matrix metalloproteinase 13
Loss of MMP 13 attenuates murine hepatic injury and fibrosis during cholestasis (Uchinami et al). 2006;44:420-429

Measles virus
Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma (Blechacz et al). 2006;44:1465-1477

Menin
Upregulation of the tumor suppressor gene menin in hepatocellular carcinomaa and its significance in fibrogenesis (Zindy et al). 2006;44:1296-1307

Mitochondrial respiratory chain (MRC)
Uric acid and anti-TNF antibody improve mitochondrial dysfunction in ob/ob mice (García-Ruiz et al). 2006;44:581-591

Monocrotaline
Monocrotaline promotes transplanted cell engraftment and advances liver repopulation in rats via liver conditioning (Joseph et al). 2006;44:1411-1420

Monocytes
Reduced monocyte HLA-DR expression: A novel biomarker of disease severity

and outcome in acetaminophen-induced acute liver failure (Antoniades et al). 2006;44:34-43

Multidrug resistance
Evolution of multi-drug resistant hepatitis B virus during sequential therapy (Yim et al). 2006;44:703-712

Multidrug resistance protein 1 (MDR1, *ABCB1*)
Interindividual variability of canalicular ATP-binding-cassette (ABC)–transporter expression in human liver (Meier et al). 2006;44:62-74

Multidrug resistance protein 3 (MDR3, *ABCB4*)
Interindividual variability of canalicular ATP-binding-cassette (ABC)–transporter expression in human liver (Meier et al). 2006;44:62-74

Multidrug resistance-associated protein 2 (MRP2, *ABCC2*)
Interindividual variability of canalicular ATP-binding-cassette (ABC)–transporter expression in human liver (Meier et al). 2006;44:62-74

Mutations
α1-Antitrypsin mutations in NAFLD: High prevalence and association with altered iron metabolism but not with liver damage (Valenti et al). 2006;44:857-864
Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection (Ozasa et al). 2006;44:326-334
JAK2 mutation: The best diagnostic tool for myeloproliferative disease in splanchnic vein thrombosis? (Janssen and Leebeek). 2006;44:1405-1407 (Editorial)
Role of the *JAK2* mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis (Primignani et al). 2006;44:1528-1534

Myeloproliferative disease
JAK2 mutation: The best diagnostic tool for myeloproliferative disease in splanchnic vein thrombosis? (Janssen and Leebeek). 2006;44:1405-1407 (Editorial)

Myeloproliferative disorders, chronic
Role of the *JAK2* mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis (Primignani et al). 2006;44:1528-1534

Myosin light chain kinase (MLCK)
An MLCK-dependent window in late G1 controls S phase entry of proliferating rodent hepatocytes via ERK-p70S6K pathway (Bessard et al). 2006;44:152-163

N

National Commission on Digestive Diseases
The National Commission on Digestive Diseases (Hoofnagle). 2006;44:6 (This Month from the NIH)

National Institutes of Health (NIH)
The National Commission on Digestive Diseases (Hoofnagle). 2006;44:6 (This Month from the NIH)
Supporting the NIH before it is too late (Liang). 2006;44:1-2 (Editor's Corner)

Natural killer cells
Hepatology Highlights (Kaplowitz). 2006;44:285-286
STAT1 inhibits liver fibrosis in mice by inhibiting stellate cell proliferation and stimulating NK cell cytotoxicity (Jeong et al). 2006;44:1441-1451

Neurotoxicity
Glutamine: A trojan horse in ammonia neurotoxicity (Albrecht and Norenberg). 2006;44:788-794

Neutrophils
Role of neutrophils in a mouse model of halothane-induced liver injury (You et al). 2006;44:1421-1431

Nitric oxide
Mechanisms of endotoxin-induced NO, IL-6, and TNF-α production in activated rat hepatic stellate cells: Role of p38 MAPK (Thirunavukkarasu et al). 2006;44:389-398
Sphingosine 1-phosphate protects rat liver sinusoidal endothelial cells from ethanol-induced apoptosis: Role of intracellular calcium and nitric oxide (Zheng et al). 2006;44:1278-1287

Nodular regenerative hyperplasia (NRH)
Nodular regenerative hyperplasia: Not all nodules are created equal (Reshamwala et al). 2006;44:7-14 (Perspectives in Clinical Hepatology)

Nonalcoholic fatty liver disease
α1-Antitrypsin mutations in NAFLD: High prevalence and association with altered iron metabolism but not with liver damage (Valenti et al). 2006;44:857-864
Controversies in the management of pediatric liver disease: Hepatitis B, C and NAFLD: Summary of a single topic conference (Shneider et al). 2006;44:1344-1354 (Meeting Report)
Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease (Merriman et al). 2006;44:874-880
Diabetic hepatosclerosis: A novel entity or a rare form of nonalcoholic fatty liver disease? (Mendoza and Younossi). 2006;44:1362-1363 (Hepatology *Elsewhere*)
Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis (Bugianesi et al). 2006;44:1648-1655
In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease (Wieckowska et al). 2006;44:27-33 (Rapid Communication)
Long-term follow-up of patients with NAFLD and elevated liver enzymes (Ekstedt et al). 2006;44:865-873
NAFLD in children: A prospective clinical-pathological study and effect of lifestyle advice (Nobili et al). 2006;44:458-465

Nonalcoholic steatohepatitis
Assessing the outcome of nonalcoholic steatohepatitis? It's time to get serious (Ratzu and Poynard). 2006;44:802-805 (Editorial)
Hepatology Highlights (Kaplowitz). 2006;44:285-286
Leptin-mediated neovascularization is a prerequisite for progression of nonalcoholic steatohepatitis in rats (Kitade et al). 2006;44:983-991
Uric acid and anti-TNF antibody improve mitochondrial dysfunction in ob/ob mice (García-Ruiz et al). 2006;44:581-591

Nonsteroidal anti-inflammatory drugs
Hepatology Highlights (Kaplowitz). 2006;44:1061-1062

Notch
Aspartyl-asparagyl β hydroxylase overexpression in human hepatoma is linked to activation of insulin-like growth factor and Notch signaling mechanisms (Cantarini et al). 2006;44:446-457

Nucleic acid testing
Characterization of HBV DNA^+/$HBsAg^-$ blood donors in Poland identified by triplex NAT (Brojer et al). 2006;44:1666-1674

Numbering systems
A comprehensive system for consistent numbering of HCV sequences, proteins and epitopes (Kuiken et al). 2006;44:1355-1361

Nutritional status
Derivation and validation of a new global method for assessing nutritional status in patients with cirrhosis (Morgan et al). 2006;44:823-835

O

Obesity
Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease (Merriman et al). 2006;44: 874-880
Protection against Western diet–induced obesity and hepatic steatosis in liver fatty acid–binding protein knockout mice (Newberry et al). 2006;44: 1191-1205

Observational studies
Beyond randomized controlled trials: A critical comparison with nonrandomized studies (Sørensen et al). 2006;44:1075-1082

Oncogenes
Oncogene-specific gene expression signatures at preneoplastic stage in mice define distinct mechanisms of hepatocarcinogenesis (Coulouarn et al). 2006;44:1003-1011

Opisthorchis viverrini
Comparison of gene expression profiles between *Opisthorchis viverrini* and non-*Opisthorchis viverrini* associated human intrahepatic cholangiocarcinoma (Jinawath et al). 2006;44:1025-1038

Oxidative stress
Oxidative-stress and IL-6 mediate the fibrogenic effects of Kupffer cells on stellate cells (Nieto). 2006;44:1487-1501

Oxidization
Inactivation of oxidized and S-nitrosylated mitochondrial proteins in alcoholic fatty liver of rats (Moon et al). 2006;44:1218-1230

Oxysterols
Hypercholesterolemia in rats with hepatomas: Increased oxysterols accelerate efflux but do not inhibit biosynthesis of cholesterol (Hirayama et al). 2006;44:602-611

P

p38
Mechanisms of endotoxin-induced NO, IL-6, and TNF-α production in activated rat hepatic stellate cells: Role of p38 MAPK (Thirunavukkarasu et al). 2006;44: 389-398

p70S6K
An MLCK-dependent window in late G1 controls S phase entry of proliferating rodent hepatocytes via ERK-p70S6K pathway (Bessard et al). 2006;44:152-163

Pancreas
Biliary papillary tumors share pathological features with intraductal papillary mucinous neoplasm of the pancreas (Zen et al). 2006;44:1333-1343

Papillary tumors, biliary
Biliary papillary tumors share pathological features with intraductal papillary mucinous neoplasm of the pancreas (Zen et al). 2006;44:1333-1343

Pathobiology
Liver biology and pathobiology (Kaplowitz). 2006;44:282 (Correction)

Pattern recognition receptors (PRRs)
Pattern recognition receptors: A contemporary view on liver diseases (Szabo et al). 2006;44:287-298 (Concise Review in Mechanisms of Disease)

Pediatric liver disease
Controversies in the management of pediatric liver disease: Hepatitis B, C and NAFLD: Summary of a single topic conference (Shneider et al). 2006;44:1344-1354 (Meeting Report)

Peginterferon
Duration of peginterferon therapy in acute hepatitis C: A randomized trial (Kamal et al). 2006;44:1055-1056 (Correction) (Rapid Communication)

Peginterferon alpha-2b
Efficacy of peginterferon alpha-2b in chronic hepatitis delta: Relevance of quantitative RT-PCR for follow-up (Castelnau et al). 2006;44:728-735
Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: Relation to treatment response (ter Borg et al). 2006;44:721-727
Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B (Wursthorn et al). 2006;44:675-684
Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta (Niro et al). 2006;44:713-720

Permeability surface area product
The brain permeability-surface product for ammonia (Lockwood and Wack). 2006;44:1052-1053 (Correspondence)
The brain permeability-surface product for ammonia (Sørensen and Keiding). 2006;44:1053-1054 (Reply)

Phenobarbital
Phenobarbital regulates nuclear expression of HNF-4α in mouse and rat hepatocytes independent of CAR and PXR (Bell and Michalopoulos). 2006;44:186-194

Phenotype
Gilbert's disease and atazanavir: From phenotype to UDP-glucuronosyltransferase haplotype (Lankisch et al). 2006;44:1324-1332

PI3-kinase
Hepatology Highlights (Kaplowitz). 2006;44:1061-1062

PI-4,5-bisphosphate
Actin organization and hepatocyte differentiation are regulated by extracellular matrix via PI-4,5-bisphosphate in the rat (Kimata et al). 2006;44:140-151

Pituitary tumor transforming gene 1 (PTTG-1)
Pituitary tumor transforming gene 1 in the liver (Grizzi et al). 2006;44: 1701-1702 (Correspondence)

Plasma cholesterol
Plasma cholesterol is hyperresponsive to statin in ABCG5/ABCG8 transgenic mice (Tang et al). 2006; 44:1259-1266

Platelet counts
H. pylori and platelet counts (Arnold and Harrison). 2006;44:1685-1686 (Hepatology *Elsewhere*)

Platelets
Hepatology Highlights (Elias). 2006;44: 519-520
Thrombin generation in patients with cirrhosis: The role of platelets (Tripodi et al). 2006;44:440-445

Poland
Characterization of HBV $DNA^+/HBsAg^-$ blood donors in Poland identified by triplex NAT (Brojer et al). 2006;44:1666-1674

Polymerase chain reaction
Efficacy of peginterferon alpha-2b in chronic hepatitis delta: Relevance of quantitative RT-PCR for follow-up (Castelnau et al). 2006;44:728-735

Porphyria
Seeing purple (Reuben). 2006;44:515 (Correction)

Portopulmonary hypertension
Hepatology Highlights (Elias). 2006;44: 1374-1375
Portopulmonary hypertension: Results from a 10-year screening algorithm (Krowka et al). 2006;44:1502-1510

Positron emission tomography
Dynamic FDG-PET is useful for detection of cholangiocarcinoma in patients with PSC listed for liver transplantation (Prytz et al). 2006; 44:1572-1580

Posture
The effect of single oral low-dose losartan on posture-related sodium handling in post-TIPS ascites-free cirrhosis (Therapondos et al). 2006; 44:640-649

Preneoplasia
Oncogene-specific gene expression signatures at preneoplastic stage in mice define distinct mechanisms of

hepatocarcinogenesis (Coulouarn et al). 2006;44:1003-1011

Primary biliary cirrhosis
An autoimmune biliary disease mouse model for primary biliary cirrhosis: Something for everyone (Mason). 2006;44:1047-1050 (Hepatology *Elsewhere*)
Biliary drainage transiently relieves intractable pruritus in primary biliary cirrhosis (Beuers et al). 2006; 44:280-281 (Correspondence)
Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis (Poupon et al). 2006;44:85-90
Fatigue in primary biliary cirrhosis is associated with excessive daytime somnolence (Newton et al). 2006; 44:91-98
Hepatology Highlights (Elias). 2006;44: 1374-1375
HLA class II alleles, genotypes, haplotypes, and amino acids in primary biliary cirrhosis: A large-scale study (Donaldson et al). 2006; 44:667-674
IL-2 receptor $\alpha^{-/-}$ mice and the development of primary biliary cirrhosis (Wakabayashi et al). 2006; 44:1240-1249
Smoking and increased severity of hepatic fibrosis in primary biliary cirrhosis: A cross validated retrospective assessment (Zein et al). 2006;44:1564-1571

Primary sclerosing cholangitis
Dynamic FDG-PET is useful for detection of cholangiocarcinoma in patients with PSC listed for liver transplantation (Prytz et al). 2006; 44:1572-1580
Hepatology Highlights (Elias). 2006;44: 1374-1375
Primary sclerosing cholangitis: Summary of a workshop (LaRusso et al). 2006; 44:746-764 (Special Article)

Probiotics
Probiotics: Application of "healthy" bacteria to liver transplant recipients (Levitsky). 2006;44:507-510 (Hepatology *Elsewhere*)

Progenitor cells
Hepatic precursors derived from murine embryonic stem cells contribute to regeneration of injured liver (Heo et al). 2006;44:1478-1486

Progressive familial intrahepatic cholestasis type 1 (PFIC1, Byler disease)
Atp8b1 deficiency in mice reduces resistance of the canalicular membrane to hydrophobic bile salts and impairs bile salt transport (Paulusma et al). 2006;44:195-204

Proteomics
HepatoProteomics: Applying proteomic technologies to the study of liver function and disease (Diamond et al). 2006;44:299-308 (Science Frontier)
Proteomic profiling of cholangiocarcinoma: Diagnostic potential of SELDI-TOF MS in malignant bile duct stricture (Scarlett et al). 2006;44:658-666

Pruritus
Gabapentin in patients with the pruritus of cholestasis: A double-blind, randomized, placebo-controlled trial (Bergasa et al). 2006;44:1317-1323

Pruritus, intractable
Biliary drainage transiently relieves intractable pruritus in primary biliary cirrhosis (Beuers et al). 2006; 44:280-281 (Correspondence)

Pyrazole
Enhancement by pyrazole of lipopolysaccharide-induced liver injury in mice: Role of cytochrome P450 2E1 and 2A5 (Lu and Cederbaum). 2006;44:263-274

Q

Quantitative RT-PCR
Efficacy of peginterferon alpha-2b in chronic hepatitis delta: Relevance of quantitative RT-PCR for follow-up (Castelnau et al). 2006;44:728-735

R

Rac1
Sustained activation of Rac1 in hepatic stellate cells promotes liver injury and fibrosis in mice (Choi et al). 2006;44:1267-1277

Racial differences
Global transcriptional response to interferon is a determinant of HCV treatment outcome and is modified by race (He et al). 2006;44:352-359

Rapamycin, mammalian target of (mTOR)
Immunosuppression using the mTOR inhibition mechanism affects replacement of rat liver with transplanted cells (Wu et al). 2006; 44:410-419

Reg2/RegIIIβ
Reg2 inactivation increases sensitivity to Fas hepatotoxicity and delays liver regeneration post-hepatectomy in mice (Lieu et al). 2006;44:1452-1464

Renal dysfunction
Contribution of hepatic adenosine A_1 receptors to renal dysfunction associated with acute liver injury in rats (Ming et al). 2006;44:813-822

Ribavirin
Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta (Niro et al). 2006;44:713-720

RNA, double-stranded
STAT1 contributes to dsRNA inhibition of liver regeneration after partial hepatectomy in mice (Sun et al). 2006;44:955-966

S

Scanning electron microscopy
Splendid isolation (Reuben). 2006;44: 1365-1370 (Landmarks in Hepatology)

Scavenger receptor class B type I (SR-BI)
Hepatology Highlights (Alter). 2006;44: 3-6

Sclerosing cholangitis
Sclerosing cholangitis: A focus on secondary causes (Abdalian and Heathcote). 2006;44:1063-1074 (Perspectives in Clinical Hepatology)

Sclerosing cholangitis, primary
Dynamic FDG-PET is useful for detection of cholangiocarcinoma in patients with PSC listed for liver transplantation (Prytz et al). 2006; 44:1572-1580
Hepatology Highlights (Elias). 2006;44: 1374-1375
Primary sclerosing cholangitis: Summary of a workshop (LaRusso et al). 2006; 44:746-764 (Special Article)

Septic shock
Adrenal insufficiency in patients with cirrhosis and septic shock: Effect of treatment with hydrocortisone on survival (Fernández et al). 2006;44: 1288-1295

Serum amyloid A
Serum amyloid A has an antiviral activity against hepatitis C virus by inhibiting virus entry (Lavie et al). 2006;44:1626-1634

Shock, septic
Adrenal insufficiency in patients with cirrhosis and septic shock: Effect of treatment with hydrocortisone on survival (Fernández et al). 2006;44: 1288-1295

Side population (SP) cells
Side population (SP) cells: Taking center stage in regeneration and liver cancer? (Forbes and Alison). 2006; 44:23-26 (Editorial)
Side population purified from hepatocellular carcinoma cells harbors cancer stem cell–like properties (Chiba et al). 2006;44: 240-251

Signal transducer and activator of transcription STAT1
STAT1 contributes to dsRNA inhibition of liver regeneration after partial hepatectomy in mice (Sun et al). 2006;44:955-966
STAT1 inhibits liver fibrosis in mice by inhibiting stellate cell proliferation

and stimulating NK cell cytotoxicity (Jeong et al). 2006;44:1441-1451

Signal transducer and activator of transcription STAT5

Hepatic expression of glutamine synthetase in rats is controlled by STAT5 and TCF transcription factors (Werth et al). 2006;44:967-975

Sinusoidal endothelial cells

Hepatology Highlights (Kaplowitz). 2006;44:1061-1062

Sphingosine 1-phosphate protects rat liver sinusoidal endothelial cells from ethanol-induced apoptosis: Role of intracellular calcium and nitric oxide (Zheng et al). 2006;44: 1278-1287

T lymphocytes interact with hepatocytes through fenestrations in murine liver sinusoidal endothelial cells (Warren et al). 2006;44:1182-1190

Smoking

Smoking and increased severity of hepatic fibrosis in primary biliary cirrhosis: A cross validated retrospective assessment (Zein et al). 2006;44:1564-1571

Time to ban smoking in patients with chronic liver disease (Bataller). 2006;44:1408-1410 (Editorial)

S-nitrosylation

Inactivation of oxidized and S-nitrosylated mitochondrial proteins in alcoholic fatty liver of rats (Moon et al). 2006;44:1218-1230

Sodium handling

The effect of single oral low-dose losartan on posture-related sodium handling in post-TIPS ascites-free cirrhosis (Therapondos et al). 2006; 44:640-649

Impaired 11β-hydroxysteroid dehydrogenase contributes to renal sodium avidity in cirrhosis: Hypothesis or fact? (Frey). 2006;44: 795-801

Somnolence, daytime

Fatigue in primary biliary cirrhosis is associated with excessive daytime somnolence (Newton et al). 2006; 44:91-98

Spain

Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: A prospective series from Spain (Lucena et al). 2006;44: 850-856

Sphingosine 1-phosphate

Sphingosine 1-phosphate protects rat liver sinusoidal endothelial cells from ethanol-induced apoptosis: Role of intracellular calcium and nitric oxide (Zheng et al). 2006;44: 1278-1287

Splanchnic vein thrombosis

JAK2 mutation: The best diagnostic tool for myeloproliferative disease in splanchnic vein thrombosis? (Janssen and Leebeek). 2006;44: 1405-1407 (Editorial)

Role of the *JAK2* mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis (Primignani et al). 2006;44:1528-1534

Statins

Different anti-HCV profiles of statins and their potential for combination therapy with interferon (Ikeda et al). 2006;44:117-125

Plasma cholesterol is hyperresponsive to statin in ABCG5/ABCG8 transgenic mice (Tang et al). 2006; 44:1259-1266

Statins and hepatic steatosis: Perspectives from the Dallas Heart Study (Browning). 2006;44:466-471

Steatohepatitis, alcoholic

Hepatology Highlights (Kaplowitz). 2006;44:285-286

Steatohepatitis, nonalcoholic

Assessing the outcome of nonalcoholic steatohepatitis? It's time to get serious (Ratzu and Poynard). 2006; 44:802-805 (Editorial)

Hepatology Highlights (Kaplowitz). 2006;44:285-286

Leptin-mediated neovascularization is a prerequisite for progression of nonalcoholic steatohepatitis in rats (Kitade et al). 2006;44:983-991

Uric acid and anti-TNF antibody improve mitochondrial dysfunction in ob/ob mice (García-Ruiz et al). 2006;44:581-591

Steatosis

Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice (Ding et al). 2006;44:515 (Correction)

Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis (Bugianesi et al). 2006;44:1648-1655

Protection against Western diet–induced obesity and hepatic steatosis in liver fatty acid–binding protein knockout mice (Newberry et al). 2006;44: 1191-1205

Statins and hepatic steatosis: Perspectives from the Dallas Heart Study (Browning). 2006;44:466-471

Stellate cells

In vivo immune modulatory activity of hepatic stellate cells in mice (Chen et al). 2006;44:1171-1181

Induction of Gas6 protein in CCl_4-induced rat liver injury and anti-apoptotic effect on hepatic stellate cells (Lafdil et al). 2006;44:228-239

Mechanisms of endotoxin-induced NO, IL-6, and TNF-α production in activated rat hepatic stellate cells: Role of p38 MAPK (Thirunavukkarasu et al). 2006;44: 389-398

Oxidative-stress and IL-6 mediate the fibrogenic effects of Kupffer cells on stellate cells (Nieto). 2006;44:1487-1501

STAT1 inhibits liver fibrosis in mice by inhibiting stellate cell proliferation and stimulating NK cell cytotoxicity (Jeong et al). 2006;44:1441-1451

Sustained activation of Rac1 in hepatic stellate cells promotes liver injury and fibrosis in mice (Choi et al). 2006;44:1267-1277

Stem cells

Hepatic precursors derived from murine embryonic stem cells contribute to regeneration of injured liver (Heo et al). 2006;44:1478-1486

Subgenotype

Hepatology Highlights (Alter). 2006;44: 775-777

Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS)

Proteomic profiling of cholangiocarcinoma: Diagnostic potential of SELDI-TOF MS in malignant bile duct stricture (Scarlett et al). 2006;44:658-666

Surgery

Hepatology Highlights (Elias). 2006;44: 519-520

Sympathetic nervous system

Effects of clonidine on diuretic response in ascitic patients with cirrhosis and activation of sympathetic nervous system (Lenaerts et al). 2006;44:844-849

T

T cells

CD4+ immune escape and subsequent T-cell failure following chimpanzee immunization against hepatitis C virus (Puig et al). 2006;44:736-745

Favored T helper 1 response in a mouse model of hepatosteatosis is associated with enhanced T cell–mediated hepatitis (Kremer et al). 2006;44:216-227

Intrahepatic virus-specific IL-10-producing CD8 T cells prevent liver damage during chronic hepatitis C virus infection (Abel et al). 2006;44: 1607-1616

T lymphocytes interact with hepatocytes through fenestrations in murine liver sinusoidal endothelial cells (Warren et al). 2006;44:1182-1190

T helper 1 cells

Favored T helper 1 response in a mouse model of hepatosteatosis is associated with enhanced T cell–mediated hepatitis (Kremer et al). 2006;44:216-227

TCF
Hepatic expression of glutamine synthetase in rats is controlled by STAT5 and TCF transcription factors (Werth et al). 2006;44:967-975
Tegafur
Uracil-tegafur as an adjuvant for hepatocellular carcinoma: A randomized trial (Hasegawa et al). 2006;44:891-895
Tenofovir
Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127 (Peters et al). 2006; 44:1110-1116
Tenofovir disoproxil fumarate: Role in hepatitis B treatment (Wong and Lok). 2006;44:309-313 (Editorial)
Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy (van Bömmel et al). 2006;44:318-325
Tensin2 variant 3
Tensin2 variant 3 is associated with aggressive tumor behavior in human hepatocellular carcinoma (Yam et al). 2006;44:881-890
Terminology
A comprehensive system for consistent numbering of HCV sequences, proteins and epitopes (Kuiken et al). 2006;44:1355-1361
Tetrahydrobiopterin
The eNOS cofactor tetrahydrobiopterin improves endothelial dysfunction in livers of rats with CCl_4 cirrhosis (Matei et al). 2006;44:44-52
Thrombin
Thrombin generation in patients with cirrhosis: The role of platelets (Tripodi et al). 2006;44:440-445
***TIP30* gene**
TIP30 inhibits growth of HCC cell lines and inhibits HCC xenografts in mice in combination with 5-FU (Zhao et al). 2006;44:205-215
Tolerance
Hepatology Highlights (Kaplowitz). 2006;44:1061-1062
Transcription
Global transcriptional response to interferon is a determinant of HCV treatment outcome and is modified by race (He et al). 2006;44:352-359
Transcription-modified amplification (TMA)
HCV RNA detection by TMA during the Hepatitis C Antiviral Long-term Treatment against Cirrhosis (Halt-C) Trial (Morishima et al). 2006;44: 360-367
Transcriptomics
Transcriptomic and genomic analysis of human hepatocellular carcinomas and hepatoblastomas (Luo et al). 2006;44:1012-1024
Transjugular intrahepatic portosystemic shunt (TIPS)
The effect of single oral low-dose losartan on posture-related sodium handling in post-TIPS ascites-free cirrhosis (Therapondos et al). 2006; 44:640-649
Transplantation
Immunosuppression using the mTOR inhibition mechanism affects replacement of rat liver with transplanted cells (Wu et al). 2006; 44:410-419
Monocrotaline promotes transplanted cell engraftment and advances liver repopulation in rats via liver conditioning (Joseph et al). 2006; 44:1411-1420
Triglycerides
A low-carbohydrate diet rapidly and dramatically reduces intrahepatic triglyceride content (Browning et al). 2006;44:487-488 (Concise Communication)
Tumor necrosis factor
Uric acid and anti-TNF antibody improve mitochondrial dysfunction in ob/ob mice (García-Ruiz et al). 2006;44:581-591
Tumor necrosis factor α
Mechanisms of endotoxin-induced NO, IL-6, and TNF-α production in activated rat hepatic stellate cells: Role of p38 MAPK (Thirunavukkarasu et al). 2006;44:389-398

U

UDP-glucuronosyltransferase
Gilbert's disease and atazanavir: From phenotype to UDP-glucuronosyltransferase haplotype (Lankisch et al). 2006;44:1324-1332
UDP-glucuronosyltransferase 1A3
Human UDP-glucuronosyltransferase (UGT)1A3 enzyme conjugates chenodeoxycholic acid in the liver (Trottier et al). 2006;44:1158-1170
The liver X-receptor alpha controls hepatic expression of the human bile acid–glucuronidating UGT1A3 enzyme in human cells and transgenic mice (Verreault et al). 2006;44:368-378
Uncoupling protein-2 (UCP2)
Hepatology Highlights (Kaplowitz). 2006;44:1061-1062
Lack of UCP2 reduces Fas-mediated liver injury in *ob/ob* mice and reveals importance of cell-specific UCP2 expression (Fülöp et al). 2006;44: 592-601
United States
Fulminant hepatitis A virus infection in the United States: Incidence, prognosis, and outcomes (Taylor et al). 2006;44:1589-1597
Uracil-tegafur
Uracil-tegafur as an adjuvant for hepatocellular carcinoma: A randomized trial (Hasegawa et al). 2006;44:891-895
Uric acid
Uric acid and anti-TNF antibody improve mitochondrial dysfunction in ob/ob mice (García-Ruiz et al). 2006;44:581-591

V

Vaccine
CD4+ immune escape and subsequent T-cell failure following chimpanzee immunization against hepatitis C virus (Puig et al). 2006;44:736-745
Variceal rebleeding
Hemodynamic response–guided therapy for prevention of variceal rebleeding: An uncontrolled pilot study (González et al). 2006;44:806-812
Viral therapy
Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma (Blechacz et al). 2006;44:1465-1477
von Willebrand factor
Elevated levels of von Willebrand factor in cirrhosis support platelet adhesion despite reduced functional capacity (Lisman et al). 2006;44:53-61

W

Water retention
Hepatology Highlights (Elias). 2006;44: 1374-1375
Western diet
Protection against Western diet–induced obesity and hepatic steatosis in liver fatty acid–binding protein knockout mice (Newberry et al). 2006;44:1191-1205
Wnt
Activation of Wnt/β-catenin pathway during hepatocyte growth factor–induced hepatomegaly in mice (Apte et al). 2006;44:992-1002
Wolkoff, Allan W.
AASLD 2006 Distinguished Service Award to Allan W. Wolkoff (Cohen). 2006;44:1376-1377